fludarabine and Recrudescence

fludarabine has been researched along with Recrudescence in 316 studies

Research

Studies (316)

Timeframe	Studies, this research(%)	All Research%
pre-1990	1 (0.32)	18.7374
1990's	23 (7.28)	18.2507
2000's	125 (39.56)	29.6817
2010's	133 (42.09)	24.3611
2020's	34 (10.76)	2.80

Authors

Authors	Studies
Beelen, D; Bethge, W; Blaise, D; Chevallier, P; Ciceri, F; de Witte, T; Ganser, A; Iacobelli, S; Koster, L; Kröger, N; Luft, T; Mufti, GJ; Nagler, A; Robin, M; Schwerdtfeger, R; Shimoni, A; Volin, L; Yakoub-Agha, I	1
Casper, J; Frietsch, JJ; Hilgendorf, I; Hochhaus, A; Köhne, CH; O'Hagan Henderson, S	1
Bierings, M; Boelens, JJ; Bresters, D; de Koning, CCH; Kollen, WJ; Lankester, AC; Lindemans, CA; Nierkens, S; Versluijs, AB	1
Baggott, C; Boelens, JJ; Brown, PA; Chinnabhandar, V; Curran, KJ; Egeler, E; Fabrizio, VA; Goksenin, AY; Hermiston, M; Karras, NA; Keating, AK; Krupski, C; Kunicki, M; Laetsch, TW; Mackall, CL; Margossian, SP; Mauguen, A; Mavroukakis, S; Moskop, A; Myers, GD; Pacenta, H; Phillips, CL; Prabhu, S; Qayed, M; Rabik, CA; Rossoff, J; Satwani, P; Schultz, LM; Stefanski, HE; Talano, JA; Verneris, MR; Wilcox, R	1
Aljurf, M; Angelucci, E; Arat, M; Bernasconi, P; Giebel, S; Labopin, M; Mohty, M; Nagler, A; Pavlu, J; Peric, Z; Pioltelli, P; Rigacci, L; Risitano, A; Rovira, M; Saccardi, R; Savani, BN; Sica, S; Socié, G; Spyridonidis, A; Swoboda, R; Tischer, J; Van Gorkom, G; Vitek, A	1
Admiraal, R; Bierings, M; Blok, H; Calkoen, FG; De Koning, C; Dekker, L; Hoogerbrugge, P; Huitema, ADR; Jiang, Y; Lindemans, CA; Nierkens, S; Nijstad, AL; Pieters, R; Spoon, M; Van Der Elst, KCM; Van Der Vlugt, M; Van Tinteren, H; Veldkamp, SR; Visscher, H; Vormoor, B; Vormoor, HJ	1
Arpinati, M; Baronciani, D; Bernasconi, P; Bonifazi, F; Brunello, L; Bruno, B; Busca, A; Carella, AM; Carluccio, P; Casini, M; Chiusolo, P; Ciceri, F; Cilloni, D; Cupri, A; Di Grazia, C; Gheorghiu, A; Giglio, F; Girmenia, C; Grassi, A; Grillo, G; Iori, AP; Luppi, M; Martino, M; Masciulli, A; Musso, M; Nozzoli, C; Oldani, E; Onida, F; Palazzo, G; Parma, M; Patriarca, F; Pavoni, C; Peccatori, J; Picardi, A; Proia, A; Rambaldi, A; Sacchi, N; Santarone, S; Sorasio, R; Tringali, S; Vacca, A; Vallisa, D	1
Alatrash, G; Alousi, AM; Anderlini, P; Bassett, R; Champlin, RE; Chen, J; Daher, M; Hosing, C; Kawedia, J; Kebriaei, P; Ledesma, C; Lu, Y; Marin, D; Mehta, R; Nieto, Y; Olson, A; Oran, B; Popat, U; Qazilbash, M; Rondon, G; Saberian, C; Shpall, EJ; Thall, PF; Valdez, BC	1
Balsat, M; Barraco, F; Ducastelle-Leprêtre, S; Fossard, G; Ghesquières, H; Gilis, L; Hayette, S; Heiblig, M; Huet, S; Labussière-Wallet, H; Larcher, MV; Loron, S; Meur, GL; Michallet, M; Plesa, A; Renault, M; Sujobert, P; Thérèse, RM; Thomas, X; Tigaud, I	1
Arat, M; Berceanu, A; Giebel, S; Hamladji, RM; Kröger, N; Labopin, M; Mohty, M; Nagler, A; Ozdogu, H; Potter, V; Rambaldi, A; Sanz, J; Savani, B; Schroeder, T; Spyridonidis, A; Swoboda, R; Yakoub-Agha, I	1
Arat, M; Bourhis, JH; Cornelissen, JJ; Giebel, S; Grillo, G; Hilgendorf, I; Kröger, N; Labopin, M; Maertens, J; Mohty, M; Nagler, A; Poiré, X; Salmenniemi, U; Savani, B; Schroeder, T; Spyridonidis, A; Swoboda, R	1
Aljurf, M; Arat, M; Bourhis, JH; Brissot, E; Forcade, E; Giebel, S; Helbig, G; Huynh, A; Kröger, N; Labopin, M; Labussière-Wallet, H; Lioure, B; Mohty, M; Nagler, A; Peric, Z; Reményi, P; Salmenniemi, U; Savani, BN; Socié, G; Spirydonidis, A; Srour, M; Tbakhi, A; Zahrani, MA	1
Arai, Y; Atsuta, Y; Doki, N; Eto, T; Fukuda, T; Harada, K; Itoh, M; Katsuoka, Y; Kawakita, T; Kondo, T; Maruyama, Y; Matsue, K; Miyakoshi, S; Mizuno, S; Nagafuji, K; Nishiwaki, K; Shibata, S; Takada, S; Tanaka, J; Uchida, N; Yanada, M	1
Bazarbachi, A; Bethge, W; Bug, G; Carlson, K; Hilgendorf, I; Kaare, A; Kröger, N; Labopin, M; Mielke, S; Mohty, M; Nagler, A; Niittyvuopio, R; Reinhardt, HC; Savani, BN; Schäfer-Eckart, K; Spyridonidis, A; Stelljes, M; Verbeek, M	1
Fan, Z; Guo, Z; Huang, F; Jin, H; Liang, X; Lin, R; Ling, Y; Liu, C; Liu, H; Liu, Q; Liu, X; Ou, R; Qu, H; Sun, J; Wu, M; Xu, N; Xu, X; Xuan, L; Yu, S; Zhai, X; Zhang, H; Zhang, Y; Zhao, Y	1
Cao, J; Chen, D; Li, S; Liu, X; Lu, Y; Pei, R; Wang, T; Xu, X; Ye, P; Zheng, ZZ	1
Bachanova, V; Bishop, MR; Brower, J; Chen, AI; Devlin, SM; Flynn, JR; Gonen, M; Ip, A; Leslie, LA; Maakaron, J; Maziarz, RT; McGuirk, JP; Nastoupil, LJ; Oluwole, OO; Parascondola, A; Perales, MA; Porter, DL; Riedell, PA; Schuster, SJ; Scordo, M; Shouval, R; Tomas, AA	1
Alshehri, H; Anteh, S; Avenoso, D; Bourlon, C; Bouziana, S; Dazzi, F; de Farias, M; Dragoi, OD; Gameil, A; Hannah, G; Kenyon, M; Krishnamurthy, P; Kulasekararaj, A; Leung, YT; Mehra, V; Pagliuca, A; Potter, V; Serpenti, F; Shah, MN; Slonim, LB; Wood, H	1
Alousi, AM; Bashir, Q; Champlin, RE; Hosing, C; Joseph, J; Kebriaei, P; Milton, DR; Olson, AL; Oran, B; Popat, UR; Qazilbash, MH; Ramdial, JL; Saini, NY; Shpall, EJ; Srour, SA	1
Behre, G; Döhring, C; Franke, GN; Grimm, J; Hille, A; Jentzsch, M; Linke, R; Niederwieser, D; Pönisch, W; Schwind, S; Vucinic, V	1
Dührsen, U; Flasshove, M; Hanoun, M; Noppeney, R; Schmitz, C; Westhus, J	1
Beutel, G; Dammann, E; Eder, M; Eggers, H; Ehrlich, S; Gabdoulline, R; Ganser, A; Göhring, G; Hambach, L; Heuser, M; Klement, P; Koenecke, C; Markel, D; Neziri, B; Rehberg, A; Reuter, M; Schlegelberger, B; Shahswar, R; Stadler, M; Thol, F; Wichmann, M	1
Al Tourah, AJ; Bruyere, H; Dueck, G; Galbraith, P; Gerrie, AS; Hardy, E; Hrynchak, M; Huang, SJ; Noble, MC; Ramadan, KM; Sehn, L; Toze, CL; Tsang, P; Tucker, T; Young, S	1
Chen, X; Chen, Y; Li, J; Li, Z; Liu, F; Liu, L; Pui, CH; Ruan, M; Wang, J; Wang, S; Wang, Y; Yang, JJ; Zhong, M; Zhu, X	1
Beitinjaneh, A; Flinn, IW; Fung, H; Goy, A; Hill, BT; Holmes, H; Houot, R; Jacobson, CA; Jaglowski, S; Jain, RK; Kersten, MJ; Locke, FL; McSweeney, PA; Miklos, DB; Milpied, N; Munoz, J; Pagel, JM; Peng, W; Rao, AV; Reagan, PM; Rossi, JM; Timmerman, JM; Topp, MS; Wang, M; Zheng, L	1
Cheah, R; Dendle, C; Gregory, G; Mohan, B; Tey, A	1
Choi, Y; Do, YR; Jung, SH; Kim, DS; Koh, Y; Lee, JH; Lee, S; Lee, SS; Lee, WS; Moon, JH; Mun, YC; Park, HS; Park, Y; Yang, DH; Yhim, HY; Yi, JH	1
Ahmed, S; Ahn, KW; Aljurf, M; Bacher, VU; Bredeson, C; Epperla, N; Farhadfar, N; Freytes, CO; Ganguly, S; Ghosh, N; Hamadani, M; Haverkos, B; Inwards, D; Kamble, RT; Khanal, M; Kharfan-Dabaja, MA; Lazarus, HM; Lekakis, L; Litovich, C; Murthy, HS; Nishihori, T; Ramakrishnan, P; Rizzieri, DA; Sureda, A; Yared, JA	1
Cao, J; Cheng, H; Gao, X; Jiao, J; Li, D; Li, W; Li, Z; Liu, H; Ma, Y; Qin, Y; Sang, T; Sang, W; Shi, M; Song, X; Sun, C; Sun, H; Sun, K; Wang, Y; Wu, M; Xu, K; Xu, L; Yan, D; Yan, Z; Yang, J; Yao, M; Zeng, L; Zhang, B; Zheng, J; Zhu, F	1
Andrew, G; Byrne, J; Craddock, C; Crawley, C; Dillon, R; Freeman, SD; Gilleece, M; Hodgkinson, A; Hunter, A; Jackson, A; Khan, N; Loke, J; Malladi, R; Mason, J; McCarthy, N; Nagra, S; Parker, A; Pavlu, J; Peniket, A; Potter, V; Protheroe, R; Salim, R; Siddique, S; Tholouli, E; Vyas, P; Wheatley, K; Wilson, K	1
Edahiro, T; Fujii, T; Fujino, K; Fukushima, N; Hirata, Y; Ichinohe, T; Kawase, T; Mino, T; Miyama, T; Morioka, T; Nagoshi, H; Nishizawa, M; Noma, M; Toishigawa, K; Yoshida, T	1
Bosch, F; Böttcher, S; Foà, R; Ilhan, O; Kisro, J; Leblond, V; Mahé, B; Mikuskova, E; Osmanov, D; Perretti, T; Reda, G; Robinson, S; Stilgenbauer, S; Tausch, E; Trask, P; Turgut, M; Van Hoef, M; Wójtowicz, M	1
Cheng, Z; Feng, L; He, F; Wei, R; Wu, Y; Xiao, M; Zhao, G	1
Chaudhury, S; Duerst, RE; Jacobsohn, D; Kletzel, M; Kwon, S; Rossoff, J; Schneiderman, J; Tse, WT	1
Atsuta, Y; Eto, T; Fukuda, T; Hara, M; Hirabayashi, S; Ichinohe, T; Kanda, Y; Kawakita, T; Kimura, T; Kondo, T; Maruyama, Y; Mizuno, S; Mukae, J; Nakano, N; Ota, S; Ozawa, Y; Shimomura, Y; Tanaka, M; Uchida, N; Yanada, M	1
Alyea, EP; Bashey, A; Deeg, HJ; Devine, SM; Fernandez, HF; Geller, NL; Giralt, S; Hamadani, M; Horowitz, MM; Horwitz, ME; Le-Rademacher, J; Leifer, E; Logan, BR; Maziarz, RT; Mendizabal, AM; Pasquini, MC; Porter, DL; Scott, BL; Warlick, ED; Wu, J	1
Baek, S; Choi, EJ; Choi, Y; Jeon, M; Jo, JC; Joo, YD; Kang, YA; Kang, YL; Kim, DY; Kim, H; Kim, SH; Ko, SH; Lee, JH; Lee, KH; Lee, YS; Lim, SN; Park, HS; Seol, M; Yun, SC	1
Chauffaille, MLLF; Fonseca, ARBMD; Goncalves, MV; Guedes, NR; Lacerda, MP; Pereira, AD; Rodrigues, CA; Yamakawa, PE; Yamamoto, M	1
Apel, A; Bernardi, M; Bonini, C; Ciceri, F; Danylesko, I; Greco, R; Lo Russo, A; Lupo Stanghellini, MT; Nagler, A; Peccatori, J; Shem-Tov, N; Shimoni, A; Vago, L; Yerushalmi, R	1
Baer, MR; Ding, J; Hess, JR; Zimrin, AB	1
Benavente, C; Bergua, J; Boluda, B; Cordón, L; Díaz-Beyá, M; Esteve, J; Garrido, A; Jiménez-Ubieto, A; Martínez, P; Martínez-Cuadrón, D; Montesinos, P; Moscardó, F; Pérez-Simón, JA; Prieto-Delgado, J; Rodríguez-Veiga, R; Salamero, O; Sanz, MA; Sempere, A; Serrano, J; Vidriales, B; Vives, S	1
Algeri, M; Aricò, M; Basso, G; Caniglia, M; Cesaro, S; Di Bartolomeo, P; Fagioli, F; Favre, C; Giardino, S; Locatelli, F; Marzollo, A; Merli, P; Messina, C; Pillon, M; Porta, F; Prete, A; Rabusin, M; Ripaldi, M; Rovelli, A; Saglio, F; Sieni, E; Zecca, M; Ziino, O	1
Alyea, EP; Antin, JH; Armand, P; Cutler, CS; Glotzbecker, BE; Gooptu, M; Ho, VT; Kim, HT; Koreth, J; Nageshwar, P; Nikiforow, S; Ritz, J; Soiffer, RJ	1
Andreeff, M; Bueso-Ramos, C; Cortes, JE; Coyle, M; Daver, N; DiNardo, CD; Futreal, PA; Garcia-Manero, G; Gumbs, C; Issa, GC; Jabbour, E; Jorgensen, J; Kadia, T; Kantarjian, HM; Konopleva, M; Little, L; Morita, K; Patel, KP; Pemmaraju, N; Ravandi, F; Sasaki, K; Song, X; Takahashi, K; Thornton, R; Tippen, S; Wang, F; Wang, S; Yan, Y; Zhang, J	1
Arad, A; Aviv, A; Bairey, O; Braester, A; Fineman, R; Goldschmidt, N; Greenbaum, U; Herishanu, Y; Joffe, E; Polliack, A; Rahimi-Levene, N; Ruchlemer, R; Shvidel, L; Tadmor, T	1
Abou Mourad, Y; Abuhaleeqa, M; Daly, A; Nitta, J; Paulson, K; Seftel, MD; Speziali, C	1
Alessandrino, EP; Bacigalupo, A; Bonifazi, F; Bosi, A; Bregante, S; Bruno, B; Carella, AM; Fanin, R; Finazzi, MC; Mammoliti, S; Masciulli, A; Messina, G; Milone, G; Narni, F; Patriarca, F; Pavoni, C; Rambaldi, A; Russo, D	1
Arai, Y; Hatsumi, N; Honda, S; Ishida, F; Kano, Y; Komatsu, N; Machida, S; Miyawaki, S; Morii, T; Naoe, T; Nishii, K; Ogura, M; Ohnishi, K; Takeshita, A; Usui, N; Yamauchi, T	1
Bashey, A; Holland, HK; Morris, LE; Solh, M; Solomon, SR; Zhang, X	1
Andersson, BS; Bayraktar, UD; Boulad, F; Castro-Malaspina, HR; Champlin, RE; Chen, J; Chiattone, A; de Lima, M; Giralt, S; Jakubowski, AA; Kernan, NA; Maloy, M; O'Reilly, RJ; Papadopoulos, EB; Rondon, G; Saliba, RM	1
Brychtová, Y; Doubek, M; Lindtnerová, M; Lysák, D; Malčíková, J; Mayer, J; Motyčková, M; Panovská, A; Pospíšilová, Š; Šimkovič, M; Smolej, L; Trbušek, M; Vodárek, P	1
Bene, MC; Blin, N; Chevallier, P; Delaunay, J; Dubruille, V; Gastinne, T; Guillaume, T; Le Bourgeois, A; Le Gouill, S; Lode, L; Loirat, M; Mahe, B; Malard, F; Mohr, C; Mohty, M; Moreau, P; Peterlin, P; Planche, L	1
Christos, P; Feldman, E; Gergis, U; Mark, T; Mayer, S; McKenna, M; Pearse, R; Ritchie, E; Roboz, G; Scandura, J; Shore, T; van Besien, K; Wissa, U	1
Badoux, X; Jones, JA; Kantarjian, H; Keating, MJ; Kipps, TJ; O'Brien, S; Plunkett, W; Tsimberidou, AM; Wen, S; Wierda, WG	1
Blaise, D; Castagna, L; Chabannon, C; Crocchiolo, R; El-Cheikh, J; Faucher, C; Furst, S; Granata, A; Lemarie, C; Oudin, C; Saillard, C; Signori, A	1
Argnani, L; Broccoli, A; Casadei, B; Pellegrini, C; Pileri, S; Zinzani, PL	1
Anasetti, C; Ayala, E; Betts, B; Fernandez, H; Field, T; Kharfan-Dabaja, MA; Kunter, G; Locke, F; Nieder, M; Nishihori, T; Ochoa-Bayona, JL; Perez, L; Perkins, JB; Pidala, J; Tomblyn, M	1
Berkahn, L; Bryant, A; Cannell, P; Doocey, R; Fay, K; George, B; Hertzberg, M; Kalff, A; Kennedy, G; Moore, J; Nivison-Smith, I; Patil, S; Pillai, ES; Ritchie, D; Spearing, R; Spencer, A	1
Beelen, D; Berdel, WE; Braess, J; Büchner, T; Fiegl, M; Grüneisen, A; Heinecke, A; Hentrich, M; Hiddemann, W; Kern, W; Reichle, A; Rieger, C; Sauerland, C; Schiel, X; Schöndube, D; Serve, H; Spiekermann, K; Staib, P; Unterhalt, M; Wörmann, B	1
Ahn, KW; Aljurf, MD; Alyea, EP; Arora, M; Brown, JR; Cortes, J; de Lima, M; Gale, RP; Holland, HK; Hsu, JW; Inamoto, Y; Kalaycio, ME; Kamble, RT; Laughlin, MJ; Lewis, ID; Maziarz, RT; Saber, W; Sabloff, M; Seftel, M; Sobecks, RM; Wirk, BM; Zhu, X	1
Appelbaum, FR; Bar, M; Baumgart, J; Deeg, HJ; Delaney, C; Estey, EH; Fang, M; Gutman, J; Gyurkocza, B; Maziarz, RT; Milano, F; Nemecek, ER; Pagel, JM; Ramakrishnan, A; Sandmaier, BM; Scott, B; Storer, BE; Wood, B	1
Forman, SJ; Kim, JH; Liu, A; Palmer, J; Rosenthal, J; Schultheiss, TE; Stein, A; Tsai, N; Wong, JY	1
Bence-Bruckler, I; Benner, A; Bloehdorn, J; Busch, R; Catalano, J; Dmoszynska, A; Döhner, H; Dornan, D; Duchateau-Nguyen, G; Dufour, A; Fink, AM; Fischer, K; Geisler, CH; Hallek, M; Larratt, L; Loscertales, J; Montillo, M; Nguyen, TQ; Palermo, G; Robak, T; Rossiev, VA; Salogub, GN; Shi, X; Solal-Celigny, P; Stilgenbauer, S; Stinson, SY; Valente, N; Warzocha, K; Weisser, M; Wenger, MK; Yeh, RF; Yu, N	1
Ding, K; Geng, L; Liu, H; Liu, X; Song, K; Sun, Z; Tang, B; Tong, J; Wang, X; Yao, W; Zheng, C; Zhu, X	1
Benjamini, O; Burger, J; Estrov, Z; Ferrajoli, A; Jain, P; Kantarjian, H; Keating, M; Lee, HJ; O'Brien, S; Qiao, W; Wierda, W	1
Awan, FT; Byrd, JC; Flinn, IW; Hellmann, A; Hillmen, P; Hughes, SG; Robak, T; Shannon, M; Trone, D	1
Ahmed, S; Alousi, A; Anderlini, P; Bassett, RL; Ciurea, S; Gulbis, A; Jabbour, E; Khouri, IF; Korbling, M; Oran, B; Popat, UR; Rondon, G; Turturro, F; Wei, W	1
Blin, N; Brissot, E; Chevallier, P; Delaunay, J; Dubruille, V; Gastinne, T; Guillaume, T; Le Bourgeois, A; Le Gouill, S; Lodé, L; Mahé, B; Mohty, M; Moreau, P; Peterlin, P	1
Anheier, N; Bergmann, M; Busch, R; Cramer, P; Döhner, H; Dürig, J; Eichhorst, B; Fink, AM; Fischer, K; Goebeler, ME; Hallek, M; Hurtz, HJ; Langerbeins, P; Stauch, MB; Stilgenbauer, S; Wendtner, CM	1
Coiteux, V; de Berranger, E; Duhamel, A; Duléry, R; Gauthier, J; Gomez, E; Langlois, C; Magro, L; Terriou, L; Yakoub-Agha, I	1
Cortes, JE; Feldman, EJ; Goldberg, SL; Hogge, DE; Kantarjian, H; Kolitz, JE; Larson, M; Louie, AC; Pigneux, A; Recher, C; Rizzeri, DA; Schiller, G; Warzocha, K	1
Ahn, HS; Jang, IJ; Jang, MK; Kang, HJ; Kim, H; Kim, NH; Kim, S; Lee, JW; Lee, SH; Park, JD; Park, KD; Shin, HY; Song, SH; Yu, KS	1
Hirabayashi, K; Koike, K; Kurata, T; Nakazawa, Y; Saito, S; Sakashita, K; Tanaka, M; Yanagisawa, R; Yoshikawa, K	1
Choi, YS; Jeon, YW; Kim, DY; Kim, HJ; Kim, JH; Kim, YJ; Lee, JH; Lee, JW; Lee, KH; Lee, S; Lee, SE; Min, CK; Min, WS; Shin, SH; Yahng, SA; Yoon, JH	1
Hasegawa, K; Hirayama, Y; Ishihara, T; Kanagawa, M; Koyama, J; Suzuki, T; Terui, T	1
Angelucci, E; Baronciani, D; Culurgioni, F; Depau, C; Derudas, D; Latte, G; Palmas, A; Tandurella, I; Targhetta, C	1
Anasetti, C; Ayala, E; Figueroa, J; Kharfan-Dabaja, MA; Kim, J; Locke, F; Nishihori, T; Perkins, J; Riches, M; Yue, B	1
Iida, H; Imahashi, N; Kasai, M; Kato, C; Kato, T; Kiyoi, H; Kohno, A; Kurahashi, S; Miyamura, K; Miyao, K; Murata, M; Naoe, T; Nishida, T; Ohashi, H; Ozawa, Y; Sakemura, R; Sawa, M; Terakura, S; Watamoto, K; Yokohata, E	1
Aldenhoven, M; Bierings, MB; Boelens, JJ; Bonney, D; Borrill, RE; Coussons, M; Jones, SA; Mercer, J; van der Ploeg, AT; van Hasselt, PM; Versluys, B; Wijburg, FA; Wynn, RF	1
Andritsos, L; Brown, JR; Bühler, A; Byrd, JC; Caligaris-Cappio, F; Devin, J; Gabrilove, J; Ghia, P; Grever, MR; Hallek, M; Heerema, NA; Janssens, A; Johnson, AJ; Kipps, TJ; Lanasa, MC; Larson, RA; Leblond, V; Milligan, DW; Stilgenbauer, S	1
Arcese, W; Barba, P; Esquirol, A; Gayoso, J; Guidi, S; Martino, R; Montesinos, P; Moscardó, F; Parody, R; Picardi, A; Piñana, JL; Sanz, G; Sanz, J; Sanz, MA; Sierra, J; Solano, C; Terol, MJ	1
Fan, X; Hu, J; Tang, W; Wang, L	1
Daimon, T; Ikegame, K; Ishii, S; Kaida, K; Kanda, Y; Kaya, H; Kodera, Y; Kurokawa, T; Maeda, Y; Ogawa, H; Okada, M; Okumura, H; Shimizu, H; Tamaki, H; Taniguchi, K; Taniguchi, S; Ueda, Y; Yoshida, T; Yoshihara, S	1
Brown, JR; Fisher, DC; Freedman, AS; Mikler, E; Neuberg, D; Reynolds, HM; Takebe, N; Tesar, B; Thompson, C; Werner, L; Yu, L	1
Boga, C; Kasar, M; Kozanoglu, I; Ozdogu, H; Sariturk, C; Yeral, M	1
Cen, X; Dong, Y; Li, Y; Liang, Z; Liu, W; Ou, J; Qiu, Z; Ren, H; Sun, Y; Wang, L; Wang, M; Wang, Q; Wang, W; Xu, W; Yin, Y; Yuan, J	1
Alatrash, G; Andersson, BS; Champlin, R; Charafeddine, Y; Chen, J; Ciurea, S; Kebriaei, P; Lee, HC; Medeiros, LJ; Oran, B; Popat, U; Rondon, G; Saliba, RM; Shpall, E	1
Cassin, R; Cortelezzi, A; Gaidano, G; Giannarelli, D; Orofino, N; Reda, G; Rossi, D; Sciumè, M; Vincenti, D	1
Armistead, P; Chung, Y; Coghill, J; Comeau, T; Gabriel, D; Ivanova, A; Rao, K; Sarantopoulos, S; Serody, J; Shea, TC; Sheets, J; Walko, C; Wood, W	1
Brown, JR; Cohen, JB; Flowers, CR; Jaye, DL; Katzen, HI; Lakhanpal, S; Leis, JF; Rosenthal, H; Sinha, R; Stock, W; Waller, EK	1
Delgado, D; Hege, K; Quigg, T	1
Freireich, EJ; Kantarjian, HM; Keating, MJ; O'Brien, SM; Plunkett, W; Smith, SC; Stingo, F; Tam, CS; Thompson, PA; Wierda, WG	1
Balser, C; Barth, J; Blau, W; Boeck, HP; Brugger, W; Hahn, L; Hinke, A; Kaiser, U; Kauff, F; Losem, C; Mueller, L; Niederle, N; Rummel, M; Sandherr, M; Stauch, M; Vereshchagina, J; von Gruenhagen, U; Weidmann, E; Welslau, M	1
Ding, K; Geng, L; Liu, H; Qiang, P; Song, K; Sun, Z; Tang, B; Tong, J; Wang, X; Yao, W; Zhang, L; Zhang, X; Zheng, C; Zhu, X	1
Bermúdez, A; Caballero, MD; Cabrero, M; Conde, E; De La Serna, J; Gómez, V; Lahuerta, JJ; Moraleda, JM; Perez, SG; Sanz, G; Sanz, J; Serrano, D; Vallejo, C	1
Alchalby, H; Ayuk, F; Cassinat, B; Christopeit, M; Kröger, N; Peffault de Latour, R; Porcher, R; Robin, M; Sicre de Fontbrune, F; Socié, G; Wolschke, C; Zabelina, T	1
Kim, BS; Kim, HJ; Kim, JA; Kim, SJ; Kim, WS; Kong, JH; Park, SK; Park, Y; Shin, DY; Won, JH; Yoon, DH	1
Hong, DS; Ji, YS; Kim, CK; Kim, HJ; Kim, KH; Kim, SH; Lee, KT; Lee, MS; Min, CW; Park, SK; Won, JH; Yun, J	1
Brundage, R; Brunstein, CG; Cao, Q; Jacobson, PA; Jensen, K; Kirstein, MN; Kurtzweil, A; Long-Boyle, J; Rogosheske, J; Sanghavi, K; Wagner, J; Warlick, ED; Weisdorf, DJ; Wiseman, A	1
Bachanova, V; Devine, SM; Fenske, T; Gersten, I; Horowitz, M; Hosing, C; Laport, GG; Lazarus, HM; Logan, B; Longo, W; Nademanee, A; Riches, ML; Wu, J	1
Deng, L; Huang, QX; Huang, R; Huang, YX; Li, YH; Song, CY; Tu, SF; Wu, BY	1
Al-Kali, A; Alkhateeb, HB; Damlaj, M; Gangat, N; Gastineau, DA; Hashmi, S; Hefazi, M; Hogan, WJ; Litzow, MR; Partain, DK; Patnaik, MM; Wolf, RC	1
Asano-Mori, Y; Ishiwata, K; Izutsu, K; Kageyama, K; Kaji, D; Makino, S; Masuoka, K; Nishida, A; Ota, H; Takagi, S; Taniguchi, S; Tsuji, M; Uchida, N; Wake, A; Yamamoto, G; Yamamoto, H; Yoneyama, A; Yuasa, M	1
Andou, T; Fujisawa, S; Hagihara, M; Ishii, Y; Itabashi, M; Koyama, S; Matsumoto, K; Motohashi, K; Numata, A; Yamamoto, W	1
Bang, SM; Kim, I; Koh, Y; Lee, JO; Park, H; Park, S; Yoon, SS; Youk, J	1
Allsup, D; Bloor, A; Collett, L; Hillmen, P; Hockaday, A; Howard, DR; Munir, T; Oughton, JB; Phillips, D; Rawstron, AC	1
Chen, P; Chen, X; Chen, Z; Hu, J; Hua, X; Le, S; Li, J; Lin, Q; Liu, T; Luo, X; Ren, J; Yang, T; Yuan, X; Zhang, L; Zheng, H; Zheng, J; Zheng, X; Zheng, Z	1
Dimopoulos, MA; Fotiou, D; Gavriatopoulou, M; Kastritis, E; Kyrtsonis, MC; Migkou, M; Mpakiri, M; Roussou, M; Tasidou, A; Terpos, E; Vassilakopoulos, TP	1
Abdulkadyrov, K; Błoński, JZ; Carey, JL; Chang, CN; Gorczyca, MM; Govind Babu, K; Grosicki, S; Gupta, IV; Homenda, W; Kryachok, I; Kuliczkowski, K; Kulyaba, Y; Kłoczko, J; Lisby, S; Loscertales, J; McKeown, A; Rekhtman, G; Robak, T; Warzocha, K	1
Choe, HK; Gergis, U; Mayer, SA; Nagar, H; Phillips, AA; Shore, TB; Smith, MJ; van Besien, K	1
Abdulkadyrov, K; Bal, V; Błoński, JZ; Chang, CN; Govind Babu, K; Grosicki, S; Gupta, IV; Homenda, W; Kryachok, I; Kuliczkowski, K; Kulyaba, Y; Kłoczko, J; Lisby, S; Loscertales, J; McKeown, A; Rekhtman, G; Robak, T; Warzocha, K	1
Belsito, V; Carella, AM; Cortellezzi, A; Cuneo, A; De Propris, MS; Ferretti, A; Foà, R; Guarini, AR; Liberati, AM; Marinelli, M; Mauro, FR; Molica, S; Nanni, M; Orlando, SM; Paoloni, F; Rizzi, R; Spriano, M; Tosi, P; Vignetti, M; Zaja, F	1
Ikegame, K; Inoue, T; Ishii, S; Kaida, K; Kojima, H; Kusunoki, Y; Ogawa, H; Okada, M; Saji, H; Soma, T; Tamaki, H; Yoshihara, K; Yoshihara, S	1
Abounader, DM; Andresen, S; Bolwell, BJ; Dean, R; Ferraro, C; Gerds, AT; Hamilton, BK; Hanna, R; Hill, BT; Kalaycio, M; Liu, H; Majhail, NS; Mustafa Ali, M; Pohlman, B; Rybicki, LA; Sobecks, RM; Starn, J; Winslow, V; Yurch, MA	1
Daly, A; Geddes, M; Lam, W; Li, H; Storek, J	1
Cairoli, R; Greco, R; Grillo, G; Mancini, V; Marbello, L; Molteni, A; Ravano, E; Riva, M; Zucchetti, E	1
Fabbri, A; Forconi, F; Gozzetti, A; Lauria, F; Lenoci, M; Raspadori, D; Sozzi, E; Tassi, M	1
Mattsson, J; Remberger, M; Ringdén, O; Svahn, BM	1
Camera, A; Cantore, N; Ferrara, F; Grimaldi, F; Guerriero, A; Luciano, L; Mastrullo, L; Mele, G; Mettivier, V; Miraglia, E; Palmieri, S; Rinaldi, CR; Rotoli, B	1
Agovi, MA; Bacigalupo, A; Bahlis, NJ; Ballen, K; Bredeson, CN; Brown, C; Chaudhry, MA; Horowitz, MM; Kurian, S; Muehlenbien, CE; Quinlan, D; Rizzo, JD; Russell, JA; Savoie, L; Stewart, DA; Zhang, MJ	1
Ambinder, RF; Bolaños-Meade, J; Brodsky, RA; Fuchs, EJ; Huff, CA; Jones, RJ; Kasamon, YL; Levy, MY; Luznik, L; Matsui, WH; Muth, M; Powell, JD; Smith, BD; Swinnen, LJ	1
Blum, KA; Brooker-McEldowney, M; Byrd, JC; Dalton, JT; Farley, KL; Fischer, B; Grever, MR; Heerema, NA; Hurh, E; Jarjoura, D; Johnson, AJ; Lin, TS; Mitchell, SM; Moran, ME; Phelps, MA; Rozewski, DM; Schaaf, LJ; Wu, D	1
Asano, S; Iseki, T; Kasahara, S; Kato, S; Konuma, T; Monma, F; Ooi, J; Sato, A; Takahashi, S; Tojo, A; Tomonari, A; Tsukada, N; Uchimaru, K	1
Borchmann, P; Elter, T; Engert, A; Hallek, M; Kilp, J; Schulz, H	1
Dumoulin, FL; Fischer, HP; Sauerbruch, T; Wasmuth, JC	1
Ativitavas, T; Jootar, S; Niparuck, P; Ungkanont, A	1
Ferrajoli, A	1
Bruns, I; Czibere, A; Fenk, R; Gräf, T; Haas, R; Kobbe, G; Schroeder, T; Zohren, F	1
Ahn, JS; Chae, YS; Cho, YY; Choi, YJ; Chung, JS; Kim, HJ; Kim, JG; Kim, YK; Lee, JJ; Lee, SR; Shin, HJ; Sohn, SK; Yang, DH	1
Chen, YM; Dou, HJ; Hu, JP; Tang, Y; Yao, YY; Zhu, Q; Zou, LF	1
Cao, TM; Franke, GN; Gyurkocza, B; Hoppe, R; Lange, T; Leisenring, W; Maloney, DG; Negrin, RS; Sandmaier, BM; Shizuru, JA; Sorror, M; Storb, RF	1
Brion, JP; Epaulard, O; Garin-Bastuji, B; Gressin, R; Maurin, M; Meneses, A; Pavese, P; Stahl, JP	1
Baurmann, H; Bethge, W; Bornhäuser, M; Brand, R; Burchert, A; Corradini, P; de Witte, TM; Dreger, P; Einsele, H; Holler, E; Kaufmann, M; Kobbe, G; Kröger, N; Kvasnicka, HM; Nagler, A; Niederwieser, D; Schubert, J; Schwerdtfeger, R; Stelljes, M; Thiele, J; Uharek, L; Wandt, H; Wulf, GG; Zabelina, T; Zander, AR	1
Buti, M; Esteban, R; Homs, M; Palacios, A; Rodriguez-Frias, F; Sanchez, MJ	1
Byrd, JC; Castro, J; Flinn, IW; Harris, S; Heerema, N; Hughes, S; Kipps, TJ; Leigh, B; Lin, TS; Molina, A; O'Brien, S; Tangri, S; Wierda, W; Woodworth, J; Wynne, D	1
Bruno, B; Chauncey, TR; Maloney, DG; Maris, MB; Nakamae, H; Panse, J; Petersdorf, E; Petersen, FB; Pulsipher, MA; Sandmaier, BM; Storb, R; Storek, J; Storer, BE; Wade, JC; Woolfrey, A	1
Bornhäuser, M; Brand, R; de Witte, T; Gahrton, G; Heinzelmann, M; Kröger, N; Morris, C; Nagler, A; Niederwieser, D; Schilling, G; Schwerdtfeger, R; Shimoni, A; Zander, AR	1
Hirayama, Y; Ishitani, K; Iyama, S; Kato, J; Kobune, M; Kohda, K; Koike, K; Kuroda, H; Neda, H; Sato, T; Takimoto, R; Terui, T	1
Aldridge, J; Alyea, EP; Antin, JH; Armand, P; Cutler, C; Ho, VT; Kim, HT; Koreth, J; Ritz, J; Soiffer, RJ	1
Chow, KU; Dreyling, M; Hess, G; Jäger, E; Kim, SZ; Krause, SW; Kruse, J; Mitrou, PS; Napieralski, S; Rech, J; Soekler, M; Subklewe, M; Weidmann, E; Weisel, KC	1
Elliott, B; Grosskreutz, C; Isola, L; Malone, A; Mandeli, J; Osman, K; Scigliano, E	1
Acholonu, S; Champlin, R; Dabaja, B; Donato, M; Duvic, M; Hosing, C; Khouri, I; Richmond, H; Singh, L; Wei, W	1
Brice, P; Copin, MC; Fermé, C; Feugier, P; Lamy, T; Morschhauser, F; Mounier, N; Sebban, C; Solal-Celigny, P; Tilly, H	1
Appelbaum, FR; Bedalov, A; Deeg, HJ; Doney, KC; Flowers, ME; Guthrie, KA; Hilger, RA; Kovacsovics, TJ; Maziarz, RT; Nemecek, ER; Pagel, JM; Sanders, JE; Scott, BL; Sickle, EJ; Sorror, ML; Witherspoon, R; Wood, BL; Woolfrey, AE	1
Anasetti, C; Ayala, E; Fernandez, H; Field, T; Kharfan-Dabaja, MA; Kim, J; Perez, L; Perkins, J; Pidala, J	1
Chao, NJ; Chute, JP; Gasparetto, C; Hogge, DE; Horwitz, ME; Kanda, J; Long, GD; Morris, A; Niedzwiecki, D; Nitta, J; Rizzieri, DA; Smith, CA; Song, K; Sullivan, KM	1
Béliveau, C; Cohen, S; Kent, D; Kiss, T; Labbé, AC; Lachance, S; Laverdière, M; Logvinenko, T; Martel-Laferrière, V; Roy, J; Snydman, DR; Su, SH	1
Aurora, M; Bachanova, V; Blazar, BR; Brunstein, C; Burns, L; Cao, Q; Cooley, S; Defor, T; Dusenbery, K; Kaufman, D; Macmillan, M; Majhail, NS; McClune, B; McGlave, P; Miller, J; Oran, B; Slungaard, A; Tomblyn, M; Vercellotti, G; Verneris, M; Wagner, J; Warlick, ED; Weisdorf, DJ	1
Choi, MK; Chung, CW; Hong, JY; Jang, JH; Kim, DH; Kim, HO; Kim, K; Kim, SJ; Kim, WS; Min, YH	1
Ancliff, P; Darbyshire, P; Goulden, N; Green, N; Hancock, J; Leighton, C; Love, S; Masurekar, A; Moorman, AV; Morgan, M; Parker, C; Révész, T; Saha, V; Sutton, R; Waters, R	1
Anasetti, C; Ayala, E; Fancher, K; Fernandez, H; Field, T; Gardiner, JA; Kharfan-Dabaja, MA; Kim, J; Miller, S; Milone, MC; Perez, L; Perkins, J; Shaw, LM; Tate, C	1
Chen, R; Delioukina, M; Forman, S; Kogut, N; Nademanee, A; Palmer, JM; Popplewell, L; Rosenthal, J; Shen, J; Smith, E	1
Badoux, XC; Burger, J; Faderl, S; Ferrajoli, A; Kantarjian, H; Keating, MJ; Koller, C; Lerner, S; O'Brien, SM; Wang, X; Wierda, WG	1
Schnaiter, A; Stilgenbauer, S	1
Castillo, JJ; Reagan, JL	1
Abraham, J; Andritsos, L; Benson, DM; Blum, W; Bunner, P; Craig, M; Cumpston, A; Devine, SM; Efebera, Y; Elder, P; Garzon, R; Gibson, L; Hamadani, M; Hofmeister, C; Leadmon, S; Penza, S; Phillips, GS; Remick, SC; Tse, W	1
Hivert, B; Leblond, V; Morel, P; Tamburini, J; Tournilhac, O; Vekhoff, A	1
Cavallin, M; Damante, G; Damiani, D; Fabbro, D; Fanin, R; Geromin, A; Michelutti, A; Pianta, A; Russo, D; Tiribelli, M	1
Batár, P; Kiss, A; Rejto, L; Reményi, G; Szász, R; Telek, B; Udvardy, M	1
Khouri, IF	1
Baumgart, J; Beelen, DW; Blau, IW; Casper, J; Einsele, H; Finke, J; Freund, M; Giebel, S; Gramatzki, M; Holowiecki, J; Kienast, J; Larsson, K; Markiewicz, M; Mylius, HA; Pichlmeier, U; Repp, R; Ruutu, T; Schnitzler, M; Stelljes, M; Stuhler, G; Trenschel, R; Uharek, L; Volin, L; Zander, AR	1
Cohen, GI; Fayad, LE; Kuepfer, C; Liebmann, JE; Modiano, MR; Pro, B; Romaguera, JE; Singer, JW; Srokowski, TP	1
Beksac, M; Björkstrand, B; Bosi, A; Corradini, P; de Witte, T; Gahrton, G; Goldschmidt, H; Greinix, H; Gruber, A; Hegenbart, U; Iacobelli, S; Milone, G; Morris, C; Musto, P; Narni, F; Niederwieser, D; Volin, L	1
Attolico, I; Crugnola, M; De Blasio, A; Ilariucci, F; Montillo, M; Morra, E; Petrizzi, VB; Ricci, F; Spedini, P; Spriano, M; Tedeschi, A; Uziel, L; Vismara, E; Zaccaria, A	1
Baccarani, M; Bandini, G; Bontadini, A; Curti, A; D'Addio, A; Dan, E; Fruet, F; Giudice, V; Isidori, A; Lemoli, RM; Martinelli, G; Motta, MR; Paolini, S; Parisi, S; Ruggeri, L; Trabanelli, S; Urbani, E; Velardi, A	1
Bahlo, J; Böttcher, S; Bühler, A; Busch, R; Cramer, P; Döhner, H; Eckart, MJ; Eichhorst, BF; Elter, T; Fischer, K; Goede, V; Hallek, M; Kiehl, M; Kneba, M; Kranz, G; Schweighofer, CD; Staib, P; Stilgenbauer, S; Wendtner, CM; Winkler, D	1
Acholonu, S; Alousi, AM; Anderlini, P; Champlin, RE; Chancoco, C; Ciurea, S; Fanale, MA; Hosing, CM; Khouri, IF; Ledesma, C; Nieto, Y; Popat, UR; Saliba, RM; Shpall, EJ; Valverde, R; Younes, A	1
Bloor, A; Bosch, F; Bühler, A; Chanan-Khan, AA; Coutré, S; Dreisbach, L; Ferrajoli, A; Frankfurt, O; Furman, RR; Gobbi, M; Gribben, JG; Hallek, M; Heerema, NA; Hillmen, P; Hurd, DD; Kimby, E; Mahadevan, D; Moutouh-de Parseval, L; Sekeres, MA; Shah, S; Stilgenbauer, S; Uharek, L; Wendtner, CM; Zhang, J	1
Brown, JR	1
Anasetti, C; Ayala, E; Fernandez, HF; Field, TL; Kharfan-Dabaja, MA; Kim, J; Perez, LE; Perkins, JB; Pidala, JA; Sullivan, DM; Tomblyn, MR	1
Connors, JM; Gerrie, AS; Zypchen, LN	1
Blaise, D; Castagna, L; Chabannon, C; Crocchiolo, R; Devillier, R; El Cheikh, J; Esterni, B; Etienne, A; Faucher, C; Fürst, S; Prebet, T; Vey, N	1
Faber, E; Hubacek, J; Indrak, K; Jarosova, M; Katrincsakova, B; Kurfurst, P; Pikalova, Z; Raida, L; Rusinakova, Z; Skoumalova, I; Tucek, P; Vondrakova, J	1
Bertz, H; Christopoulos, P; Finke, J; Ihorst, G; Marks, R; Wäsch, R	1
Agrawal, S; Auer, RL; Cavenagh, JD; Davies, JK; Gribben, JG; Lister, TA; MacDougall, F; Oakervee, HE; Syndercombe-Court, D; Taussig, D	1
Borthakur, G; Brandt, M; Burger, J; Cortes, J; Faderl, S; Gandhi, V; Garcia-Manero, G; Huang, X; Jabbour, E; Kadia, T; Kantarjian, H; Konopleva, M; O'Brien, S; Plunkett, W; Ravandi, F	1
Avery, S; Campbell, P; Coutsouvelis, J; Fong, CY; Grigoriadis, G; Hocking, J; Muirhead, J; Patil, S; Paul, E; Schwarer, A; Spencer, A; Walker, P; Wei, A	1
Bucher, C; Buser, A; Gerull, S; Halter, J; Heim, D; O'Meara, A; Passweg, J; Stern, M	1
Brychtova, Y; Chovancova, J; Doubek, M; Francova, HS; Horky, O; Krejci, M; Mayer, J; Navratil, M; Pospisilova, S; Stehlikova, O; Tichy, B; Tomiska, M	1
Dallas, MH; Hartford, C; Laver, J; Leung, W; Pillai, A; Shook, DR; Srinivasan, A; Triplett, BM	1
Agha, M; Boyiadzis, M; Duggal, S; Hou, JZ; Im, A; Lin, Y; McLaughlin, B; Raptis, A; Redner, R; Smith, C	1
Forman, SJ; Htut, M; Karanes, C; Krishnan, AY; Murata-Collins, J; Palmer, J; Rincon, A; Sahebi, F; Shen, Y; Somlo, G; Thomas, SH	1
Bacher, U; Bokemeyer, C; Fiedler, W; Haalck, T; Janjetovic, S; Janning, M	1
Blaise, D; Siddiqi, T	1
Bertz, H; Christopoulos, P; Finke, J; Marks, R; Schmoor, C; Wäsch, R; Waterhouse, M	1
Chakrabarti, S; Chakraverty, RK; Chopra, R; Devereux, S; Goldstone, AH; Hale, G; Kottaridis, PD; Linch, DC; MacKinnon, S; Mahendra, P; Marsh, JC; Milligan, DW; Morgan, GJ; Peggs, K; Pettengell, R; Robinson, S; Ruiz de Elvira, MC; Schey, S; Verfuerth, S; Waldmann, H; Williams, CD	1
Champlin, RE; Keating, MJ; Khouri, IF; Saliba, RM	1
Amir, G; Cohen, Y; Da'as, N; Gillis, S; Polliack, A; Rund, D	1
Böck, HP; Forstpointner, R; Hänel, A; Hartmann, F; Hermann, S; Hiddemann, W; Metzner, B; Pott, C; Repp, R; Rothmann, F; Unterhalt, M; Wandt, H	1
Altés, A; Bellosillo, B; Besalduch, J; Bosch, F; Cobo, F; Colomer, D; Esteve, J; Ferrer, A; Giné, E; López-Guillermo, A; Montserrat, E; Perales, M; Ribera, JM; Villamor, N	1
Adams, DJ; Chao, NJ; DeCastro, CM; Foster, T; Gasparetto, C; Gockerman, JP; Ibom, VK; Long, GD; Moore, JO; Payne, N; Rizzieri, DA; Rosner, GL; Thompson, M; Vredenburgh, JJ	1
Beyer, J; Bornhäuser, M; Ehninger, G; Fauser, AA; Hensel, M; Ho, AD; Kiehl, M; Kienast, J; Kröger, N; Neubauer, A; Scheffold, C; Schetelig, J; Schwerdtfeger, R; Siegert, W; Thiede, C; Zander, AR	1
Bay, JO; Bilger, K; Blaise, D; Chabannon, C; Choufi, B; Coso, D; Faucher, C; Maraninchi, D; Mohty, M; Stoppa, AM; Tournilhac, O; Vey, N; Viens, P	1
Anasetti, C; Appelbaum, FR; Bornhauser, M; Deeg, HJ; Ehninger, G; Hansen, J; Jenke, A; Martin, PJ; McDonald, GB; Nichols, WG; Radich, J; Schleyer, E; Slattery, JT; Storer, B; Thiede, C; Woolfrey, A	1
Kami, M; Kanda, Y; Makimoto, A; Mineishi, S; Nakai, K; Saito, T; Takaue, Y; Tanosaki, R; Tobinai, K; Wakasugi, H	1
Barker, JN; Blazar, BR; DeFor, TE; Miller, JS; Wagner, JE; Weisdorf, DJ	1
Amir, G; Cohen, Y; Da'as, N; Libster, D; Polliack, A	1
Alliot, C	1
Albitar, M; Cortes, J; Estey, E; Faderl, S; Garcia-Manero, G; Giles, FJ; Kantarjian, H; Thomas, D; Tsimberidou, A; Verstovsek, S	1
Cortes, JE; Estey, E; Faderl, S; Ferrajoli, A; Garcia-Manero, G; Giles, FJ; Kantarjian, HM; Keating, MJ; O'Brien, S; Thomas, DA; Tsimberidou, AM; Verstovsek, S	1
Huang, F; Liu, QF; Liu, XL; Meng, FY; Sun, J; Xu, B; Yang, LJ; Zhang, Y; Zheng, WY	1
Beelen, D; Bornhäuser, M; Ehninger, G; Fauser, AA; Held, TK; Kiehl, M; Kröger, N; Runde, V; Schetelig, J; Schwerdtfeger, R; Siegert, W; Thiede, C; Zabelina, T; Zander, A	1
Champlin, RE; Khouri, IF	1
Hamaki, T; Heike, Y; Hori, A; Imataki, O; Kami, M; Kim, SW; Kishi, Y; Kojima, R; Masuo, S; Miyakoshi, S; Murashige, N; Onishi, Y; Sakiyama, M; Takaue, Y; Taniguchi, S; Tanosaki, R; Tobinai, K	1
Bucher, C; Buser, AS; Gratwohl, A; Heim, D; Passweg, JR; Tichelli, A	1
Beran, M; Cortes, JE; Estey, E; Giles, FJ; Kantarjian, HM; O'Brien, SM	1
Käser, L; Kolyvanos Naumann, U; Vetter, W	1
Assmann, M; Bartsch, R; Eschenburg, H; Franke, A; Herold, M; Jentsch-Ullrich, K; Kahl, C; Knauf, W; Koenigsmann, M; Lakner, V; Mohren, M; Müller, G; Pasold, R	1
Baker, JE; Baron, F; Blume, KG; Chauncey, TR; Gooley, TA; Grumet, FC; Heimfeld, S; Little, MT; Maloney, DG; Maris, MB; Oparin, D; Radich, JP; Sandmaier, BM; Storb, R; Zellmer, E	1
Böck, HP; Dreyling, M; Forstpointner, R; Hänel, A; Hartmann, F; Hermann, S; Hiddemann, W; Metzner, B; Pott, C; Repp, R; Rohrberg, R; Rothmann, F; Unterhalt, M; Wandt, H	1
Balleari, E; Ballerini, F; Balocco, M; Canepa, L; Clavio, M; Garrone, A; Gobbi, M; Michelis, GL; Miglino, M; Pierri, I; Venturino, C	1
Baumbach, T; Benner, A; Ho, AD; Kerowgan, M; Kraemer, A; Leo, A; Leo, E; Mey, U; Parwaresch, R; Scheuer, L; Schmidt-Wolf, IG; Schmitt, C	1
Alegre, A; Ayuk, F; Beyer, J; Brand, R; Fauser, A; Kiehl, M; Klingemann, H; Kröger, N; Leon, A; Martino, R; Myint, H; Nagler, A; Perez-Simon, JA; San Miguel, JF; Sayer, HG; Schwerdtfeger, R; Shimoni, A; Tomas, JF; Zabelina, T; Zander, AR	1
Kolb, HJ; Ledderose, G; Rolf, B; Schleuning, M; Schnittger, S; Schoch, C; Schwerdtfeger, R; Weisser, M	1
Batár, P; Kiss, A; Méhes, L; Rejto, L; Telek, B; Udvardy, M	1
Cooper, BW; Creger, RJ; Gerson, SL; Gosky, D; Hoppel, CL; Ingalls, ST; Koc, ON; Lazarus, HM; Meyerson, HJ; Nowell, GM; Pearson, G; Radivoyevitch, T; Tilby, MJ; Veal, GJ	1
Alessandrino, EP; Bernasconi, P; Caldera, D; Colombo, AA; Lazzarino, M; Malcovati, L; Montanari, F; Troletti, D; Vanelli, L; Varettoni, M	1
Badowska, W; Balcerska, A; Balwierz, W; Czyzewski, K; Debski, R; Juraszewska, E; Konatkowska, B; Kowalczyk, J; Krawczuk-Rybak, M; Kuzmicz, M; Malinowska, I; Matysiak, M; Olejnik, I; Ploszynska, A; Sońta-Jakimczyk, D; Stanczak, E; Stefaniak, J; Styczynski, J; Szczepanski, T; Wachowiak, J; Wieczorek, M; Wysocki, M	1
Diaconescu, R; Maloney, DG; Maris, MB; McSweeney, P; Parikh, CR; Sandmaier, BM; Schrier, RW; Sorror, ML; Storb, R; Storer, B	1
Albitar, M; Beran, M; Cortes, J; Do, KA; Faderl, S; Ferrajoli, A; Garcia-Manero, G; Giles, F; Kantarjian, H; Keating, M; Koller, C; Lerner, S; O'Brien, S; Thomas, D; Wen, S; Wierda, W	1
Ayuk, F; Beyer, J; Binder, T; Bornhäuser, M; Eiermann, T; Iacobelli, S; Kiehl, M; Kröger, N; Madrigal, A; Marks, DI; Nagler, A; Peggs, K; Sayer, HG; Schwerdtfeger, R; Shaw, B; Shimoni, A; Zabelina, T; Zander, AR	1
Amin, CJ; Rabinowitz, I	1
Adler, SS; Enschede, SH; Gregory, SA; Porter, C; Rao, R; Shammo, JM; Venugopal, P	1
Hillmen, P; Johnson, SA; Owen, RG; Rule, SA; Seymour, JF; Thomas, DW; Wolf, MM	1
Ahmed, P; Anwar, M; Hashmi, KU; Hussain, I; Iqbal, H; Khan, B; Mahmood, A; Malik, HS; Raza, S	1
Carluccio, P; Ciuffreda, L; Liso, A; Liso, V; Mestice, A; Pastore, D; Pietrantuono, G; Rizzi, R; Specchia, G	1
Aulitzky, W; Borchmann, P; Elter, T; Engert, A; Gramatzki, M; Hallek, M; Hasan, I; Jensen, M; Josting, A; Rech, J; Reiser, M; Schinköthe, T; Schnell, R; Schulz, H; Staib, P; Stützer, H; Trelle, S	1
Baumgart, J; Casper, J; Freund, M; Grobe, N; Hähling, D; Hartung, G; Hilgendorf, I; Junghanss, C; Kahl, C; Lück, A; Pichlmeier, U; Steiner, B; Wilhelm, S; Wolff, D	1
Bhatia, M; Bradley, B; Cairo, MS; Cooney, E; Del Toro, G; Foley, S; Garvin, J; George, D; Harrison, L; Hawks, R; Militano, O; Roman, E; Satwani, P; Unal, E; van de Ven, C; Wolownik, K	1
Begum, G; Chopra, R; Cook, G; Cook, M; Craddock, C; Goldstone, A; Hale, G; Hunter, A; Jackson, G; Khwaja, A; Littlewood, T; Mackinnon, S; Mahendra, P; Marsh, J; Milligan, D; Parker, A; Peggs, K; Peniket, A; Russell, N; Tauro, S	1
Blau, IW; Fietz, T; Gentilini, C; Glass, B; Marinets, O; Muessig, A; Munz, DL; Rieger, K; Sandrock, D; Thiel, E; Uharek, L	1
Bornhäuser, M; Ehninger, G; Fruehauf, S; Kiehl, MG; Kienast, J; Kröger, N; Mundhenk, P; Sayer, HG; Schafer-Eckart, K; Scheid, C; Schwerdtfeger, R; Stelljes, M; Theuser, C; Wandt, H; Zander, AR	1
Cortes, J; Do, KA; Faderl, S; Ferrajoli, A; Garcia-Manero, G; Giles, F; Kantarjian, H; Keating, M; Lerner, S; O'brien, S; Ravandi-Kashani, F; Thomas, D; Wang, X; Wierda, W	1
Atanackovic, D; Ayuk, F; Dahlke, J; Kröger, N; Nagler, A; Panse, J; Renges, H; Schieder, H; Shimoni, A; Wolschke, C; Zabelina, T; Zander, A	1
Cairoli, R; Colosimo, A; Intropido, L; Miqueleiz, S; Montagna, M; Montillo, M; Morra, E; Nichelatti, M; Regazzi, M; Ricci, F; Scarpati, B; Tedeschi, A; Veronese, S	1
Kotani, T; Nakamura, Y; Ueda, M; Yamaguchi, M	1
Anderlini, P; Champlin, RE; Couriel, D; de Lima, M; Giralt, S; Hosing, C; Khouri, IF; Korbling, M; Lekakis, L; Martin, T; Shpall, EJ	1
Fujii, H; Goto, H; Ikuta, K; Isaki, S; Kajiwara, R; Kuroki, F; Takahashi, H; Yanagimachi, M; Yokota, S	1
Böck, HP; Dreyling, M; Einsele, H; Forstpointner, R; Hänel, A; Hartmann, F; Hiddemann, W; Lehmann, T; Metzner, B; Pott, C; Repp, R; Seymour, JF; Unterhalt, M; Wandt, H	1
Dmoszyńska, A; Giannopoulos, K; Roliński, J	1
Benedetti, F; Boccadoro, M; Chisesi, T; De Blasio, A; Drandi, D; Gallamini, A; Ladetto, M; Locasciulli, A; Majolino, I; Tarella, C	1
Alyea, EP; Antin, JH; Cutler, C; DeAngelo, DJ; Ho, V; Kim, HT; Ritz, J; Soiffer, RJ; Stone, R	1
Fujioka, T; Hasei, H; Ikegame, K; Inoue, T; Kaida, K; Kawakami, M; Kawase, I; Kim, EH; Masuda, T; Ogawa, H; Taniguchi, Y; Yoshihara, S	1
Anhalt, GJ; Cummins, DL; Meyerle, JH; Mimouni, D; Owens, N; Tzu, J	1
Hartmann, JT; Kanz, L; Klingel, K; Kröber, SM; Meisinger, I; Weisel, K	1
Abrahamsson, J; Clausen, N; Forestier, E; Gustafsson, G; Hasle, H; Heldrup, J; Hovi, L; Jonmundsson, G; Zeller, B	1
Bociek, RG; Boyd, TE; Chanan-Khan, AA; Koziner, B; Larratt, LM; Moore, JO; O'Brien, S; Pavletic, S; Rai, KR; Seymour, JF; Skotnicki, A	1
Allwinn, R; Beske, F; Klingebiel, T; Kriener, S; Lehrnbecher, T; Modrow, S; Schmidt, H; Schwabe, D; Sörensen, J	1
Blau, IW; Blau, O; Göldner, H; Hopfenmüller, W; Knauf, W; Leschinger, N; Schmidt-Hieber, M; Thiel, E	1
Blaise, D; Faucher, C; Mohty, M; Vey, N	1
Cantú-Rodríguez, OG; Gómez-Almaguer, D; Gonzalez-Llano, O; Gutierrez-Aguirre, CH; Jaime-Pérez, JC; Martinez-González, O; Morales-Toquero, A; Ruiz-Argüelles, GJ; Salazar-Riojas, R; Tarín-Arzaga, LC	1
Cho, BS; Cho, SG; Eom, KS; Kim, CC; Kim, DW; Kim, HJ; Kim, SY; Kim, YJ; Lee, JW; Lee, S; Min, CK; Min, WS	1
Goto, H; Ito, S; Kajiwara, R; Kuroki, F; Yanagimachi, M; Yokosuka, T; Yokota, S	1
Chae, YS; Cho, GJ; Cho, YY; Chung, JS; Kim, HJ; Kim, JG; Kim, YK; Lee, JJ; Moon, JH; Shin, HJ; Sohn, SK; Yang, DH	1
Giles, FJ; Gojo, I; Greer, J; Johnson, B; Karp, JE; Low, J; Morris, L; Sznol, M; Thein, M	1
Alousi, A; Anagnostopoulos, A; Anderlini, P; Carrasco-Yalan, A; Champlin, RE; Couriel, D; de Lima, M; Detry, MA; Giralt, S; Hosing, C; Kebriaei, P; Khouri, IF	1
Hardan, I; Herscovici, C; Nagler, A; Rand, A; Shem-Tov, N; Shimoni, A; Yerushalmi, R	1
Díaz, MA; González-Vicent, M; Madero, L; Pérez, A; Ramirez, M; Sevilla, J	1
Arai, Y; Doki, N; Ishida, F; Kano, Y; Kawai, Y; Komatsu, N; Miyawaki, S; Morii, T; Ogura, M; Ohno, R; Takeshita, A; Usui, N	1
Bertz, H; Finke, J; Grüllich, C; Müller, CI; Spyridonidis, A	1
Acholonu, S; Anderlini, P; Andersson, B; Champlin, RE; Couriel, D; de Lima, M; Fayad, L; Giralt, SA; Hagemeister, F; Hosing, C; Khouri, IF; Munsell, MF; Pro, B; Qazilbash, MH; Romaguera, J; Saliba, R; Ueno, NT; Younes, A	1
Altés, A; Asensio, A; Besalduch, J; Briones, J; Campo, E; Colomer, D; de Sevilla, AF; Domingo-Doménech, E; Escoda, L; Estany, C; Galán, P; Gardella, S; López-Guillermo, A; Montoto, S; Montserrat, E; Moreno, C; Oriol, A; Pedro, C; Ribera, JM; Vivancos, P	1
Cortes, J; Do, KA; Kantarjian, H; Keating, MJ; Lerner, S; O'Brien, S; Tam, CS; Thomas, DA; Wen, S; Wierda, W	1
Alousi, A; Anderlini, P; Champlin, RE; Couriel, D; de Lima, M; Fayad, L; Giralt, S; Hagemeister, F; Hosing, C; Khouri, IF; Korbling, M; Kwak, LW; Lee, MS; McLaughlin, P; Medeiros, LJ; Neelapu, SS; Saliba, RM; Samaniego, F; Samuels, BI; Ueno, NT	1
Auberger, J; Clausen, J; Erdel, M; Gastl, G; Gunsilius, E; Nachbaur, D; Petzer, A; Willenbacher, W	1
Casper, J; Freund, M; Giebel, S; Holowiecka-Goral, A; Holowiecki, J; Krawczyk-Kulis, M; Markiewicz, M; Wojnar, J	1
Bendandi, M; Tura, S; Zinzani, PL	1
Byrd, JC; Diehl, LF; Freiman, J; Hertler, AA; Kweder, SL; Weiss, RB	1
Leoni, P; Montillo, M; Tedeschi, A	1
Juliusson, G; Liliemark, J	1
Berman, E; Kempin, S; Spiess, T; Weiss, M	1
Bendandi, M; Benfenati, D; Bocchia, M; Fanin, R; Gozzetti, A; Lauria, F; Raspadori, D; Rondelli, D; Zaja, F; Zinzani, PL	1
Estey, E; Gandhi, V; Keating, MJ; Plunkett, W	1
Błasinka-Morawiec, M; Ceglarek, B; Dmoszynska, A; Durzynski, T; Dwilewicz-Trojaczek, J; Grieb, P; Hansz, J; Hellmann, A; Kasznicki, M; Komarnicki, M; Konopka, L; Kopec, I; Kotlarek-Haus, S; Krykowski, E; Lewandowski, K; Maj, S; Mazur, G; Potemski, P; Płuzanska, A; Robak, T; Sikorska, A; Skotnicki, AB; Urasinski, I; Zaucha, JM; Zdziarska, B	1
Bowen, AL; Catovsky, D; Dyer, MJ; Emmett, E; Matutes, E; Zomas, A	1
Bergmann, L	1
Hilgenfeld, E; Jäger, U; Knauf, WU; Mitterbauer, M; Wilfing, A	1
Bendandi, M; Gherlinzoni, F; Magagnoli, M; Merla, E; Tura, S; Zinzani, PL	1
Andreeff, M; Beran, M; Estey, EH; Kantarjian, HM; Keating, M; Kornblau, S; O'Brien, S; Pierce, S	1
Baccarani, M; Marin, L; Rogato, A; Russo, D; Silvestri, F; Zaja, F	1
Ferrara, F; Latagliata, R; Magrin, S; Mele, G; Mirto, S; Montillo, M; Petti, MC; Pinto, A; Tedeschi, A; Zagonel, V	1
Anderlini, P; Andersson, B; Champlin, R; Claxton, D; Donato, M; Gajewski, J; Gee, A; Giralt, S; Ippoliti, C; Keating, M; Khouri, IF; Körbling, M; O'Brien, S; Przepiorka, D; Ueno, N; von Wolff, B	1
Curti, A; Lemoli, RM; Leopardi, G; Motta, MR; Rizzi, S; Testoni, N; Tura, S; Visani, G	1
Brugiatelli, M; Callea, V; Iuliano, F; Kropp, MG; Levato, D; Molica, S; Morabito, F; Nobile, F; Oriana, V; Stelitano, C	1
Lossos, IS; Paltiel, O; Polliack, A	1
Hieke, K; Howard, P; Kerrigan, M; McIntyre, AM; Smartt, PF; Sweetenham, J; Townshend, S	1
Aitini, E; Battista, R; Bendandi, M; Bocchia, M; Cellini, C; De Renzo, A; Fattori, PP; Gentilini, P; Gherlinzoni, F; Guardigni, L; Magagnoli, M; Moretti, L; Ronconi, F; Tura, S; Zaccaria, A; Zinzani, PL	1
Horning, SJ	1
Balzarotti, M; Bonadonna, G; De Paoli, A; Luoni, M; Rampinelli, I; Santoro, A; Tondini, C; Valagussa, P	1
Bornhäuser, M; Ehninger, G; Freiberg-Richter, J; Helwig, A; Kroschinsky, F; Naumann, R; Neubauer, A; Platzbecker, U; Plettig, R; Röllig, C; Schuler, U; Thiede, C	1
Crawley, CR; Foran, JM; Gupta, RK; Johnson, PW; Johnson, SA; Lister, TA; Matthews, J; Micallef, IN; Radford, JA; Rohatiner, AZ; Summers, K; Sweetenham, JW	1
Chakrabarti, S; Chakraverty, RK; Chopra, R; de Elvira, MC; Devereux, S; Goldstone, AH; Hale, G; Kottaridis, PD; Linch, DC; Mackinnon, S; Mahendra, P; Marsh, JC; Milligan, DW; Morgan, GJ; Peggs, K; Pettengell, R; Robinson, S; Schey, S; Verfuerth, S; Waldmann, H; Williams, CD	1
Kelleher, JF; King, AK; Konefal, S; Monteleone, PM; Steele, DA	1
Chisesi, T; Congiu, AM; Gallamini, A; Gobbi, M; Marino, G; Mattei, D; Nati, S; Pierluigi, D; Rossi, E; Rubagotti, A; Santini, G; Sertoli, MR; Spriano, M; Truini, M; Vimercati, R	1
Aker, M; Brautbar, C; Nagler, A; Naparstek, E; Or, R; Slavin, S; Varadi, G	1
Cantú, OG; Gómez-Almaguer, D; González-Llano, O; Jaime-Pérez, JC; Ruiz-Argüelles, A; Ruiz-Argüelles, GJ	1
Akiyama, H; Hiruma, K; Kaku, H; Karasawa, K; Kono, N; Maeda, Y; Mizuchi, D; Mori, S; Ohashi, K; Okamoto, R; Okoshi, Y; Okuyama, Y; Sakamaki, H; Sasaki, E; Sasaki, T	1
Abonour, R; Kim, K; Longo, WL; Mosher, DF; Turman, NJ; Vidarsson, B; Wiersma, SR; Williams, EC; Woodson, RD	1
Ghalie, R; Gregory, SA; Kraemer, K; Menduni, T; Modiano, M; Rifkin, R; Rubin, A; Vose, J	1
Brandt, L; Glimelius, B; Kimby, E; Nygren, P	1
Churn, M; Clough, V	1
Amin, K; Chen, YH; Devine, H; Devine, SM; Huml, M; Jessop, E; Maningo, M; Peace, D; Sanborn, R; Stock, W; Thomason, D; van Besien, K; Wickrema, A; Yassine, M	1
Cazin, B; Deconinck, E; Desablens, B; Fermand, JP; Gardembas, M; Guibon, O; Guilhot, F; Harousseau, JL; Leblond, V; Lévy, V; Maloisel, F; Marit, G; Philippe, G; Porcher, R; Remenieras, L; Stamatoullas, A	1
Kabisch, H; Kröger, N; Krüger, W; Renges, H; Schetelig, J; Schrum, J; Siegert, W; Stute, N; Zabelina, T; Zander, AR	1
Beran, M; Cortes, JE; Estey, EH; Giles, FJ; Kantarjian, HM; O'Brien, S; Pierce, SA; Thall, PF; Wang, X	1
Anderlini, P; Cabanillas, FF; Champlin, RE; Donato, ML; Gajewski, JL; Giralt, SA; Hagemeister, FB; Ippoliti, C; Khouri, IF; Korbling, M; Lee, MS; McLaughlin, P; Okoroji, GJ; Saliba, RM; Younes, A	1
Benedetti, F; Bordignon, C; Bregni, M; Ciceri, F; Corradini, P; Dodero, A; Falda, M; Gianni, AM; Ladetto, M; Lucesole, M; Olivieri, A; Pileri, A; Rambaldi, A; Sajeva, MR; Tarella, C; Tresoldi, M; Voena, C; Zallio, F	1
Barrett, AJ; Carter, C; Childs, R; de Witte, M; Kang, EM; Leitman, SF; Little, R; Malech, H; Morgan, RA; Phang, S; Tisdale, JF	1
Fox, RM; Grigg, AP; Seymour, JF; Szer, J	1
Bertz, H; Finke, J; Illerhaus, G; Veelken, H	1
Mounter, PJ; Proctor, SJ; Summerfield, GP; Taylor, PR	1
Goldschmidt, H; Görner, M; Ho, AD; Kordelas, L; Luft, T; Moos, M; Pfeiffer, S; Punzel, M; Thalheimer, M; Ustaoglu, F; Weber-Nordt, R	1
Amir, G; Cohen, Y; Polliack, A	1
Bosanquet, AG; Chapman, CS; Hutchinson, RM; Parker, AN	1
Crowley, J; Eyre, HJ; Hynes, HE; Jaeckle, C; Pollock, TW; Stephens, RL; Taylor, SA	1
Danhauser, L; Gandhi, V; Iacoboni, S; Keating, M; Liliemark, J; Plunkett, W	1

Reviews

16 review(s) available for fludarabine and Recrudescence

Article	Year
Lenalidomide enhances the efficacy of anti-BCMA CAR-T treatment in relapsed/refractory multiple myeloma: a case report and revies of the literature. Cancer immunology, immunotherapy : CII, 2022, Volume: 71, Issue:1 Topics: B-Cell Maturation Antigen; Cyclophosphamide; Hematopoietic Stem Cell Transplantation; Humans; Immunoglobulin D; Immunologic Factors; Immunotherapy, Adoptive; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Proteasome Inhibitors; Receptors, Chimeric Antigen; Recurrence; Transplantation Conditioning; Treatment Outcome; Vidarabine	2022
Successful use of entecavir for a severe case of reactivation of hepatitis B virus following polychemotherapy containing rituximab. Journal of hepatology, 2009, Volume: 51, Issue:6 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Antiviral Agents; Guanine; Hepatitis B; Hepatitis B Surface Antigens; Hepatitis B virus; Humans; Immunosuppressive Agents; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Mutation; Recurrence; Rituximab; Vidarabine	2009
Refractory chronic lymphocytic leukemia--new therapeutic strategies. Oncotarget, 2010, Volume: 1, Issue:7 Topics: Antibodies, Monoclonal; Antineoplastic Agents; Drug Resistance, Neoplasm; Histone Deacetylase Inhibitors; Humans; Immunotherapy; Leukemia, Lymphocytic, Chronic, B-Cell; Recurrence; Survival Analysis; Therapies, Investigational; Vidarabine	2010
Ofatumumab for newly diagnosed and relapsed/refractory chronic lymphocytic leukemia. Expert review of anticancer therapy, 2011, Volume: 11, Issue:2 Topics: Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antigens, CD20; Antineoplastic Agents; Clinical Trials as Topic; Cytotoxicity, Immunologic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Recurrence; Vidarabine	2011
[Practical considerations and questions in the treatment of chronic lymphocytic leukemia]. Orvosi hetilap, 2011, Jun-12, Volume: 152, Issue:24 Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Drug Resistance, Neoplasm; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Molecular Targeted Therapy; Neoplasm, Residual; Prognosis; Recurrence; Remission Induction; Rituximab; Treatment Outcome; Vidarabine	2011
Allogeneic stem cell transplantation in follicular lymphoma. Best practice & research. Clinical haematology, 2011, Volume: 24, Issue:2 Topics: Animals; Antibodies, Monoclonal, Murine-Derived; Bone Marrow; Cyclophosphamide; Disease-Free Survival; Graft vs Host Disease; Graft vs Tumor Effect; Hematopoietic Stem Cell Transplantation; HLA Antigens; Humans; Lymphoma, Follicular; Mice; Myeloablative Agonists; Recurrence; Remission Induction; Risk Factors; Rituximab; Transplantation Conditioning; Transplantation, Autologous; Transplantation, Homologous; Vidarabine	2011
The treatment of relapsed refractory chronic lymphocytic leukemia. Hematology. American Society of Hematology. Education Program, 2011, Volume: 2011 Topics: Antineoplastic Agents; Drug Resistance, Neoplasm; Humans; Immunotherapy; Leukemia, Lymphocytic, Chronic, B-Cell; Recurrence; Vidarabine	2011
Does antithymocyte globulin have a place in reduced-intensity conditioning for allogeneic hematopoietic stem cell transplantation? Hematology. American Society of Hematology. Education Program, 2012, Volume: 2012 Topics: Adult; Antilymphocyte Serum; Child; Comorbidity; Cyclophosphamide; Cyclosporine; Graft vs Leukemia Effect; Hematology; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Leukemia, Myeloid, Acute; Male; Middle Aged; Randomized Controlled Trials as Topic; Recurrence; Stem Cell Transplantation; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine	2012
[Waldenstrom macroglobulinemia]. Praxis, 2004, Mar-31, Volume: 93, Issue:14 Topics: Adrenal Cortex Hormones; Anti-Inflammatory Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents, Alkylating; Blood Transfusion; Chlorambucil; Diagnosis, Differential; Drug Therapy, Combination; Follow-Up Studies; Humans; Immunosuppressive Agents; Male; Middle Aged; Plasmapheresis; Prednisone; Prognosis; Recurrence; Rituximab; Time Factors; Vidarabine; Waldenstrom Macroglobulinemia	2004
[New perspectives in the evolution of prognosis and treatment of chronic lymphocytic leukaemia]. Orvosi hetilap, 2004, Aug-29, Volume: 145, Issue:35 Topics: ADP-ribosyl Cyclase; ADP-ribosyl Cyclase 1; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cyclophosphamide; Humans; Immunotherapy; Leukemia, Lymphocytic, Chronic, B-Cell; Membrane Glycoproteins; Mutation; Predictive Value of Tests; Prognosis; Protein-Tyrosine Kinases; Recurrence; Remission Induction; Rituximab; Stem Cell Transplantation; Vidarabine; ZAP-70 Protein-Tyrosine Kinase	2004
Current status of reduced-intensity-conditioning allogeneic stem cell transplantation for acute myeloid leukemia. Haematologica, 2007, Volume: 92, Issue:4 Topics: Acute Disease; Adult; Aged; Antibodies, Monoclonal; Antilymphocyte Serum; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Clinical Trials as Topic; Combined Modality Therapy; Disease-Free Survival; Female; Graft vs Leukemia Effect; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid; Lymphocyte Depletion; Male; Middle Aged; Recurrence; Remission Induction; Survival Analysis; T-Lymphocytes; Time Factors; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine	2007
Present status of purine analogs in the therapy of chronic lymphocytic leukemias. Leukemia, 1997, Volume: 11 Suppl 2 Topics: Antineoplastic Agents; Cladribine; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Pentostatin; Prognosis; Recurrence; Remission Induction; Vidarabine	1997
Is there a place for 2-CDA in the treatment of B-CLL? Leukemia, 1997, Volume: 11 Suppl 2 Topics: Antineoplastic Agents; Cladribine; Clinical Trials as Topic; Drug Resistance, Neoplasm; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Recurrence; Thrombocytopenia; Vidarabine	1997
Follicular lymphoma: have we made any progress? Annals of oncology : official journal of the European Society for Medical Oncology, 2000, Volume: 11 Suppl 1 Topics: Antineoplastic Agents; Combined Modality Therapy; Dose-Response Relationship, Drug; Female; Genetic Therapy; Hematopoietic Stem Cell Transplantation; Humans; Interferons; Lymphoma, Follicular; Male; Prognosis; Recurrence; Survival Rate; Vidarabine	2000
Bilateral breast relapse in acute myelogenous leukemia. Journal of pediatric hematology/oncology, 2001, Volume: 23, Issue:2 Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy; Bone Marrow Transplantation; Breast; Child; Combined Modality Therapy; Cytarabine; Daunorubicin; Dexamethasone; Etoposide; Female; Graft vs Host Disease; Humans; Idarubicin; Immunologic Factors; Interleukin-2; Leukemia, Myeloid, Acute; Leukemic Infiltration; Radiotherapy, High-Energy; Recurrence; Salvage Therapy; Thioguanine; Transplantation Conditioning; Vidarabine	2001
A systematic overview of chemotherapy effects in B-cell chronic lymphocytic leukaemia. Acta oncologica (Stockholm, Sweden), 2001, Volume: 40, Issue:2-3 Topics: Adolescent; Adult; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Child; Clinical Trials as Topic; Combined Modality Therapy; Cyclophosphamide; Disease Progression; Doxorubicin; Humans; Leukemia, B-Cell; Prednisolone; Prognosis; Recurrence; Risk Factors; Salvage Therapy; Vidarabine; Vincristine	2001

Trials

129 trial(s) available for fludarabine and Recrudescence

Article	Year
Myeloablative conditioning with thiotepa-busulfan-fludarabine does not improve the outcome of patients transplanted with active leukemia: final results of the GITMO prospective trial GANDALF-01. Bone marrow transplantation, 2022, Volume: 57, Issue:6 Topics: Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia; Prospective Studies; Recurrence; Thiotepa; Transplantation Conditioning; Vidarabine	2022
Vorinostat Combined with Busulfan, Fludarabine, and Clofarabine Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Acute Leukemia: Long-Term Study Outcomes. Transplantation and cellular therapy, 2022, Volume: 28, Issue:8 Topics: Acute Disease; Busulfan; Clofarabine; Drug Therapy, Combination; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Recurrence; Vidarabine; Vorinostat	2022
Busulfan Plus Fludarabine Compared With Busulfan Plus Cyclophosphamide for AML Undergoing HLA-Haploidentical Hematopoietic Cell Transplantation: A Multicenter Randomized Phase III Trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2023, 10-10, Volume: 41, Issue:29 Topics: Adolescent; Adult; Aged; Busulfan; Cyclophosphamide; Drug Therapy, Combination; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Middle Aged; Recurrence; Transplantation Conditioning; Vidarabine; Young Adult	2023
FLA-IDA salvage chemotherapy combined with a seven-day course of venetoclax (FLAVIDA) in patients with relapsed/refractory acute leukaemia. British journal of haematology, 2020, Volume: 188, Issue:3 Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Humans; Leukemia; Male; Middle Aged; Recurrence; Salvage Therapy; Sulfonamides; Vidarabine	2020
Treatment of Testicular Relapse of B-cell Acute Lymphoblastic Leukemia With CD19-specific Chimeric Antigen Receptor T Cells. Clinical lymphoma, myeloma & leukemia, 2020, Volume: 20, Issue:6 Topics: Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cyclophosphamide; Humans; Immunotherapy, Adoptive; Male; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Testicular Neoplasms; Vidarabine	2020
KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma. The New England journal of medicine, 2020, 04-02, Volume: 382, Issue:14 Topics: Adult; Aged; Antigens, CD19; Antineoplastic Agents; Combined Modality Therapy; Humans; Immunotherapy, Adoptive; Infusions, Intravenous; Leukapheresis; Lymphoma, Mantle-Cell; Middle Aged; Receptors, Chimeric Antigen; Recurrence; Survival Analysis; T-Lymphocytes; Vidarabine	2020
Phase II trial of co-administration of CD19- and CD20-targeted chimeric antigen receptor T cells for relapsed and refractory diffuse large B cell lymphoma. Cancer medicine, 2020, Volume: 9, Issue:16 Topics: Adult; Aged; Anemia; Antigens, CD19; Antigens, CD20; Antineoplastic Agents; B-Lymphocytes; CD4-CD8 Ratio; Confidence Intervals; Cyclophosphamide; Cytokine Release Syndrome; Female; Glycolysis; Humans; Ifosfamide; Immunotherapy, Adoptive; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Neutropenia; Progression-Free Survival; Receptors, Chimeric Antigen; Recurrence; T-Lymphocytes; Thrombocytopenia; Time Factors; Transplantation Conditioning; Treatment Outcome; Vidarabine; Young Adult	2020
Augmented Reduced-Intensity Regimen Does Not Improve Postallogeneic Transplant Outcomes in Acute Myeloid Leukemia. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2021, 03-01, Volume: 39, Issue:7 Topics: Adult; Aged; Amsacrine; Busulfan; Cytarabine; Female; Graft vs Host Disease; Humans; Immunosuppressive Agents; Leukemia, Myeloid, Acute; Male; Middle Aged; Myeloablative Agonists; Myelodysplastic Syndromes; Progression-Free Survival; Recurrence; Stem Cell Transplantation; Time Factors; Transplantation Conditioning; Transplantation, Homologous; United Kingdom; Vidarabine; Young Adult	2021
Safety and efficacy of obinutuzumab alone or with chemotherapy in previously untreated or relapsed/refractory chronic lymphocytic leukaemia patients: Final analysis of the Phase IIIb GREEN study. British journal of haematology, 2021, Volume: 193, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Biomarkers, Pharmacological; Chlorambucil; Cyclophosphamide; Female; Humans; Immunoglobulin Heavy Chains; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm, Residual; Neutropenia; Non-Randomized Controlled Trials as Topic; Progression-Free Survival; Recurrence; Safety; Thrombocytopenia; Treatment Outcome; Vidarabine	2021
Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2017, Apr-10, Volume: 35, Issue:11 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cause of Death; Cyclosporine; Disease-Free Survival; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Melphalan; Middle Aged; Myelodysplastic Syndromes; Recurrence; Survival Rate; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation; Young Adult	2017
Reduced-Intensity Conditioning with Busulfan, Fludarabine, and Antithymocyte Globulin for Hematopoietic Cell Transplantation from Unrelated or Haploidentical Family Donors in Patients with Acute Myeloid Leukemia in Remission. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2017, Volume: 23, Issue:9 Topics: Acute Disease; Adolescent; Adult; Aged; Antilymphocyte Serum; Busulfan; Chronic Disease; Cyclophosphamide; Cyclosporine; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Histocompatibility Testing; Humans; Immunosuppressive Agents; Male; Methotrexate; Middle Aged; Multiple Myeloma; Myeloablative Agonists; Prospective Studies; Recurrence; Remission Induction; Siblings; Survival Analysis; Transplantation Conditioning; Transplantation, Haploidentical; Unrelated Donors; Vidarabine	2017
A phase I-II study of plerixafor in combination with fludarabine, idarubicin, cytarabine, and G-CSF (PLERIFLAG regimen) for the treatment of patients with the first early-relapsed or refractory acute myeloid leukemia. Annals of hematology, 2018, Volume: 97, Issue:5 Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzylamines; Cyclams; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Heterocyclic Compounds; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence; Remission Induction; Survival Rate; Vidarabine; Young Adult	2018
Busulfan- or Thiotepa-Based Conditioning in Myelofibrosis: A Phase II Multicenter Randomized Study from the GITMO Group. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2019, Volume: 25, Issue:5 Topics: Adult; Blood Donors; Busulfan; Female; Follow-Up Studies; Graft Survival; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Primary Myelofibrosis; Prognosis; Recurrence; Survival Analysis; Thiotepa; Transplantation Conditioning; Treatment Outcome; Vidarabine	2019
Phase II study of FLAGM (fludarabine + high-dose cytarabine + granulocyte colony-stimulating factor + mitoxantrone) for relapsed or refractory acute myeloid leukemia. International journal of hematology, 2019, Volume: 109, Issue:4 Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Disease-Free Survival; Female; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Recurrence; Survival Rate; Vidarabine	2019
Fludarabine and Total-Body Irradiation Conditioning before Ablative Haploidentical Transplantation: Long-Term Safety and Efficacy. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2019, Volume: 25, Issue:11 Topics: Acute Disease; Adult; Disease-Free Survival; Female; Follow-Up Studies; Graft vs Host Disease; Hematologic Neoplasms; Humans; Male; Middle Aged; Recurrence; Retrospective Studies; Survival Rate; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation	2019
The outcome of chronic lymphocytic leukemia patients who relapsed after fludarabine, cyclophosphamide, and rituximab. European journal of haematology, 2013, Volume: 90, Issue:6 Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-Free Survival; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Recurrence; Retrospective Studies; Rituximab; Survival Rate; Time Factors; Vidarabine	2013
A phase I study of CPX-351 in combination with busulfan and fludarabine conditioning and allogeneic stem cell transplantation in adult patients with refractory acute leukemia. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2013, Volume: 19, Issue:7 Topics: Adult; Aged; Busulfan; Case-Control Studies; Cytarabine; Daunorubicin; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myeloablative Agonists; Prognosis; Recurrence; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Vidarabine	2013
Phase I-II clinical trial of oxaliplatin, fludarabine, cytarabine, and rituximab therapy in aggressive relapsed/refractory chronic lymphocytic leukemia or Richter syndrome. Clinical lymphoma, myeloma & leukemia, 2013, Volume: 13, Issue:5 Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Disease Progression; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Recurrence; Rituximab; Transplantation, Homologous; Treatment Outcome; Vidarabine	2013
Chemomodulation of sequential high-dose cytarabine by fludarabine in relapsed or refractory acute myeloid leukemia: a randomized trial of the AMLCG. Leukemia, 2014, Volume: 28, Issue:5 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Prognosis; Recurrence; Survival Analysis; Vidarabine; Young Adult	2014
Treosulfan, fludarabine, and 2-Gy total body irradiation followed by allogeneic hematopoietic cell transplantation in patients with myelodysplastic syndrome and acute myeloid leukemia. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2014, Volume: 20, Issue:4 Topics: Adolescent; Adult; Busulfan; Child; Child, Preschool; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Infant; Leukemia, Myeloid, Acute; Male; Middle Aged; Myeloablative Agonists; Myelodysplastic Syndromes; Neoplasm, Residual; Prospective Studies; Recurrence; Remission Induction; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation	2014
Extramedullary relapse following total marrow and lymphoid irradiation in patients undergoing allogeneic hematopoietic cell transplantation. International journal of radiation oncology, biology, physics, 2014, May-01, Volume: 89, Issue:1 Topics: Adolescent; Adult; Age Factors; Aged; Antineoplastic Agents; Blast Crisis; Bone Marrow; Busulfan; Child; Cyclophosphamide; Etoposide; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Lymphatic Irradiation; Melphalan; Middle Aged; Myelodysplastic Syndromes; Organ Sparing Treatments; Organs at Risk; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prospective Studies; Radiotherapy Dosage; Recurrence; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation; Young Adult	2014
PTK2 expression and immunochemotherapy outcome in chronic lymphocytic leukemia. Blood, 2014, Jul-17, Volume: 124, Issue:3 Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; Disease-Free Survival; Focal Adhesion Kinase 1; Gene Expression; Humans; Immunotherapy; Leukemia, Lymphocytic, Chronic, B-Cell; Proportional Hazards Models; Recurrence; Retrospective Studies; Rituximab; RNA, Messenger; RNA, Neoplasm; Vidarabine	2014
A randomized, open-label, multicentre, phase 2/3 study to evaluate the safety and efficacy of lumiliximab in combination with fludarabine, cyclophosphamide and rituximab versus fludarabine, cyclophosphamide and rituximab alone in subjects with relapsed ch British journal of haematology, 2014, Volume: 167, Issue:4 Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Recurrence; Rituximab; Vidarabine	2014
BFR (bendamustine, fludarabine, and rituximab) allogeneic conditioning for chronic lymphocytic leukemia/lymphoma: reduced myelosuppression and GVHD. Blood, 2014, Oct-02, Volume: 124, Issue:14 Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Bendamustine Hydrochloride; Combined Modality Therapy; Drug Combinations; Female; Graft vs Host Disease; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma; Male; Middle Aged; Nitrogen Mustard Compounds; Recurrence; Rituximab; Transplantation Conditioning; Transplantation, Homologous; Vidarabine	2014
Poor efficacy and tolerability of R-CHOP in relapsed/refractory chronic lymphocytic leukemia and Richter transformation. American journal of hematology, 2014, Volume: 89, Issue:12 Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Hemoglobins; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Prednisone; Purpura, Thrombocytopenic, Idiopathic; Recurrence; Rituximab; Survival Analysis; Treatment Failure; Vidarabine; Vincristine	2014
Phase II, multicenter, randomized trial of CPX-351 (cytarabine:daunorubicin) liposome injection versus intensive salvage therapy in adults with first relapse AML. Cancer, 2015, Jan-15, Volume: 121, Issue:2 Topics: Adult; Aged; Aminoglycosides; Amsacrine; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Cytarabine; Daunorubicin; Disease-Free Survival; Etoposide; Female; Gemtuzumab; Humans; Injections; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Liposomes; Male; Middle Aged; Mitoxantrone; Recurrence; Remission Induction; Risk Assessment; Salvage Therapy; Treatment Outcome; Vidarabine	2015
Reduced-toxicity myeloablative conditioning consisting of 8-Gy total body irradiation, cyclophosphamide and fludarabine for pediatric hematological malignancies. Scientific reports, 2014, Nov-06, Volume: 4 Topics: Adolescent; Child; Child, Preschool; Cyclophosphamide; Female; Gamma Rays; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Infant; Leukemia; Male; Myeloablative Agonists; Myelodysplastic Syndromes; Quality of Life; Recurrence; Retrospective Studies; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation; Young Adult	2014
Treosulfan-fludarabine-thiotepa conditioning before allogeneic haemopoietic stem cell transplantation for patients with advanced lympho-proliferative disease. A single centre study. Hematological oncology, 2016, Volume: 34, Issue:1 Topics: Adult; Bone Marrow Transplantation; Busulfan; Combined Modality Therapy; Disease-Free Survival; Female; Graft Survival; Graft vs Host Disease; Hematologic Neoplasms; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Peripheral Blood Stem Cell Transplantation; Recurrence; Remission Induction; Salvage Therapy; Thiotepa; Transplantation Conditioning; Transplantation, Autologous; Transplantation, Homologous; Treatment Outcome; Vidarabine; Young Adult	2016
Final results of EFC6663: a multicenter, international, phase 2 study of alvocidib for patients with fludarabine-refractory chronic lymphocytic leukemia. Leukemia research, 2015, Volume: 39, Issue:5 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Female; Flavonoids; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Piperidines; Recurrence; Survival Analysis; Treatment Failure; Vidarabine	2015
Umbilical cord blood transplantation in adults with advanced hodgkin's disease: high incidence of post-transplant lymphoproliferative disease. European journal of haematology, 2016, Volume: 96, Issue:2 Topics: Acute Disease; Adult; Antilymphocyte Serum; Busulfan; Chronic Disease; Cord Blood Stem Cell Transplantation; Cyclophosphamide; Female; Graft Survival; Graft vs Host Disease; Herpesvirus 4, Human; Hodgkin Disease; Humans; Infectious Mononucleosis; Male; Middle Aged; Myeloablative Agonists; Recurrence; Survival Analysis; Thiotepa; Transplantation Conditioning; Vidarabine	2016
Busulfan and fludarabine conditioning regimen given at hematological nadir of cytoreduction fludarabine, cytarabine, and idarubicin chemotherapy in patients with refractory acute myeloid leukemia undergoing allogeneic stem cell transplantation: a single a Medicine, 2015, Volume: 94, Issue:15 Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cytarabine; Disease-Free Survival; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence; Remission Induction; Stem Cell Transplantation; Transplantation Conditioning; Vidarabine; Young Adult	2015
Unmanipulated Haploidentical Reduced-Intensity Stem Cell Transplantation Using Fludarabine, Busulfan, Low-Dose Antithymocyte Globulin, and Steroids for Patients in Non-Complete Remission or at High Risk of Relapse: A Prospective Multicenter Phase I/II Stu Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2015, Volume: 21, Issue:8 Topics: Adult; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Female; Hematopoietic Stem Cell Transplantation; Humans; Japan; Male; Middle Aged; Prospective Studies; Recurrence; Steroids; Transplantation Conditioning; Vidarabine	2015
Obatoclax in combination with fludarabine and rituximab is well-tolerated and shows promising clinical activity in relapsed chronic lymphocytic leukemia. Leukemia & lymphoma, 2015, Volume: 56, Issue:12 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Chromosome Aberrations; Combined Modality Therapy; Disease Progression; Female; Humans; Indoles; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Mutation; Neoplasm Staging; Pyrroles; Recurrence; Retreatment; Rituximab; Treatment Outcome; Vidarabine	2015
Phase I/II Trial of Dose-Escalated Busulfan Delivered by Prolonged Continuous Infusion in Allogeneic Transplant Patients. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2015, Volume: 21, Issue:12 Topics: Adult; Area Under Curve; Busulfan; Drug Administration Schedule; Female; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Myeloablative Agonists; Prospective Studies; Recurrence; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine	2015
A Phase 2 Trial of Fludarabine Combined With Subcutaneous Alemtuzumab for the Treatment of Relapsed/Refractory B-Cell Chronic Lymphocytic Leukemia. Clinical lymphoma, myeloma & leukemia, 2015, Volume: 15, Issue:11 Topics: Adult; Aged; Aged, 80 and over; Alemtuzumab; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Female; Follow-Up Studies; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Recurrence; Retreatment; Treatment Outcome; Vidarabine	2015
Bendamustine plus rituximab versus fludarabine plus rituximab for patients with relapsed indolent and mantle-cell lymphomas: a multicentre, randomised, open-label, non-inferiority phase 3 trial. The Lancet. Oncology, 2016, Volume: 17, Issue:1 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Disease-Free Survival; Female; Humans; Infections; Lymphoma, Mantle-Cell; Male; Middle Aged; Recurrence; Retreatment; Rituximab; Survival Rate; Treatment Outcome; Vidarabine	2016
Toxicity and efficacy of busulfan and fludarabine myeloablative conditioning for HLA-identical sibling allogeneic hematopoietic cell transplantation in AML and MDS. Bone marrow transplantation, 2016, Volume: 51, Issue:7 Topics: Adult; Aged; Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Hepatic Veno-Occlusive Disease; Histocompatibility; Humans; Leukemia, Myeloid, Acute; Middle Aged; Mucositis; Myeloablative Agonists; Myelodysplastic Syndromes; Recurrence; Survival Analysis; Transplantation Conditioning; Vidarabine; Young Adult	2016
Results of a phase II study of vorinostat in combination with intravenous fludarabine, mitoxantrone, and dexamethasone in patients with relapsed or refractory mantle cell lymphoma: an interim analysis. Cancer chemotherapy and pharmacology, 2016, Volume: 77, Issue:4 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Hydroxamic Acids; Infusions, Intravenous; Lymphoma, Mantle-Cell; Male; Middle Aged; Mitoxantrone; Quality of Life; Recurrence; Vidarabine; Vorinostat	2016
Reduced-Intensity Conditioning with Fludarabine, Cyclophosphamide, and High-Dose Rituximab for Allogeneic Hematopoietic Cell Transplantation for Follicular Lymphoma: A Phase Two Multicenter Trial from the Blood and Marrow Transplant Clinical Trials Networ Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2016, Volume: 22, Issue:8 Topics: Adult; Aged; Antineoplastic Agents, Immunological; Cyclophosphamide; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Follicular; Middle Aged; Myeloablative Agonists; Recurrence; Remission Induction; Rituximab; Salvage Therapy; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine	2016
Chemotherapy plus Ofatumumab at Standard or Mega dose in relapsed CLL (COSMIC) trial: study protocol for a phase II randomised controlled trial. Trials, 2016, 09-20, Volume: 17, Issue:1 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Clinical Protocols; Cyclophosphamide; Drug Dosage Calculations; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Neoplasm, Residual; Recurrence; Research Design; Time Factors; Treatment Outcome; United Kingdom; Vidarabine	2016
Phase 2 study of ofatumumab, fludarabine and cyclophosphamide in relapsed/refractory Waldenström's macroglobulinemia. Leukemia & lymphoma, 2017, Volume: 58, Issue:6 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Drug Resistance, Neoplasm; Humans; Recurrence; Retreatment; Survival Analysis; Treatment Outcome; Vidarabine; Waldenstrom Macroglobulinemia	2017
Ofatumumab plus fludarabine and cyclophosphamide in relapsed chronic lymphocytic leukemia: results from the COMPLEMENT 2 trial. Leukemia & lymphoma, 2017, Volume: 58, Issue:5 Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Humans; Kaplan-Meier Estimate; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm Grading; Neoplasm Staging; Recurrence; Treatment Outcome; Vidarabine	2017
Fludarabine, cyclophosphamide and lenalidomide in patients with relapsed/refractory chronic lymphocytic leukemia. A multicenter phase I-II GIMEMA trial. Leukemia & lymphoma, 2017, Volume: 58, Issue:7 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cause of Death; Cyclophosphamide; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Maximum Tolerated Dose; Middle Aged; Recurrence; Remission Induction; Survival Analysis; Thalidomide; Treatment Outcome; Vidarabine	2017
Low-dose oral fludarabine plus cyclophosphamide in elderly patients with untreated and relapsed or refractory chronic lymphocytic Leukaemia. Hematological oncology, 2008, Volume: 26, Issue:4 Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Drug Resistance, Neoplasm; Female; Humans; Immune Tolerance; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Recurrence; Vidarabine	2008
Sequential continuous infusion of fludarabine and cytarabine associated with liposomal daunorubicin (DaunoXome) (FLAD) in primary refractory or relapsed adult acute myeloid leukemia patients. Annals of hematology, 2009, Volume: 88, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Disease-Free Survival; Female; Humans; Infusions, Intravenous; Leukemia, Myeloid, Acute; Liposomes; Male; Middle Aged; Recurrence; Salvage Therapy; Stem Cell Transplantation; Survival Rate; Time Factors; Vidarabine	2009
Clinical response and pharmacokinetics from a phase 1 study of an active dosing schedule of flavopiridol in relapsed chronic lymphocytic leukemia. Blood, 2009, Mar-19, Volume: 113, Issue:12 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Area Under Curve; Cell Cycle; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Flavonoids; Humans; Inactivation, Metabolic; Infusions, Intravenous; Injections, Intravenous; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Models, Biological; Piperidines; Protein Kinase Inhibitors; Recurrence; Salvage Therapy; Treatment Outcome; Tumor Lysis Syndrome; Uridine Diphosphate Glucuronic Acid; Vidarabine	2009
Incorporating the use of GM-CSF in the treatment of chronic lymphocytic leukemia. Leukemia & lymphoma, 2009, Volume: 50, Issue:3 Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Recurrence; Remission Induction; Rituximab; Salvage Therapy; Treatment Outcome; Vidarabine	2009
Fludarabine, amsacrine, high-dose cytarabine and 12 Gy total body irradiation followed by allogeneic hematopoietic stem cell transplantation is effective in patients with relapsed or high-risk acute lymphoblastic leukemia. Bone marrow transplantation, 2009, Volume: 44, Issue:12 Topics: Adolescent; Adult; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Disease-Free Survival; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Risk Factors; Survival Rate; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation	2009
[Clinical study on fludarabine combined with cytarabine regimen in the treatment of patients with refractory and relapsed acute myeloid leukemia]. Zhongguo shi yan xue ye xue za zhi, 2009, Volume: 17, Issue:3 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence; Vidarabine	2009
Allogeneic stem cell transplantation after reduced-intensity conditioning in patients with myelofibrosis: a prospective, multicenter study of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Blood, 2009, Dec-17, Volume: 114, Issue:26 Topics: Adult; Aged; Busulfan; Disease-Free Survival; Female; Graft vs Host Disease; Humans; Male; Middle Aged; Myeloablative Agonists; Primary Myelofibrosis; Recurrence; Stem Cell Transplantation; Transplantation Conditioning; Transplantation, Homologous; Vidarabine	2009
Phase 1/2 study of lumiliximab combined with fludarabine, cyclophosphamide, and rituximab in patients with relapsed or refractory chronic lymphocytic leukemia. Blood, 2010, Jan-21, Volume: 115, Issue:3 Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Recurrence; Rituximab; Vidarabine	2010
Low-dose total body irradiation and fludarabine conditioning for HLA class I-mismatched donor stem cell transplantation and immunologic recovery in patients with hematologic malignancies: a multicenter trial. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2010, Volume: 16, Issue:3 Topics: Adolescent; Adult; Aged; Blood Cell Count; Cell Count; Communicable Diseases; Dendritic Cells; Disease-Free Survival; Female; Graft Rejection; Graft vs Host Disease; Hematologic Neoplasms; Histocompatibility; Histocompatibility Antigens Class I; Humans; Kaplan-Meier Estimate; Lymphocytes; Male; Middle Aged; Myeloablative Agonists; Peripheral Blood Stem Cell Transplantation; Postoperative Complications; Recurrence; T-Lymphocytes; Tissue Donors; Transplantation Chimera; Transplantation Conditioning; Treatment Outcome; Vidarabine; Whole-Body Irradiation; Young Adult	2010
A phase II study of alemtuzumab, fludarabine, cyclophosphamide, and doxorubicin (Campath-FCD) in peripheral T-cell lymphomas. Leukemia & lymphoma, 2010, Volume: 51, Issue:3 Topics: Adult; Aged; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Female; Humans; Lymphoma, T-Cell; Male; Middle Aged; Recurrence; Treatment Outcome; Vidarabine	2010
Total skin electron beam and non-myeloablative allogeneic hematopoietic stem-cell transplantation in advanced mycosis fungoides and Sezary syndrome. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, May-10, Volume: 28, Issue:14 Topics: Adult; Antibodies, Monoclonal; Antilymphocyte Serum; Disease Progression; Disease-Free Survival; Female; Graft vs Host Disease; Graft vs Tumor Effect; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Kaplan-Meier Estimate; Male; Melphalan; Methotrexate; Middle Aged; Mycosis Fungoides; Myeloablative Agonists; Recurrence; Sezary Syndrome; Tacrolimus; Time Factors; Transplantation Chimera; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Whole-Body Irradiation; Young Adult	2010
Efficacy and safety of the combination of rituximab, fludarabine, and mitoxantrone for rituximab-naive, recurrent/refractory follicular non-Hodgkin lymphoma with high tumor burden: a multicenter phase 2 trial by the Groupe d'Etude des Lymphomes de l'Adult Cancer, 2010, Sep-15, Volume: 116, Issue:18 Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Lymphoma, Follicular; Male; Middle Aged; Mitoxantrone; Neoplasms, Second Primary; Recurrence; Rituximab; Tumor Burden; Vidarabine	2010
Conditioning with treosulfan and fludarabine followed by allogeneic hematopoietic cell transplantation for high-risk hematologic malignancies. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2011, Volume: 17, Issue:3 Topics: Adolescent; Adult; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Child; Child, Preschool; Female; Hematologic Neoplasms; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Risk Factors; Survival Analysis; Transplantation Conditioning; Vidarabine; Young Adult	2011
Reduced-intensity conditioning followed by related allografts in hematologic malignancies: long-term outcomes most successful in indolent and aggressive non-Hodgkin lymphomas. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2011, Volume: 17, Issue:7 Topics: Adult; Aged; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; Disease-Free Survival; Female; Graft vs Tumor Effect; Hematologic Neoplasms; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Myelodysplastic Syndromes; Peripheral Blood Stem Cell Transplantation; Prospective Studies; Recurrence; Survival Rate; T-Lymphocytes; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Whole-Body Irradiation; Young Adult	2011
Effect of mitoxantrone on outcome of children with first relapse of acute lymphoblastic leukaemia (ALL R3): an open-label randomised trial. Lancet (London, England), 2010, Dec-11, Volume: 376, Issue:9757 Topics: Adolescent; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool; Cyclophosphamide; Cytarabine; Dexamethasone; Disease-Free Survival; Etoposide; Female; Humans; Idarubicin; Infant; Kaplan-Meier Estimate; Leukocyte Count; Male; Mercaptopurine; Methotrexate; Mitoxantrone; Polyethylene Glycols; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Risk Assessment; Treatment Outcome; United Kingdom; Vidarabine; Vincristine	2010
Fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy is highly effective treatment for relapsed patients with CLL. Blood, 2011, Mar-17, Volume: 117, Issue:11 Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-Free Survival; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Middle Aged; Multivariate Analysis; Neoplasm, Residual; Proportional Hazards Models; Recurrence; Rituximab; Time Factors; Treatment Outcome; Vidarabine	2011
Reduced-toxicity conditioning with treosulfan and fludarabine in allogeneic hematopoietic stem cell transplantation for myelodysplastic syndromes: final results of an international prospective phase II trial. Haematologica, 2011, Volume: 96, Issue:9 Topics: Adult; Antineoplastic Agents; Busulfan; Chimerism; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Myelodysplastic Syndromes; Recurrence; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Young Adult	2011
Pixantrone dimaleate in combination with fludarabine, dexamethasone, and rituximab in patients with relapsed or refractory indolent non-Hodgkin lymphoma: phase 1 study with a dose-expansion cohort. Cancer, 2011, Nov-15, Volume: 117, Issue:22 Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Isoquinolines; Lymphoma, Non-Hodgkin; Male; Middle Aged; Recurrence; Retreatment; Rituximab; Vidarabine	2011
An open-label, pilot study of fludarabine, cyclophosphamide, and alemtuzumab in relapsed/refractory patients with B-cell chronic lymphocytic leukemia. Blood, 2011, Oct-13, Volume: 118, Issue:15 Topics: Administration, Oral; Adult; Aged; Alemtuzumab; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-Free Survival; Female; Humans; Injections, Subcutaneous; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Pilot Projects; Recurrence; Survival Rate; Time Factors; Vidarabine	2011
Successful transfer of alloreactive haploidentical KIR ligand-mismatched natural killer cells after infusion in elderly high risk acute myeloid leukemia patients. Blood, 2011, Sep-22, Volume: 118, Issue:12 Topics: Antigens, CD; Cell Separation; Cyclophosphamide; Flow Cytometry; Graft vs Leukemia Effect; Hematopoietic Stem Cell Transplantation; Histocompatibility Testing; Humans; Immunophenotyping; Immunosuppressive Agents; Immunotherapy, Adoptive; Interleukin-2; Killer Cells, Natural; Leukapheresis; Leukemia, Myeloid, Acute; Male; Middle Aged; Receptors, KIR; Recurrence; Remission Induction; Risk Factors; Transplantation, Homologous; Vidarabine	2011
Bendamustine combined with rituximab in patients with relapsed and/or refractory chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2011, Sep-10, Volume: 29, Issue:26 Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Drug Resistance, Neoplasm; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Intention to Treat Analysis; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm, Residual; Nitrogen Mustard Compounds; Prospective Studies; Recurrence; Rituximab; Survival Analysis; Vidarabine	2011
Gemcitabine, fludarabine and melphalan as a reduced-intensity conditioning regimen for allogeneic stem cell transplant in relapsed and refractory Hodgkin lymphoma: preliminary results. Leukemia & lymphoma, 2012, Volume: 53, Issue:3 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Hodgkin Disease; Humans; Kaplan-Meier Estimate; Male; Melphalan; Middle Aged; Recurrence; Remission Induction; Salvage Therapy; Stem Cell Transplantation; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Young Adult	2012
Final results of a multicenter phase 1 study of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia. Leukemia & lymphoma, 2012, Volume: 53, Issue:3 Topics: Adjuvants, Immunologic; Adult; Aged; Aged, 80 and over; Allopurinol; Antimetabolites, Antineoplastic; Dose-Response Relationship, Immunologic; Drug Resistance, Neoplasm; Female; Humans; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neutropenia; Recurrence; Salvage Therapy; Thalidomide; Thrombocytopenia; Tumor Lysis Syndrome; Vidarabine	2012
Maximally tolerated busulfan systemic exposure in combination with fludarabine as conditioning before allogeneic hematopoietic cell transplantation. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2012, Volume: 18, Issue:7 Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Busulfan; Drug Administration Schedule; Drug Dosage Calculations; Female; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Myeloablative Agonists; Prospective Studies; Recurrence; Survival Rate; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine	2012
Twice-daily fludarabine and cytarabine combination with or without gentuzumab ozogamicin is effective in patients with relapsed/refractory acute myeloid leukemia, high-risk myelodysplastic syndrome, and blast- phase chronic myeloid leukemia. Clinical lymphoma, myeloma & leukemia, 2012, Volume: 12, Issue:4 Topics: Adult; Aged; Aged, 80 and over; Aminoglycosides; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Cytarabine; Disease-Free Survival; Gemtuzumab; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Middle Aged; Myelodysplastic Syndromes; Prognosis; Recurrence; Remission Induction; Risk Factors; Survival Analysis; Vidarabine; Young Adult	2012
Allogeneic stem cell transplantation for relapsed or refractory lymphoma after conditioning with BEAM/fludarabine/TBI. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2013, Volume: 19, Issue:1 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Disease-Free Survival; Female; Graft vs Host Disease; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma; Melphalan; Middle Aged; Myeloablative Agonists; Podophyllotoxin; Recurrence; Stem Cell Transplantation; Survival Rate; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation	2013
Fludarabine with cytarabine followed by reduced-intensity conditioning and allogeneic hematopoietic stem cell transplantation in patients with poor-risk chronic lymphocytic leukemia. Annals of hematology, 2013, Volume: 92, Issue:2 Topics: Adult; Alemtuzumab; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Cyclophosphamide; Cytarabine; Dexamethasone; Disease Progression; Drug Resistance, Neoplasm; Female; Humans; Immunosuppressive Agents; Kaplan-Meier Estimate; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm, Residual; Peripheral Blood Stem Cell Transplantation; Prednisolone; Prospective Studies; Recurrence; Risk; Rituximab; Salvage Therapy; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Vincristine; Whole-Body Irradiation	2013
Fludarabine and cytarabine in patients with relapsed acute myeloid leukemia refractory to initial salvage therapy. International journal of hematology, 2012, Volume: 96, Issue:6 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemical and Drug Induced Liver Injury; Cytarabine; Etoposide; Female; Gastrointestinal Diseases; Hematologic Diseases; Humans; Karyotype; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Neoplasms, Second Primary; Recurrence; Remission Induction; Salvage Therapy; Vidarabine	2012
In vivo CAMPATH-1H prevents GvHD following nonmyeloablative stem-cell transplantation. Cytotherapy, 2001, Volume: 3, Issue:3 Topics: Adolescent; Adult; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Agents, Alkylating; Drug Therapy, Combination; Female; Graft Survival; Graft vs Host Disease; Hematologic Neoplasms; Humans; Immunosuppression Therapy; Immunosuppressive Agents; Male; Melphalan; Middle Aged; Recurrence; Stem Cell Transplantation; Survival Rate; Transplantation Chimera; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine	2001
[Increased response rate with rituximab in relapsed and refractory follicular and mantle cell lymphomas -- results of a prospective randomized study of the German Low-Grade Lymphoma Study Group]. Deutsche medizinische Wochenschrift (1946), 2002, Oct-25, Volume: 127, Issue:43 Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antimetabolites; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Female; Humans; Immunosuppressive Agents; Immunotherapy; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Male; Middle Aged; Mitoxantrone; Recurrence; Remission Induction; Retrospective Studies; Rituximab; Time Factors; Vidarabine	2002
Fludarabine, cyclophosphamide and mitoxantrone in the treatment of resistant or relapsed chronic lymphocytic leukaemia. British journal of haematology, 2002, Volume: 119, Issue:4 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cell Survival; Cyclophosphamide; Disease-Free Survival; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Mitoxantrone; Recurrence; Survival Rate; Treatment Outcome; Tumor Cells, Cultured; Vidarabine	2002
Phase I evaluation of prolonged-infusion gemcitabine with fludarabine for relapsed or refractory acute myelogenous leukemia. Clinical cancer research : an official journal of the American Association for Cancer Research, 2003, Volume: 9, Issue:2 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Deoxycytidine; Esophagitis; Gemcitabine; Humans; Infusions, Intravenous; Injections, Intravenous; Leukemia, Myeloid, Acute; Metabolic Clearance Rate; Middle Aged; Recurrence; Stomatitis; Vidarabine	2003
Conditioning with fludarabine and targeted busulfan for transplantation of allogeneic hematopoietic stem cells. Blood, 2003, Aug-01, Volume: 102, Issue:3 Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Child; Female; Follow-Up Studies; Graft Survival; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Myelodysplastic Syndromes; Peripheral Blood Stem Cell Transplantation; Recurrence; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Vidarabine	2003
Rapid and complete donor chimerism in adult recipients of unrelated donor umbilical cord blood transplantation after reduced-intensity conditioning. Blood, 2003, Sep-01, Volume: 102, Issue:5 Topics: Adult; Aged; Busulfan; Cord Blood Stem Cell Transplantation; Fetal Blood; Graft Survival; Graft vs Host Disease; Humans; Immunosuppressive Agents; Incidence; Middle Aged; Recurrence; Risk Factors; Survival Rate; Transplantation Chimera; Transplantation Conditioning; Vidarabine	2003
Gemtuzumab ozogamicin, fludarabine, cytarabine and cyclosporine combination regimen in patients with CD33+ primary resistant or relapsed acute myeloid leukemia. Leukemia research, 2003, Volume: 27, Issue:10 Topics: Acute Disease; Adult; Aged; Aminoglycosides; Anti-Bacterial Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Antineoplastic Combined Chemotherapy Protocols; Cyclosporine; Cytarabine; Drug Resistance, Neoplasm; Female; Gemtuzumab; Humans; Leukemia, Myeloid; Male; Middle Aged; Platelet Count; Recurrence; Remission Induction; Sialic Acid Binding Ig-like Lectin 3; Survival Rate; Vidarabine	2003
[Effect of modified FLAG regimen therapy on 33 patients with relapsed/refractory leukemia]. Ai zheng = Aizheng = Chinese journal of cancer, 2003, Volume: 22, Issue:12 Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Child; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Treatment Outcome; Vidarabine	2003
Nonmyeloablative stem cell transplantation for lymphoma. Seminars in oncology, 2004, Volume: 31, Issue:1 Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Drug Administration Schedule; Graft vs Host Disease; Humans; Immunosuppressive Agents; Lymphoma; Middle Aged; Recurrence; Rituximab; Stem Cell Transplantation; Survival Rate; Transplantation Conditioning; Vidarabine	2004
Reduced-intensity stem cell transplantation from an HLA-identical sibling donor in patients with myeloid malignancies. Bone marrow transplantation, 2004, Volume: 33, Issue:9 Topics: Adult; Aged; Antilymphocyte Serum; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Busulfan; CD3 Complex; Cladribine; Disease-Free Survival; Feasibility Studies; Female; Graft vs Host Disease; Graft vs Leukemia Effect; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Histocompatibility Testing; HLA Antigens; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Recurrence; Time Factors; Transplantation Chimera; Transplantation, Homologous; Treatment Outcome; Vidarabine	2004
High-dose chemotherapy using BEAM for tumor debulking without stem cell support followed by early allogeneic reduced intensity conditioning transplantation to induce a graft-versus-lymphoma effect in patients with high risk or refractory lymphoma. Bone marrow transplantation, 2004, Volume: 33, Issue:10 Topics: Adolescent; Adult; Antineoplastic Agents; Disease Progression; Drug Therapy; Female; Graft vs Tumor Effect; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Lymphoma; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neutropenia; Prognosis; Prospective Studies; Recurrence; Remission Induction; Risk; Time Factors; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine	2004
A fludarabine, topotecan, and cytarabine regimen is active in patients with refractory acute myelogenous leukemia. Leukemia research, 2004, Volume: 28, Issue:4 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence; Remission Induction; Topotecan; Treatment Outcome; Vidarabine	2004
Fludarabine and bendamustine in refractory and relapsed indolent lymphoma--a multicenter phase I/II Trial of the east german society of hematology and oncology (OSHO). Leukemia & lymphoma, 2004, Volume: 45, Issue:9 Topics: Adult; Aged; Bendamustine Hydrochloride; Female; Germany; Hematology; Humans; Lymphoma; Male; Medical Oncology; Middle Aged; Neoplasm Staging; Nitrogen Mustard Compounds; Recurrence; Remission Induction; Societies, Medical; Time Factors; Vidarabine	2004
The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell Blood, 2004, Nov-15, Volume: 104, Issue:10 Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Humans; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Male; Middle Aged; Mitoxantrone; Prospective Studies; Recurrence; Rituximab; Survival Analysis; Vidarabine	2004
Combination of liposomal daunorubicin (DaunoXome), fludarabine, and cytarabine (FLAD) in patients with poor-risk acute leukemia. Annals of hematology, 2004, Volume: 83, Issue:11 Topics: Acute Disease; Adolescent; Adult; Aged; Cytarabine; Daunorubicin; Drug Therapy, Combination; Female; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid; Male; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Risk Factors; Survival Rate; Vidarabine	2004
Significant thrombocytopenia associated with the addition of rituximab to a combination of fludarabine and cyclophosphamide in the treatment of relapsed follicular lymphoma. European journal of haematology, 2004, Volume: 73, Issue:4 Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Humans; Lymphoma, Follicular; Male; Middle Aged; Recurrence; Rituximab; Vidarabine	2004
Relapse to prior autograft and chronic graft-versus-host disease are the strongest prognostic factors for outcome of melphalan/fludarabine-based dose-reduced allogeneic stem cell transplantation in patients with multiple myeloma. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2004, Volume: 10, Issue:10 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chronic Disease; Female; Graft Survival; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Prognosis; Recurrence; Remission Induction; Salvage Therapy; Survival Analysis; Transplantation, Autologous; Transplantation, Homologous; Treatment Outcome; Vidarabine	2004
Reduced-intensity conditioning using TBI (8 Gy), fludarabine, cyclophosphamide and ATG in elderly CML patients provides excellent results especially when performed in the early course of the disease. Bone marrow transplantation, 2004, Volume: 34, Issue:12 Topics: Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; Dose-Response Relationship, Radiation; Female; Follow-Up Studies; Graft Survival; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Recurrence; Survival Analysis; Time Factors; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation	2004
A phase I and pharmacodynamic study of fludarabine, carboplatin, and topotecan in patients with relapsed, refractory, or high-risk acute leukemia. Clinical cancer research : an official journal of the American Association for Cancer Research, 2004, Oct-15, Volume: 10, Issue:20 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; DNA Adducts; Drug Resistance, Neoplasm; Female; Humans; Infusions, Intravenous; Leukemia, Myeloid, Acute; Male; Maximum Tolerated Dose; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prognosis; Recurrence; Topotecan; Vidarabine	2004
Reduced-intensity conditioning regimen with thiotepa and fludarabine followed by allogeneic blood stem cell transplantation in haematological malignancies. Bone marrow transplantation, 2004, Volume: 34, Issue:12 Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Blood Transfusion; Female; Graft Survival; Hematologic Neoplasms; Humans; Male; Middle Aged; Peripheral Blood Stem Cell Transplantation; Recurrence; Remission Induction; Survival Analysis; Thiotepa; Transplantation Chimera; Transplantation Conditioning; Transplantation, Homologous; Vidarabine	2004
The combination of fludarabine, cyclophosphamide, and granulocyte-macrophage colony-stimulating factor in the treatment of patients with relapsed chronic lymphocytic leukemia and low-grade Non-Hodgkin's lymphoma. Clinical lymphoma, 2005, Volume: 6, Issue:1 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Neoplasm Staging; Neutropenia; Patient Selection; Recurrence; Treatment Outcome; Vidarabine	2005
Fludarabine in combination with alemtuzumab is effective and feasible in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: results of a phase II trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, Oct-01, Volume: 23, Issue:28 Topics: Adult; Aged; Aged, 80 and over; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Drug Resistance, Neoplasm; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Recurrence; Treatment Outcome; Vidarabine	2005
Preliminary results of the safety of immunotherapy with gemtuzumab ozogamicin following reduced intensity allogeneic stem cell transplant in children with CD33+ acute myeloid leukemia. Clinical cancer research : an official journal of the American Association for Cancer Research, 2005, Oct-01, Volume: 11, Issue:19 Pt 2 Topics: Adolescent; Aminoglycosides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Busulfan; Child; Child, Preschool; Combined Modality Therapy; Female; Gemtuzumab; Graft vs Host Disease; Histocompatibility Testing; Humans; Immunotherapy; Infant; Leukemia, Myeloid, Acute; Male; Pilot Projects; Recurrence; Sialic Acid Binding Ig-like Lectin 3; Stem Cell Transplantation; Time Factors; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine	2005
Allogeneic stem-cell transplantation using a reduced-intensity conditioning regimen has the capacity to produce durable remissions and long-term disease-free survival in patients with high-risk acute myeloid leukemia and myelodysplasia. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, Dec-20, Volume: 23, Issue:36 Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Female; Graft vs Host Disease; Humans; Leukemia, Myeloid; Male; Melphalan; Middle Aged; Myelodysplastic Syndromes; Recurrence; Risk Factors; Stem Cell Transplantation; Survival Analysis; Transplantation, Homologous; Treatment Outcome; Vidarabine	2005
Reduced-toxicity conditioning with treosulfan, fludarabine and ATG as preparative regimen for allogeneic stem cell transplantation (alloSCT) in elderly patients with secondary acute myeloid leukemia (sAML) or myelodysplastic syndrome (MDS). Bone marrow transplantation, 2006, Volume: 37, Issue:4 Topics: Acute Disease; Adult; Aged; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Disease-Free Survival; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; HLA Antigens; Humans; Leukemia, Myeloid; Male; Middle Aged; Myelodysplastic Syndromes; Prospective Studies; Recurrence; Siblings; Survival Rate; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine	2006
Alemtuzumab as consolidation after a response to fludarabine is effective in purging residual disease in patients with chronic lymphocytic leukemia. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, May-20, Volume: 24, Issue:15 Topics: Adult; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antigens, CD34; Antineoplastic Agents; Antiviral Agents; Cytomegalovirus Infections; Feasibility Studies; Female; Ganciclovir; Hematopoietic Stem Cells; Humans; Injections, Subcutaneous; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm, Residual; Peripheral Blood Stem Cell Transplantation; Recurrence; Remission Induction; Treatment Outcome; Vidarabine	2006
Phase II study of unrelated cord blood transplantation for adults with high-risk hematologic malignancies. Bone marrow transplantation, 2006, Volume: 38, Issue:6 Topics: Adult; Antilymphocyte Serum; Cord Blood Stem Cell Transplantation; Disease-Free Survival; Female; Follow-Up Studies; Graft Rejection; Graft Survival; Graft vs Host Disease; Hematologic Neoplasms; Humans; Immunosuppressive Agents; Male; Melphalan; Methotrexate; Middle Aged; Myeloablative Agonists; Recurrence; Risk Factors; Tacrolimus; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation	2006
Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular Blood, 2006, Dec-15, Volume: 108, Issue:13 Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-Free Survival; Female; Germany; Humans; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Male; Middle Aged; Mitoxantrone; Prospective Studies; Recurrence; Remission Induction; Rituximab; Salvage Therapy; Survival Rate; Vidarabine	2006
Unmanipulated HLA 2-3 antigen-mismatched (haploidentical) stem cell transplantation using nonmyeloablative conditioning. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2006, Volume: 12, Issue:10 Topics: Adult; Antilymphocyte Serum; Bone Marrow; Busulfan; CD4 Lymphocyte Count; Combined Modality Therapy; Cytokines; Disease-Free Survival; Family; Female; Graft Survival; Graft vs Host Disease; Hematologic Neoplasms; Histocompatibility; HLA Antigens; Humans; Immunosuppressive Agents; Incidence; Male; Methylprednisolone; Middle Aged; Myelodysplastic Syndromes; Peripheral Blood Stem Cell Transplantation; Recurrence; Remission Induction; T-Lymphocytes; Tacrolimus; Tissue Donors; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine	2006
Randomized phase III trial of fludarabine plus cyclophosphamide with or without oblimersen sodium (Bcl-2 antisense) in patients with relapsed or refractory chronic lymphocytic leukemia. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2007, Mar-20, Volume: 25, Issue:9 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Drug Administration Schedule; Female; Follow-Up Studies; Genes, bcl-2; Humans; Kaplan-Meier Estimate; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Oligonucleotides, Antisense; Proportional Hazards Models; Recurrence; Thionucleotides; Time Factors; Treatment Failure; Treatment Outcome; Vidarabine	2007
Non-myeloablative hematopoietic stem cell transplantation is of limited value in advanced or refractory acute myeloblastic leukemia. The Mexican experience. Hematology (Amsterdam, Netherlands), 2007, Volume: 12, Issue:3 Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Child; Child, Preschool; Cyclophosphamide; Cyclosporine; Graft Survival; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Mexico; Middle Aged; Recurrence; Salvage Therapy; Transplantation Conditioning; Treatment Outcome; Vidarabine	2007
The beneficial effect of chronic graft-versus-host disease on the clinical outcome of transplantation with fludarabine/busulfan-based reduced-intensity conditioning for patients with de novo myelodysplastic syndrome. International journal of hematology, 2007, Volume: 85, Issue:5 Topics: Adolescent; Adult; Antineoplastic Agents; Busulfan; Chronic Disease; Female; Follow-Up Studies; Graft vs Host Disease; Graft vs Tumor Effect; Hematopoietic Stem Cell Transplantation; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Myeloablative Agonists; Myelodysplastic Syndromes; Recurrence; Transplantation Chimera; Transplantation Conditioning; Transplantation, Homologous; Vidarabine	2007
A phase I study of the novel ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, Triapine) in combination with the nucleoside analog fludarabine for patients with refractory acute leukemias and aggressive myeloprol Leukemia research, 2008, Volume: 32, Issue:1 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Myeloproliferative Disorders; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyridines; Recurrence; Thiosemicarbazones; Treatment Outcome; Vidarabine	2008
Phase I trial of FLAGM with high doses of cytosine arabinoside for relapsed, refractory acute myeloid leukemia: study of the Japan Adult Leukemia Study Group (JALSG). International journal of hematology, 2007, Volume: 86, Issue:4 Topics: Adult; Cytarabine; Dose-Response Relationship, Drug; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Granulocyte Colony-Stimulating Factor; Humans; Japan; Leukemia, Myeloid, Acute; Middle Aged; Mitoxantrone; Recurrence; Vidarabine	2007
A fludarabine, thiotepa reduced toxicity conditioning regimen designed specifically for allogeneic second haematopoietic cell transplantation after failure of previous autologous or allogeneic transplantation. Bone marrow transplantation, 2008, Volume: 41, Issue:10 Topics: Adult; Aged; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Cyclosporine; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Lymphoma; Male; Middle Aged; Multiple Myeloma; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Survival Rate; Thiotepa; Transplantation Conditioning; Transplantation, Autologous; Transplantation, Homologous; Treatment Failure; Vidarabine	2008
Fludarabine-melphalan as a preparative regimen for reduced-intensity conditioning allogeneic stem cell transplantation in relapsed and refractory Hodgkin's lymphoma: the updated M.D. Anderson Cancer Center experience. Haematologica, 2008, Volume: 93, Issue:2 Topics: Adult; Disease-Free Survival; Female; Follow-Up Studies; Hodgkin Disease; Hospitals, University; Humans; Male; Melphalan; Middle Aged; Myeloablative Agonists; Pilot Projects; Prospective Studies; Recurrence; Stem Cell Transplantation; Survival Rate; Tissue Donors; Transplantation Conditioning; Transplantation, Homologous; Vidarabine	2008
High clinical and molecular response rates with fludarabine, cyclophosphamide and mitoxantrone in previously untreated patients with advanced stage follicular lymphoma. Haematologica, 2008, Volume: 93, Issue:2 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; beta 2-Microglobulin; Cyclophosphamide; Disease-Free Survival; Female; Follow-Up Studies; Humans; Lymphoma, Follicular; Male; Middle Aged; Mitoxantrone; Neoplasm Staging; Recurrence; Survival Rate; Vidarabine	2008
Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia. Blood, 2008, Aug-15, Volume: 112, Issue:4 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Follow-Up Studies; Humans; Infections; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Prognosis; Recurrence; Remission Induction; Rituximab; Survival Analysis; Treatment Outcome; Vidarabine	2008
Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximab. Blood, 2008, Jun-15, Volume: 111, Issue:12 Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; B-Lymphocytes; Combined Modality Therapy; Cyclophosphamide; Female; Follow-Up Studies; Graft vs Host Disease; Graft vs Tumor Effect; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Follicular; Male; Middle Aged; Myeloablative Agonists; Prospective Studies; Recurrence; Remission Induction; Rituximab; Survival Rate; Transplantation Chimera; Transplantation Conditioning; Transplantation, Homologous; Vidarabine	2008
Treosulfan and fludarabine low-toxicity conditioning for allogeneic haematopoietic stem cell transplantation in chronic myeloid leukaemia. British journal of haematology, 2008, Volume: 142, Issue:2 Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Busulfan; Disease-Free Survival; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Recurrence; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Young Adult	2008
FMP regimen (fludarabine, mitoxantrone, prednisone) as therapy in recurrent low-grade non-Hodgkin's lymphoma. European journal of haematology, 1995, Volume: 55, Issue:4 Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Mitoxantrone; Neoplasm Staging; Prednisone; Recurrence; Vidarabine	1995
Fludarabine: an active agent in the treatment of previously-treated and untreated low-grade non-Hodgkin's lymphoma. Annals of oncology : official journal of the European Society for Medical Oncology, 1993, Volume: 4, Issue:7 Topics: Adult; Aged; Antineoplastic Agents; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Recurrence; Remission Induction; Survival Analysis; Vidarabine	1993
Intermittent 2-hour intravenous infusions of 2-chlorodeoxyadenosine in the treatment of 110 patients with refractory or previously untreated B-cell chronic lymphocytic leukemia. Leukemia & lymphoma, 1996, Volume: 22, Issue:5-6 Topics: Adult; Aged; Antineoplastic Agents; Cladribine; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Infusions, Intravenous; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm Staging; Recurrence; Vidarabine	1996
Fludarabine-mitoxantrone combination-containing regimen in recurrent low-grade non-Hodgkin's lymphoma. Annals of oncology : official journal of the European Society for Medical Oncology, 1997, Volume: 8, Issue:4 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Mitoxantrone; Prednisone; Recurrence; Treatment Outcome; Vidarabine	1997
Fludarabine, cytarabine, and G-CSF (FLAG) for the treatment of poor risk acute myeloid leukemia. American journal of hematology, 1998, Volume: 58, Issue:2 Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Child; Cytarabine; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid; Male; Middle Aged; Recurrence; Retreatment; Risk Factors; Survival Rate; Transplantation, Autologous; Vidarabine	1998
Fludarabine-based chemotherapy in untreated mantle cell lymphomas: an encouraging experience in 29 patients. Haematologica, 1999, Volume: 84, Issue:11 Topics: Adult; Aged; Agranulocytosis; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Idarubicin; Lymphoma, Mantle-Cell; Male; Middle Aged; Prospective Studies; Recurrence; Risk Factors; Survival Rate; Treatment Outcome; Vidarabine	1999
Fludarabine and cladribine in relapsed/refractory low-grade non-Hodgkin's lymphoma: a phase II randomized study. Annals of oncology : official journal of the European Society for Medical Oncology, 2000, Volume: 11, Issue:2 Topics: Adult; Aged; Antineoplastic Agents; Cladribine; Confidence Intervals; Cross-Over Studies; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Hematologic Diseases; Humans; Infusions, Intravenous; Lymphoma, Non-Hodgkin; Male; Middle Aged; Recurrence; Survival Rate; Vidarabine	2000
A phase II study to evaluate the combination of fludarabine, mitoxantrone and dexamethasone (FMD) in patients with follicular lymphoma. Annals of oncology : official journal of the European Society for Medical Oncology, 2000, Volume: 11, Issue:7 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; DNA, Neoplasm; Female; Humans; Lymphoma, Follicular; Male; Middle Aged; Mitoxantrone; Polymerase Chain Reaction; Recurrence; Treatment Outcome; Vidarabine	2000
In vivo CAMPATH-1H prevents graft-versus-host disease following nonmyeloablative stem cell transplantation. Blood, 2000, Oct-01, Volume: 96, Issue:7 Topics: Adolescent; Adult; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Agents; Cyclosporine; Drug Therapy, Combination; Female; Graft vs Host Disease; Granulocyte Colony-Stimulating Factor; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Histocompatibility Testing; Humans; Immunosuppressive Agents; Male; Melphalan; Methotrexate; Microsatellite Repeats; Middle Aged; Nuclear Family; Polymerase Chain Reaction; Recurrence; Transplantation Chimera; Transplantation Conditioning; Treatment Outcome; Vidarabine	2000
Fludarabine in combination with cyclophosphamide or with cyclophosphamide plus mitoxantrone for relapsed or refractory low-grade non-Hodgkin's lymphoma. Haematologica, 2001, Volume: 86, Issue:3 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Mitoxantrone; Recurrence; Treatment Outcome; Vidarabine	2001
Mitoxantrone and fludarabine in the treatment of patients with non-Hodgkin's lymphoma failing primary therapy with a doxorubicinor mitoxantrone-containing regimen. Leukemia & lymphoma, 2001, Volume: 40, Issue:3-4 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Disease-Free Survival; Doxorubicin; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Mitoxantrone; Recurrence; Remission Induction; Salvage Therapy; Survival Rate; Treatment Failure; Vidarabine	2001
Fludarabine and melphalan-based conditioning for patients with advanced hematological malignancies relapsing after a previous hematopoietic stem cell transplant. Bone marrow transplantation, 2001, Volume: 28, Issue:6 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cause of Death; Female; Graft Survival; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Male; Melphalan; Middle Aged; Recurrence; Salvage Therapy; Survival Rate; Transplantation Chimera; Transplantation Conditioning; Treatment Outcome; Vidarabine	2001
Multicenter, randomized comparative trial of fludarabine and the combination of cyclophosphamide-doxorubicin-prednisone in 92 patients with Waldenström macroglobulinemia in first relapse or with primary refractory disease. Blood, 2001, Nov-01, Volume: 98, Issue:9 Topics: Adult; Aged; Alopecia; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Drug Resistance; Female; Humans; Male; Middle Aged; Mouth Mucosa; Prednisone; Recurrence; Salvage Therapy; Stomatitis; Survival Analysis; Therapeutic Equivalency; Treatment Outcome; Vidarabine; Waldenstrom Macroglobulinemia	2001
Comparison of idarubicin + ara-C-, fludarabine + ara-C-, and topotecan + ara-C-based regimens in treatment of newly diagnosed acute myeloid leukemia, refractory anemia with excess blasts in transformation, or refractory anemia with excess blasts. Blood, 2001, Dec-15, Volume: 98, Issue:13 Topics: Anemia, Refractory, with Excess of Blasts; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Disease-Free Survival; Humans; Idarubicin; Leukemia, Myeloid, Acute; Prognosis; Recurrence; Remission Induction; Survival Rate; Time Factors; Topotecan; Treatment Failure; Vidarabine	2001
Nonablative allogeneic hematopoietic transplantation as adoptive immunotherapy for indolent lymphoma: low incidence of toxicity, acute graft-versus-host disease, and treatment-related mortality. Blood, 2001, Dec-15, Volume: 98, Issue:13 Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Cyclophosphamide; Female; Graft Survival; Graft vs Host Disease; Graft vs Tumor Effect; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Immunotherapy, Adoptive; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Follicular; Male; Methotrexate; Middle Aged; Platelet Transfusion; Recurrence; Remission Induction; Rituximab; Tacrolimus; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine	2001
Cisplatin, fludarabine, and cytarabine: a novel, pharmacologically designed salvage therapy for patients with refractory, histologically aggressive or mantle cell non-Hodgkin's lymphoma. Cancer, 2002, Feb-01, Volume: 94, Issue:3 Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cytarabine; Disease-Free Survival; Female; Hematopoietic Stem Cell Transplantation; Humans; Infusions, Intravenous; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neutropenia; Prognosis; Recurrence; Salvage Therapy; Thrombocytopenia; Treatment Outcome; Vidarabine	2002
Allogeneic hematopoetic stem-cell transplantation for patients with relapsed or refractory lymphomas: comparison of high-dose conventional conditioning versus fludarabine-based reduced-intensity regimens. Annals of oncology : official journal of the European Society for Medical Oncology, 2002, Volume: 13, Issue:1 Topics: Adult; Drug Resistance, Neoplasm; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma; Middle Aged; Recurrence; Survival Rate; Time Factors; Transplantation, Homologous; Treatment Outcome; Vidarabine	2002
Objective antitumor activity of acivicin in patients with recurrent CNS malignancies: a Southwest Oncology Group trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1991, Volume: 9, Issue:8 Topics: Adolescent; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Astrocytoma; Brain Neoplasms; Drug Evaluation; Female; Glioblastoma; Humans; Isoxazoles; Magnetic Resonance Imaging; Male; Middle Aged; Recurrence; Tomography, X-Ray Computed; Vidarabine	1991

Other Studies

171 other study(ies) available for fludarabine and Recrudescence

Article	Year
Allogeneic hematopoietic cell transplantation in patients with myelodysplastic syndrome using treosulfan based compared to other reduced-intensity or myeloablative conditioning regimens. A report of the chronic malignancies working party of the EBMT. British journal of haematology, 2021, Volume: 195, Issue:3 Topics: Adolescent; Adult; Aged; Allografts; Busulfan; Cyclophosphamide; Disease Progression; Female; Follow-Up Studies; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Living Donors; Male; Middle Aged; Myeloablative Agonists; Myelodysplastic Syndromes; Recurrence; Registries; Transplantation Conditioning; Treatment Outcome; Vidarabine; Young Adult	2021
Combination of treosulfan, fludarabine and cytarabine as conditioning in patients with acute myeloid leukemia, myelodysplastic syndrome and myeloproliferative neoplasms. Journal of cancer research and clinical oncology, 2022, Volume: 148, Issue:10 Topics: Busulfan; Cytarabine; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Middle Aged; Myelodysplastic Syndromes; Myeloproliferative Disorders; Recurrence; Retrospective Studies; Transplantation Conditioning; Vidarabine	2022
Clofarabine-fludarabine-busulfan in HCT for pediatric leukemia: an effective, low toxicity, TBI-free conditioning regimen. Blood advances, 2022, 03-22, Volume: 6, Issue:6 Topics: Busulfan; Child; Clofarabine; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Recurrence; Vidarabine	2022
Optimal fludarabine lymphodepletion is associated with improved outcomes after CAR T-cell therapy. Blood advances, 2022, 04-12, Volume: 6, Issue:7 Topics: Adolescent; Adult; Child; Child, Preschool; Humans; Immunotherapy, Adoptive; Infant; Prospective Studies; Recurrence; Retrospective Studies; Vidarabine; Young Adult	2022
Total body irradiation plus fludarabine versus thiotepa, busulfan plus fludarabine as a myeloablative conditioning for adults with acute lymphoblastic leukemia treated with haploidentical hematopoietic cell transplantation. A study by the Acute Leukemia W Bone marrow transplantation, 2022, Volume: 57, Issue:3 Topics: Adult; Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Retrospective Studies; Thiotepa; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation	2022
Fludarabine exposure predicts outcome after CD19 CAR T-cell therapy in children and young adults with acute leukemia. Blood advances, 2022, 04-12, Volume: 6, Issue:7 Topics: Antigens, CD19; Child; Humans; Immunotherapy, Adoptive; Leukemia, Myeloid, Acute; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prospective Studies; Recurrence; Retrospective Studies; Vidarabine; Young Adult	2022
Impact on Outcome of Minimal Residual Disease after Hematopoietic Stem Cell Transplantation with Fludarabine, Amsacrine, and Cytosine Arabinoside-Busulfan Conditioning: A Retrospective Monocentric Study. Transplantation and cellular therapy, 2023, Volume: 29, Issue:1 Topics: Amsacrine; Busulfan; Cytarabine; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Neoplasm, Residual; Recurrence; Retrospective Studies	2023
Total body irradiation plus fludarabine versus busulfan plus fludarabine as a myeloablative conditioning for adults with acute myeloid leukemia treated with allogeneic hematopoietic cell transplantation. A study on behalf of the Acute Leukemia Working Par Bone marrow transplantation, 2023, Volume: 58, Issue:3 Topics: Acute Disease; Adult; Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Recurrence; Retrospective Studies; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation	2023
Fludarabine versus cyclophospamide in combination with myeloablative total body irradiation as conditioning for patients with acute myeloid leukemia treated with allogeneic hematopoietic cell transplantation. A study from the Acute Leukemia Working Party American journal of hematology, 2023, Volume: 98, Issue:4 Topics: Acute Disease; Adult; Bone Marrow; Busulfan; Cyclophosphamide; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Recurrence; Retrospective Studies; Transplantation Conditioning; Whole-Body Irradiation	2023
Fludarabine or cyclophosphamide in combination with total body irradiation as myeloablative conditioning prior to allogeneic hematopoietic cell transplantation for acute lymphoblastic leukemia: an analysis by the Acute Leukemia Working Party of the EBMT. Bone marrow transplantation, 2023, Volume: 58, Issue:5 Topics: Acute Disease; Adult; Cyclophosphamide; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Retrospective Studies; Transplantation Conditioning; Transplantation, Homologous; Whole-Body Irradiation	2023
Advantages of Higher Busulfan Dose Intensity in Fludarabine-Combined Conditioning for Patients with Acute Myeloid Leukemia Undergoing Cord Blood Transplantation. Transplantation and cellular therapy, 2023, Volume: 29, Issue:5 Topics: Busulfan; Cohort Studies; Cord Blood Stem Cell Transplantation; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Middle Aged; Recurrence; Retrospective Studies	2023
Fludarabine/TBI 8 Gy versus fludarabine/treosulfan conditioning in patients with AML in first complete remission: a study from the Acute Leukemia Working Party of the EBMT. Bone marrow transplantation, 2023, Volume: 58, Issue:6 Topics: Acute Disease; Adult; Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Middle Aged; Recurrence; Retrospective Studies; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation	2023
Intensified conditioning regimen with fludarabine combined with post-transplantation cyclophosphamide for haploidentical allogeneic hematopoietic stem cell transplantation in children with high-risk acute leukemia. Hematology (Amsterdam, Netherlands), 2023, Volume: 28, Issue:1 Topics: Acute Disease; Adult; Antilymphocyte Serum; Busulfan; Child; Cyclophosphamide; Cytarabine; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Recurrence; Retrospective Studies; Transplantation Conditioning	2023
Identifying an optimal fludarabine exposure for improved outcomes after axi-cel therapy for aggressive B-cell non-Hodgkin lymphoma. Blood advances, 2023, 09-26, Volume: 7, Issue:18 Topics: Adult; Humans; Immunotherapy, Adoptive; Lymphoma, Non-Hodgkin; Recurrence	2023
Myeloablative Dose of Busulfan and Fludarabine Combined with In Vivo T Cell Depletion Is Safe and Effective Conditioning for Acute Myeloid Leukemia and Myelodysplastic Syndrome Patients. Transplantation and cellular therapy, 2023, Volume: 29, Issue:11 Topics: Busulfan; Graft vs Host Disease; Humans; Leukemia, Myeloid, Acute; Middle Aged; Myelodysplastic Syndromes; Recurrence; T-Lymphocytes	2023
Transplantation Outcomes of Myelofibrosis with Busulfan and Fludarabine Myeloablative Conditioning. Transplantation and cellular therapy, 2023, Volume: 29, Issue:12 Topics: Busulfan; Graft vs Host Disease; Humans; Methotrexate; Primary Myelofibrosis; Recurrence; Tacrolimus	2023
Comparison of non-myeloablative and reduced-intensity allogeneic stem cell transplantation in older patients with myelodysplastic syndromes. American journal of hematology, 2019, Volume: 94, Issue:12 Topics: Age Factors; Aged; Aged, 80 and over; Busulfan; Comorbidity; Graft vs Host Disease; Humans; Immunosuppressive Agents; Kaplan-Meier Estimate; Middle Aged; Myeloablative Agonists; Myelodysplastic Syndromes; Myeloproliferative Disorders; Peripheral Blood Stem Cell Transplantation; Proportional Hazards Models; Recurrence; Retrospective Studies; Transplantation Conditioning; Treatment Outcome; Vidarabine; Whole-Body Irradiation	2019
Etoposide Combined with FLAG Salvage Therapy Is Effective in Multiple Relapsed/Refractory Acute Myeloid leukemia. Acta haematologica, 2020, Volume: 143, Issue:5 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Disease-Free Survival; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Hemorrhage; Humans; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence; Remission Induction; Salvage Therapy; Vidarabine	2020
Comparison of real-world treatment patterns in chronic lymphocytic leukemia management before and after availability of ibrutinib in the province of British Columbia, Canada. Leukemia research, 2020, Volume: 91 Topics: Adenine; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; British Columbia; Chromosome Deletion; Chromosomes, Human, Pair 17; Cyclophosphamide; Disease Management; Doxorubicin; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm, Residual; Piperidines; Prednisone; Prognosis; Pyrazoles; Pyrimidines; Recurrence; Remission Induction; Retrospective Studies; Rituximab; Smith-Magenis Syndrome; Survival Analysis; Transplantation, Homologous; Treatment Outcome; Vidarabine; Vincristine	2020
Disseminated Lomentospora prolificans infection in a patient on idelalisib-rituximab therapy for relapsed chronic lymphocytic leukaemia. Annals of hematology, 2020, Volume: 99, Issue:10 Topics: Antifungal Agents; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Drug Resistance, Multiple, Fungal; Drug Substitution; Fatal Outcome; Febrile Neutropenia; Female; Filgrastim; Fluconazole; Humans; Immunocompromised Host; Invasive Fungal Infections; Leukemia, Lymphocytic, Chronic, B-Cell; Middle Aged; Piperacillin, Tazobactam Drug Combination; Purines; Quinazolinones; Recurrence; Rituximab; Scedosporium; Triazoles; Valacyclovir; Vidarabine	2020
Reduced-Intensity Conditioning with Busulfan and Fludarabine for Allogeneic Hematopoietic Stem Cell Transplantation in Acute Lymphoblastic Leukemia. Yonsei medical journal, 2020, Volume: 61, Issue:6 Topics: Acute Disease; Adolescent; Adult; Aged; Busulfan; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Kaplan-Meier Estimate; Middle Aged; Multivariate Analysis; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Proportional Hazards Models; Recurrence; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Young Adult	2020
Association of Reduced-Intensity Conditioning Regimens With Overall Survival Among Patients With Non-Hodgkin Lymphoma Undergoing Allogeneic Transplant. JAMA oncology, 2020, 07-01, Volume: 6, Issue:7 Topics: Allografts; Busulfan; Cohort Studies; Cyclophosphamide; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Lymphoma, Non-Hodgkin; Melphalan; Myeloablative Agonists; Recurrence; Registries; Survival Analysis; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation	2020
Allogeneic hematopoietic cell transplantation using fludarabine plus myeloablative busulfan and melphalan confers promising survival in high-risk hematopoietic neoplasms: a single-center retrospective analysis. Hematology (Amsterdam, Netherlands), 2021, Volume: 26, Issue:1 Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Combined Modality Therapy; Female; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Male; Melphalan; Middle Aged; Myeloablative Agonists; Recurrence; Remission Induction; Retrospective Studies; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Young Adult	2021
Reduced-toxicity conditioning regimen with busulfan, fludarabine, rATG, and 400 cGy TBI in pediatric patients undergoing hematopoietic stem cell transplant for high-risk hematologic malignancies. Pediatric blood & cancer, 2021, Volume: 68, Issue:8 Topics: Antilymphocyte Serum; Busulfan; Child; Hematopoietic Stem Cell Transplantation; Humans; Leukemia; Prospective Studies; Recurrence; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation	2021
Comparison of fludarabine, a myeloablative dose of busulfan, and melphalan vs conventional myeloablative conditioning regimen in patients with relapse and refractory acute myeloid leukemia in non-remission status. Bone marrow transplantation, 2021, Volume: 56, Issue:9 Topics: Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Melphalan; Recurrence; Retrospective Studies; Transplantation Conditioning; Vidarabine	2021
Treatment of refractory autoimmune hemolytic anemia with venetoclax in relapsed chronic lymphocytic leukemia with del(17p). Annals of hematology, 2017, Volume: 96, Issue:9 Topics: Alemtuzumab; Anemia, Hemolytic, Autoimmune; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Blood Transfusion; Bridged Bicyclo Compounds, Heterocyclic; Chromosome Deletion; Chromosomes, Human, Pair 17; Cyclophosphamide; Humans; In Situ Hybridization, Fluorescence; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Recurrence; Remission Induction; Rituximab; Sulfonamides; Vidarabine	2017
Missing HLA C group 1 ligand in patients with AML and MDS is associated with reduced risk of relapse and better survival after allogeneic stem cell transplantation with fludarabine and treosulfan reduced toxicity conditioning. American journal of hematology, 2017, Volume: 92, Issue:10 Topics: Adult; Aged; Busulfan; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Genotype; Hematopoietic Stem Cell Transplantation; HLA-C Antigens; Humans; Leukemia, Myeloid, Acute; Ligands; Male; Middle Aged; Myelodysplastic Syndromes; Receptors, KIR; Recurrence; Retrospective Studies; Siblings; Transplantation Conditioning; Unrelated Donors; Vidarabine; Young Adult	2017
Intravenous immunoglobulin as salvage therapy for refractory thrombotic thrombocytopenic purpura. American journal of hematology, 2018, Volume: 93, Issue:3 Topics: Adult; Combined Modality Therapy; Cyclosporine; Drug Therapy, Combination; Female; Humans; Immunoglobulins, Intravenous; Immunosuppressive Agents; Male; Middle Aged; Plasma Exchange; Purpura, Thrombotic Thrombocytopenic; Recurrence; Registries; Retrospective Studies; Salvage Therapy; Splenectomy; Treatment Outcome; Vidarabine; Vincristine; Young Adult	2018
Outcomes of Children with Hemophagocytic Lymphohistiocytosis Given Allogeneic Hematopoietic Stem Cell Transplantation in Italy. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2018, Volume: 24, Issue:6 Topics: Adolescent; Busulfan; Child; Child, Preschool; Female; Graft Rejection; Hematopoietic Stem Cell Transplantation; Histocompatibility; Humans; Infant; Italy; Lymphohistiocytosis, Hemophagocytic; Male; Recurrence; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine	2018
A Comparison of the Myeloablative Conditioning Regimen Fludarabine/Busulfan with Cyclophosphamide/Total Body Irradiation, for Allogeneic Stem Cell Transplantation in the Modern Era: A Cohort Analysis. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2018, Volume: 24, Issue:8 Topics: Adult; Aged; Busulfan; Cohort Studies; Cyclophosphamide; Female; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myeloablative Agonists; Myelodysplastic Syndromes; Recurrence; Retrospective Studies; Survival Analysis; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation	2018
Clearance of Somatic Mutations at Remission and the Risk of Relapse in Acute Myeloid Leukemia. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2018, 06-20, Volume: 36, Issue:18 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase II as Topic; Clofarabine; Cohort Studies; Cytarabine; DNA, Neoplasm; Female; High-Throughput Nucleotide Sequencing; Humans; Idarubicin; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Recurrence; Sequence Analysis, DNA; Vidarabine	2018
Outcomes of second-line treatment after fludarabine cyclophosphamide and rituximab in patients with chronic lymphocytic leukemia outside clinical trials. European journal of haematology, 2018, Volume: 101, Issue:3 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Drug Resistance, Neoplasm; Female; Humans; Kaplan-Meier Estimate; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Proportional Hazards Models; Recurrence; Retreatment; Retrospective Studies; Rituximab; Treatment Outcome; Vidarabine; Young Adult	2018
Fludarabine, busulfan, and low-dose TBI conditioning versus cyclophosphamide and TBI in allogeneic hematopoietic cell transplantation for adult acute lymphoblastic leukemia. Leukemia & lymphoma, 2019, Volume: 60, Issue:3 Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Combined Modality Therapy; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prognosis; Recurrence; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Whole-Body Irradiation; Young Adult	2019
Ex vivo T cell-depleted versus unmodified allografts in patients with acute myeloid leukemia in first complete remission. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2013, Volume: 19, Issue:6 Topics: Adult; Aged; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busulfan; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Lymphocyte Depletion; Male; Melphalan; Middle Aged; Recurrence; Remission Induction; Retrospective Studies; Survival Analysis; T-Lymphocytes; Thiotepa; Transplantation, Homologous; Treatment Outcome; Vidarabine	2013
Comparison of outcomes after two standards-of-care reduced-intensity conditioning regimens and two different graft sources for allogeneic stem cell transplantation in adults with hematologic diseases: a single-center analysis. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2013, Volume: 19, Issue:6 Topics: Adult; Aged; Antilymphocyte Serum; Busulfan; Cord Blood Stem Cell Transplantation; Cyclophosphamide; Female; Graft Survival; Graft vs Host Disease; Hematologic Neoplasms; Humans; Male; Middle Aged; Myeloablative Agonists; Peripheral Blood Stem Cell Transplantation; Recurrence; Retrospective Studies; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine	2013
National Institutes of Health classification for chronic graft-versus-host disease predicts outcome of allo-hematopoietic stem cell transplant after fludarabine-busulfan-antithymocyte globulin conditioning regimen. Leukemia & lymphoma, 2014, Volume: 55, Issue:5 Topics: Adolescent; Adult; Aged; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Chemoprevention; Chronic Disease; Disease Progression; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Middle Aged; Recurrence; Severity of Illness Index; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Young Adult	2014
Fludarabine-mitoxantrone-rituximab regimen in untreated intermediate/high-risk follicular non-Hodgkin's lymphoma: experience on 142 patients. American journal of hematology, 2013, Volume: 88, Issue:11 Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Female; Follow-Up Studies; Humans; Lymphoma, Follicular; Male; Middle Aged; Mitoxantrone; Neoplasm Grading; Neoplasm Staging; Prognosis; Recurrence; Retrospective Studies; Rituximab; Survival Analysis; Vidarabine	2013
Pharmacokinetically-targeted BU and fludarabine as conditioning before allogeneic hematopoietic cell transplantation for adults with ALL in first remission. Bone marrow transplantation, 2014, Volume: 49, Issue:1 Topics: Adult; Aged; Busulfan; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Male; Middle Aged; Neutrophils; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prognosis; Recurrence; Remission Induction; Retrospective Studies; Risk Factors; Transplantation Conditioning; Treatment Outcome; Vidarabine; Young Adult	2014
Fludarabine Melphalan reduced-intensity conditioning allotransplanation provides similar disease control in lymphoid and myeloid malignancies: analysis of 344 patients. Bone marrow transplantation, 2014, Volume: 49, Issue:1 Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Australia; Bone Marrow Transplantation; Disease-Free Survival; Female; Follow-Up Studies; Humans; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Lymphoma; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Multivariate Analysis; Myeloablative Agonists; New Zealand; Recurrence; Remission Induction; Retrospective Studies; Risk Factors; Transplantation Conditioning; Treatment Outcome; Vidarabine; Young Adult	2014
Does total body irradiation conditioning improve outcomes of myeloablative human leukocyte antigen-identical sibling transplantations for chronic lymphocytic leukemia? Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2014, Volume: 20, Issue:3 Topics: Adult; Female; Hematopoietic Stem Cell Transplantation; HLA Antigens; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Myeloablative Agonists; Recurrence; Siblings; Survival Analysis; Transplantation Conditioning; Transplantation, Isogeneic; Treatment Outcome; Vidarabine; Whole-Body Irradiation	2014
A myeloablative conditioning regimen with fludarabine demonstrates good results in UCBT for 30 pediatric patients with hematologic malignancies, especially acute lymphoblastic leukemia. Neoplasma, 2014, Volume: 61, Issue:5 Topics: Adolescent; Child; Cord Blood Stem Cell Transplantation; Female; Graft vs Host Disease; Humans; Male; Myeloablative Agonists; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Transplantation Conditioning; Vidarabine	2014
FCR and bevacizumab treatment in patients with relapsed chronic lymphocytic leukemia. Cancer, 2014, Nov-15, Volume: 120, Issue:22 Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cyclophosphamide; Disease-Free Survival; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Proportional Hazards Models; Recurrence; Rituximab; Vidarabine	2014
Complete donor T cell chimerism predicts lower relapse incidence after standard double umbilical cord blood reduced-intensity conditioning regimen allogeneic transplantation in adults. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2015, Volume: 21, Issue:1 Topics: Adolescent; Adult; Aged; Cord Blood Stem Cell Transplantation; Cyclophosphamide; Female; Graft Survival; Graft vs Host Disease; Hematologic Neoplasms; Humans; Immunosuppressive Agents; Male; Middle Aged; Myeloablative Agonists; Prognosis; Recurrence; Retrospective Studies; Survival Analysis; T-Lymphocytes; Transplantation Chimera; Transplantation Conditioning; Transplantation, Autologous; Transplantation, Homologous; Treatment Outcome; Unrelated Donors; Vidarabine; Whole-Body Irradiation	2015
Bone marrow graft as a source of allogeneic hematopoietic stem cells in patients undergoing a reduced intensity conditioning regimen. Bone marrow transplantation, 2014, Volume: 49, Issue:12 Topics: Adolescent; Adult; Aged; Bone Marrow; Bone Marrow Transplantation; Female; Graft vs Host Disease; Hematologic Neoplasms; Humans; Male; Melphalan; Middle Aged; Recurrence; Retrospective Studies; Stem Cell Transplantation; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Young Adult	2014
Favorable outcome of hematopoietic stem cell transplantation using a targeted once-daily intravenous busulfan-fludarabine-etoposide regimen in pediatric and infant acute lymphoblastic leukemia patients. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2015, Volume: 21, Issue:1 Topics: Child; Child, Preschool; Cyclophosphamide; Drug Administration Schedule; Etoposide; Female; Graft Survival; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Infant; Injections, Intravenous; Male; Myeloablative Agonists; Neutrophils; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Retrospective Studies; Siblings; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Unrelated Donors; Vidarabine; Young Adult	2015
Feasible outcomes of T cell-replete haploidentical stem cell transplantation with reduced-intensity conditioning in patients with myelodysplastic syndrome. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2015, Volume: 21, Issue:2 Topics: Acute Disease; Adult; Aged; Antilymphocyte Serum; Busulfan; Chronic Disease; Female; Graft vs Host Disease; Haplotypes; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myeloablative Agonists; Myelodysplastic Syndromes; Recurrence; Retrospective Studies; Survival Analysis; T-Lymphocytes; Tissue Donors; Transplantation Conditioning; Transplantation, Isogeneic; Treatment Outcome; Vidarabine; Whole-Body Irradiation	2015
B-cell lymphoma developing de novo hepatitis B after salvage therapies including rituximab through seroconversion of surface antibody. [Rinsho ketsueki] The Japanese journal of clinical hematology, 2014, Volume: 55, Issue:11 Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Cytarabine; Dexamethasone; Doxorubicin; Etoposide; Female; Hepatitis B; Hepatitis B Antibodies; Hepatitis B Surface Antigens; Hepatitis B virus; Humans; Lymphoma, B-Cell; Prednisone; Recurrence; Remission Induction; Risk; Rituximab; Salvage Therapy; Vidarabine; Vincristine; Virus Activation	2014
Myeloablative intravenous pharmacokinetically targeted busulfan plus fludarabine as conditioning for allogeneic hematopoietic cell transplantation in patients with non-Hodgkin lymphoma. Clinical lymphoma, myeloma & leukemia, 2015, Volume: 15, Issue:6 Topics: Administration, Intravenous; Adult; Aged; Antineoplastic Agents; Busulfan; Disease-Free Survival; Drug Therapy, Combination; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Lymphoma, Non-Hodgkin; Male; Methotrexate; Middle Aged; Myeloablative Agonists; Recurrence; Retrospective Studies; Survival Rate; Tacrolimus; Transplantation Conditioning; Transplantation, Homologous; Vidarabine	2015
Chimerism status after unrelated donor bone marrow transplantation with fludarabine-melphalan conditioning is affected by the melphalan dose and is predictive of relapse. Annals of hematology, 2015, Volume: 94, Issue:7 Topics: Adolescent; Adult; Aged; Bone Marrow Transplantation; Chimerism; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Male; Melphalan; Middle Aged; Predictive Value of Tests; Prospective Studies; Recurrence; Transplantation Conditioning; Unrelated Donors; Vidarabine; Young Adult	2015
Hematopoietic cell transplantation for mucopolysaccharidosis patients is safe and effective: results after implementation of international guidelines. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2015, Volume: 21, Issue:6 Topics: Acute Disease; Busulfan; Child; Child, Preschool; Chronic Disease; Cord Blood Stem Cell Transplantation; Cyclophosphamide; Female; Follow-Up Studies; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Infant; Infant, Newborn; Male; Mucopolysaccharidoses; Myeloablative Agonists; Neurodegenerative Diseases; Practice Guidelines as Topic; Prognosis; Recurrence; Siblings; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Unrelated Donors; Vidarabine	2015
Clinical Relevance of Apheretic Graft Composition in Patients With Acute Myeloblastic Leukemia Who Received a Busulfan-Fludarabine-Antithymocyte Globulin Conditioning Regimen for Allogeneic Transplant. Experimental and clinical transplantation : official journal of the Middle East Society for Organ Transplantation, 2015, Volume: 13, Issue:5 Topics: Adult; Antigens, CD34; Antilymphocyte Serum; B-Lymphocyte Subsets; Blood Component Removal; Busulfan; Cross-Sectional Studies; Disease-Free Survival; Female; Flow Cytometry; Hematopoietic Stem Cell Transplantation; Humans; Kaplan-Meier Estimate; Killer Cells, Natural; Leukemia, Myeloid, Acute; Lymphocyte Count; Male; Middle Aged; Myeloablative Agonists; Proportional Hazards Models; Prospective Studies; Recurrence; Risk Factors; T-Lymphocyte Subsets; Time Factors; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Turkey; Vidarabine	2015
[Combination of busulfan with increased-dose of fludarabine as conditioning regimen for MDS and MDS-AML patients with allo-HSCT]. Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi, 2015, Volume: 36, Issue:6 Topics: Busulfan; Disease-Free Survival; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Recurrence; Remission Induction; Retrospective Studies; Tissue Donors; Transplantation Conditioning; Transplantation, Homologous; Vidarabine	2015
Mixed T Lymphocyte Chimerism after Allogeneic Hematopoietic Transplantation Is Predictive for Relapse of Acute Myeloid Leukemia and Myelodysplastic Syndromes. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2015, Volume: 21, Issue:11 Topics: Adult; Busulfan; Female; Graft Survival; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myeloablative Agonists; Myelodysplastic Syndromes; Prognosis; Recurrence; Remission Induction; Retrospective Studies; Survival Analysis; T-Lymphocytes; Transplantation Chimera; Transplantation Conditioning; Transplantation, Homologous; Vidarabine	2015
Low-dose alemtuzumab in refractory/relapsed chronic lymphocytic leukemia: Genetic profile and long-term outcome from a single center experience. American journal of hematology, 2015, Volume: 90, Issue:11 Topics: Adult; Aged; Aged, 80 and over; Alemtuzumab; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Drug Administration Schedule; Female; Gene Expression; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Mutation; Phosphoproteins; Receptor, Notch1; Recurrence; Remission Induction; Retrospective Studies; Ribonucleoprotein, U2 Small Nuclear; Risk Factors; RNA Splicing Factors; Survival Analysis; Treatment Outcome; Tumor Suppressor Protein p53; Vidarabine	2015
Alemtuzumab, Fludarabine, Low-Dose TBI, and Double Umbilical Cord Transplant for Primary Graft Failure in a Patient with Recurrent HLH. Pediatric blood & cancer, 2016, Volume: 63, Issue:2 Topics: Alemtuzumab; Antibodies, Monoclonal, Humanized; Combined Modality Therapy; Cord Blood Stem Cell Transplantation; Graft vs Host Disease; Humans; Infant; Lymphohistiocytosis, Hemophagocytic; Male; Recurrence; Salvage Therapy; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation	2016
Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia. Blood, 2016, Jan-21, Volume: 127, Issue:3 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cause of Death; Cyclophosphamide; Female; Humans; Immunoglobulin Heavy Chains; Incidence; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Mutation; Neoplasm Staging; Neoplasm, Residual; Neoplasms, Second Primary; Prognosis; Recurrence; Remission Induction; Retreatment; Rituximab; Survival Analysis; Treatment Outcome; Vidarabine; Young Adult	2016
[The curative efficacy of unrelated umbilical cord blood stem cells transplantation in intensified myeloablative conditioned patients with acute lymphoblastic leukemia]. Zhonghua nei ke za zhi, 2016, Volume: 55, Issue:3 Topics: Adolescent; Adult; Busulfan; Child; Child, Preschool; Cord Blood Stem Cell Transplantation; Cyclophosphamide; Cytarabine; Disease-Free Survival; Female; Fetal Blood; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Incidence; Male; Middle Aged; Mycophenolic Acid; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Remission Induction; Retrospective Studies; Survival Rate; Transplantation Conditioning; Treatment Outcome; Vidarabine; Young Adult	2016
Outcome after Transplantation According to Reduced-Intensity Conditioning Regimen in Patients Undergoing Transplantation for Myelofibrosis. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2016, Volume: 22, Issue:7 Topics: Aged; Busulfan; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Male; Melphalan; Middle Aged; Myeloablative Agonists; Primary Myelofibrosis; Recurrence; Survival Analysis; Transplantation Conditioning; Treatment Outcome; Vidarabine	2016
Does anti-thymocyte globulin have a place in busulfan/fludarabine conditioning for matched related donor hematopoietic stem cell transplantation? The Korean journal of internal medicine, 2016, Volume: 31, Issue:4 Topics: Acute Disease; Adult; Antilymphocyte Serum; Busulfan; Chronic Disease; Disease-Free Survival; Drug Therapy, Combination; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Incidence; Kaplan-Meier Estimate; Living Donors; Male; Middle Aged; Myeloablative Agonists; Proportional Hazards Models; Recurrence; Republic of Korea; Retrospective Studies; Risk Factors; Time Factors; Transplantation Conditioning; Treatment Outcome; Vidarabine	2016
Personalized fludarabine dosing to reduce nonrelapse mortality in hematopoietic stem-cell transplant recipients receiving reduced intensity conditioning. Translational research : the journal of laboratory and clinical medicine, 2016, Volume: 175 Topics: Adult; Aged; Cohort Studies; Dose-Response Relationship, Drug; Female; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Precision Medicine; Recurrence; Regression Analysis; Transplantation Conditioning; Vidarabine; Young Adult	2016
[Clinical Summarization of Allogeneic Hematopoietic Stem Cell Transplantation for Leukemia: A Report of 100 Cases]. Zhongguo shi yan xue ye xue za zhi, 2016, Volume: 24, Issue:2 Topics: Antilymphocyte Serum; Disease-Free Survival; Graft vs Host Disease; HLA Antigens; Humans; Incidence; Leukemia; Peripheral Blood Stem Cell Transplantation; Recurrence; Retrospective Studies; Transplantation Conditioning; Treatment Outcome; Vidarabine	2016
Fludarabine-Busulfan Reduced-Intensity Conditioning in Comparison with Fludarabine-Melphalan Is Associated with Increased Relapse Risk In Spite of Pharmacokinetic Dosing. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2016, Volume: 22, Issue:8 Topics: Adolescent; Adult; Aged; Area Under Curve; Busulfan; Female; Humans; Karnofsky Performance Status; Leukemia, Myeloid, Acute; Male; Melphalan; Middle Aged; Myeloablative Agonists; Myelodysplastic Syndromes; Recurrence; Retrospective Studies; Survival Analysis; Transplantation Conditioning; Vidarabine; Young Adult	2016
A Novel Reduced-Toxicity Myeloablative Conditioning Regimen Using Full-Dose Busulfan, Fludarabine, and Melphalan for Single Cord Blood Transplantation Provides Durable Engraftment and Remission in Nonremission Myeloid Malignancies. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2016, Volume: 22, Issue:10 Topics: Adult; Aged; Busulfan; Female; Graft Survival; Humans; Leukemia, Myeloid; Male; Melphalan; Middle Aged; Myeloablative Agonists; Recurrence; Remission Induction; Survival Analysis; Transplantation Conditioning; Vidarabine; Young Adult	2016
Allogeneic Hematopoietic Stem Cell Transplantation after Conditioning Regimens with Fludarabine/melphalan or Fludarabine/busulfan for Patients with Hematological Malignancies: A Single-center Analysis. Internal medicine (Tokyo, Japan), 2016, Volume: 55, Issue:13 Topics: Adult; Antineoplastic Agents; Busulfan; Drug Therapy, Combination; Female; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Male; Melphalan; Middle Aged; Recurrence; Retrospective Studies; Transplantation Conditioning; Transplantation, Homologous; Vidarabine	2016
Comparison of cladribine- and fludarabine-based induction chemotherapy in relapsed or refractory acute myeloid leukaemia. Annals of hematology, 2016, Volume: 95, Issue:11 Topics: Adult; Aged; Aged, 80 and over; Allografts; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Combined Modality Therapy; Cytarabine; Disease-Free Survival; Drug Evaluation; Drug Resistance, Neoplasm; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Middle Aged; Proportional Hazards Models; Recurrence; Retrospective Studies; Salvage Therapy; Treatment Outcome; Vidarabine	2016
A 5-day cytoreductive chemotherapy followed by haplo-identical hsct (FA5-BUCY) as a tumor-ablative regimen improved the survival of patients with advanced hematological malignancies. Oncotarget, 2016, Nov-29, Volume: 7, Issue:48 Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Chemotherapy, Adjuvant; Child; Child, Preschool; Cyclophosphamide; Cytarabine; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Female; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Infant; Kaplan-Meier Estimate; Male; Middle Aged; Neoadjuvant Therapy; Proportional Hazards Models; Recurrence; Remission Induction; Time Factors; Transplantation Conditioning; Transplantation, Haploidentical; Treatment Outcome; Vidarabine; Young Adult	2016
The Addition of Low-Dose Total Body Irradiation to Fludarabine and Melphalan Conditioning in Haplocord Transplantation for High-Risk Hematological Malignancies. Transplantation, 2017, Volume: 101, Issue:1 Topics: Adult; Aged; Cord Blood Stem Cell Transplantation; Disease-Free Survival; Female; Graft Rejection; Graft Survival; Graft vs Host Disease; Hematologic Neoplasms; Humans; Kaplan-Meier Estimate; Male; Melphalan; Middle Aged; Myeloablative Agonists; Radiation Dosage; Recurrence; Retrospective Studies; Risk Factors; Time Factors; Transplantation Conditioning; Treatment Outcome; Vidarabine; Whole-Body Irradiation; Young Adult	2017
Health-related quality of life and patient-reported outcomes of ofatumumab plus fludarabine and cyclophosphamide versus fludarabine and cyclophosphamide in the COMPLEMENT 2 trial of patients with relapsed CLL. Leukemia & lymphoma, 2017, Volume: 58, Issue:7 Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Follow-Up Studies; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Patient Reported Outcome Measures; Quality of Life; Recurrence; Vidarabine	2017
Spousal hematopoietic stem cell transplantation. International journal of hematology, 2017, Volume: 105, Issue:5 Topics: Adult; Allografts; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Fatal Outcome; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Histocompatibility; HLA Antigens; Humans; Leukemia; Male; Melphalan; Middle Aged; Radiotherapy Dosage; Recurrence; Spouses; Transplantation Conditioning; Treatment Outcome; Vidarabine	2017
Comparative Effectiveness of Busulfan and Fludarabine versus Fludarabine and 400 cGy Total Body Irradiation Conditioning Regimens for Acute Myeloid Leukemia/Myelodysplastic Syndrome. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2017, Volume: 23, Issue:5 Topics: Adult; Aged; Busulfan; Erythrocyte Transfusion; Female; Graft vs Host Disease; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Quality of Life; Recurrence; Survival Analysis; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation	2017
Incidence and risk factor of hemorrhagic cystitis after allogeneic transplantation with fludarabine, busulfan, and anti-thymocyte globulin myeloablative conditioning. Transplant infectious disease : an official journal of the Transplantation Society, 2017, Volume: 19, Issue:3 Topics: Antilymphocyte Serum; BK Virus; Busulfan; Case-Control Studies; Cystitis; Disease-Free Survival; Drug Therapy, Combination; Female; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Incidence; Length of Stay; Male; Middle Aged; Myeloablative Agonists; Polyomavirus Infections; Recurrence; Risk Factors; Sex Factors; Transplantation Conditioning; Transplantation, Homologous; Vidarabine	2017
Clofarabine-based chemotherapy as a bridge to transplant in the setting of refractory or relapsed acute myeloid leukemia, after at least one previous unsuccessful salvage treatment containing fludarabine: a single institution experience. International journal of hematology, 2017, Volume: 105, Issue:6 Topics: Adenine Nucleotides; Adolescent; Adult; Aged; Allografts; Arabinonucleosides; Clofarabine; Disease-Free Survival; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence; Retrospective Studies; Salvage Therapy; Vidarabine	2017
Using reduced intensity conditioning and HLA-identical sibling donors, antithymocyte globulin increases the risk of relapse, which can be overcome by a high stem cell dose. Bone marrow transplantation, 2008, Volume: 42, Issue:11 Topics: Adult; Aged; Antilymphocyte Serum; Antineoplastic Agents; Female; Hematopoietic Stem Cells; HLA Antigens; Humans; Leukemia; Male; Middle Aged; Recurrence; Siblings; Stem Cell Transplantation; Transplantation Conditioning; Vidarabine	2008
Outcomes following HSCT using fludarabine, busulfan, and thymoglobulin: a matched comparison to allogeneic transplants conditioned with busulfan and cyclophosphamide. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2008, Volume: 14, Issue:9 Topics: Acute Disease; Adolescent; Adult; Aged; Antibodies, Monoclonal; Antilymphocyte Serum; Busulfan; Chronic Disease; Cyclophosphamide; Disease-Free Survival; Female; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Myeloablative Agonists; Prospective Studies; Randomized Controlled Trials as Topic; Recurrence; Retrospective Studies; Risk Factors; Survival Rate; Transplantation Conditioning; Transplantation, Homologous; Vidarabine	2008
Salvage transplantation for allograft failure using fludarabine and alemtuzumab as conditioning regimen. Bone marrow transplantation, 2009, Volume: 43, Issue:6 Topics: Adult; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Female; Graft Rejection; Humans; Immunosuppressive Agents; Male; Middle Aged; Recurrence; Retrospective Studies; Salvage Therapy; Transplantation Conditioning; Treatment Outcome; Vidarabine	2009
Second myeloablative allogeneic stem cell transplantation (SCT) using cord blood for leukemia relapsed after initial allogeneic SCT. Leukemia research, 2009, Volume: 33, Issue:6 Topics: Adolescent; Adult; Antineoplastic Agents; Busulfan; Cyclophosphamide; Female; Fetal Blood; Humans; Male; Recurrence; Stem Cell Transplantation; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine	2009
Pharmacokinetics of alemtuzumab in combination with fludarabine in patients with relapsed or refractory B-cell chronic lymphocytic leukemia. Haematologica, 2009, Volume: 94, Issue:1 Topics: Aged; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Humans; Immunotherapy; Leukemia, Lymphocytic, Chronic, B-Cell; Middle Aged; Recurrence; Vidarabine	2009
Fatal acute liver failure due to reactivation of hepatitis B following treatment with fludarabine/cyclophosphamide/rituximab for low grade non-Hodgkin's lymphoma. European journal of medical research, 2008, Oct-27, Volume: 13, Issue:10 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Diagnosis, Differential; Fatal Outcome; Hepatitis B, Chronic; Humans; Liver; Liver Failure, Acute; Lymphoma, Non-Hodgkin; Male; Middle Aged; Recurrence; Rituximab; Vidarabine	2008
The combined use of Flu/ATG in nonmyeloablative SCT for severe aplastic anemia with multiple earlier transfusions. Bone marrow transplantation, 2009, Volume: 43, Issue:11 Topics: Adult; Anemia, Aplastic; Antilymphocyte Serum; Combined Modality Therapy; Drug Therapy, Combination; Female; Follow-Up Studies; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Recurrence; Treatment Outcome; Vidarabine; Young Adult	2009
The clinical outcome of FLAG chemotherapy without idarubicin in patients with relapsed or refractory acute myeloid leukemia. Journal of Korean medical science, 2009, Volume: 24, Issue:3 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Disease-Free Survival; Female; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence; Treatment Outcome; Vidarabine	2009
Salvage allogeneic hematopoietic cell transplantation with fludarabine and low-dose total body irradiation after rejection of first allografts. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2009, Volume: 15, Issue:10 Topics: Acute Disease; Adolescent; Adult; Aged; Anemia, Aplastic; Child; Chronic Disease; Female; Follow-Up Studies; Graft Rejection; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Living Donors; Male; Middle Aged; Myeloablative Agonists; Neoplasms; Recurrence; Retrospective Studies; Salvage Therapy; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation	2009
[Brucella bacteremia reactivation 70 years after the primary infection]. Medecine et maladies infectieuses, 2010, Volume: 40, Issue:4 Topics: Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bacteremia; Brucella melitensis; Brucellosis; Combined Modality Therapy; Cyclophosphamide; Doxycycline; Drug Therapy, Combination; Female; France; Humans; Immunocompromised Host; Immunoglobulins, Intravenous; Lymphoma, Non-Hodgkin; Recurrence; Rifampin; Rituximab; Spain; Time Factors; Vidarabine	2010
Unrelated stem cell transplantation after reduced intensity conditioning for patients with multiple myeloma relapsing after autologous transplantation. British journal of haematology, 2010, Volume: 148, Issue:2 Topics: Adolescent; Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Disease-Free Survival; Female; Graft vs Host Disease; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Prospective Studies; Recurrence; Stem Cell Transplantation; Survival Analysis; Transplantation, Autologous; Transplantation, Homologous; Vidarabine; Young Adult	2010
[Successful induction of complete remission by gemtuzumab ozogamicin following chemotherapy in three patients with relapsed or refractory acute myeloid leukemia]. [Rinsho ketsueki] The Japanese journal of clinical hematology, 2009, Volume: 50, Issue:8 Topics: Aminoglycosides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Administration Schedule; Female; Gemtuzumab; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Recurrence; Remission Induction; Vidarabine	2009
Reduced-intensity conditioning hematopoietic stem cell transplantation in patients over 60 years: hematologic malignancy outcomes are not impaired in advanced age. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2010, Volume: 16, Issue:6 Topics: Age Factors; Aged; Aging; Blood Donors; Busulfan; Disease-Free Survival; Female; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Myeloablative Agonists; Recurrence; Retrospective Studies; Risk; Survival Analysis; Transplantation Conditioning; Transplantation Immunology; Treatment Outcome; Vidarabine	2010
Non-myeloablative conditioning and allogeneic transplantation for multiple myeloma. American journal of hematology, 2010, Volume: 85, Issue:4 Topics: Adult; Aged; Aging; Antilymphocyte Serum; beta 2-Microglobulin; Cohort Studies; Female; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Kaplan-Meier Estimate; Male; Middle Aged; Multiple Myeloma; Myeloablative Agonists; Recurrence; Retrospective Studies; Salvage Therapy; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Whole-Body Irradiation	2010
Targeted i.v. BU and fludarabine (t-i.v. BU/Flu) provides effective control of AML in adults with reduced toxicity. Bone marrow transplantation, 2011, Volume: 46, Issue:5 Topics: Adult; Aged; Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Injections, Intravenous; Leukemia, Myeloid, Acute; Middle Aged; Myeloablative Agonists; Recurrence; Remission Induction; Treatment Outcome; Vidarabine	2011
Adult dual umbilical cord blood transplantation using myeloablative total body irradiation (1350 cGy) and fludarabine conditioning. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2011, Volume: 17, Issue:6 Topics: Adult; Cord Blood Stem Cell Transplantation; Cryopreservation; Disease-Free Survival; Female; Graft Rejection; Graft vs Host Disease; HLA Antigens; Humans; Lymphocyte Count; Male; Middle Aged; Prospective Studies; Recurrence; Transplantation Conditioning; Treatment Outcome; Vidarabine; Whole-Body Irradiation	2011
High incidence of herpes zoster in nonmyeloablative hematopoietic stem cell transplantation. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2011, Volume: 17, Issue:7 Topics: Antiviral Agents; Cyclophosphamide; Female; Graft vs Host Disease; Hematologic Neoplasms; Herpes Zoster; Herpesvirus 3, Human; Humans; Immunosuppressive Agents; Incidence; Male; Middle Aged; Neuralgia, Postherpetic; Peripheral Blood Stem Cell Transplantation; Postoperative Complications; Recurrence; Retrospective Studies; Siblings; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Virus Activation	2011
Feasibility of second hematopoietic stem cell transplantation using reduced-intensity conditioning with fludarabine and melphalan after a failed autologous hematopoietic stem cell transplantation. Transplantation proceedings, 2010, Volume: 42, Issue:9 Topics: Adult; Disease-Free Survival; Feasibility Studies; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Multiple Myeloma; Myeloablative Agonists; Recurrence; Reoperation; Republic of Korea; Retrospective Studies; Salvage Therapy; Survival Rate; Time Factors; Transplantation Chimera; Transplantation Conditioning; Transplantation, Autologous; Treatment Failure; Vidarabine	2010
Pharmacokinetic targeting of i.v. BU with fludarabine as conditioning before hematopoietic cell transplant: the effect of first-dose area under the concentration time curve on transplant-related outcomes. Bone marrow transplantation, 2011, Volume: 46, Issue:11 Topics: Adult; Aged; Area Under Curve; Busulfan; Disease-Free Survival; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myeloablative Agonists; Recurrence; Retrospective Studies; Transplantation Conditioning; Vidarabine	2011
Reduced intensity allogeneic hematopoietic cell transplantation can induce durable remission in heavily pretreated relapsed Hodgkin lymphoma. Annals of hematology, 2011, Volume: 90, Issue:7 Topics: Adolescent; Adult; Antineoplastic Agents; Clinical Trials as Topic; Disease Progression; Disease-Free Survival; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Male; Melphalan; Middle Aged; Myeloablative Agonists; Recurrence; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Young Adult	2011
Higher busulfan dose intensity does not improve outcomes of patients undergoing allogeneic haematopoietic cell transplantation following fludarabine, busulfan-based reduced toxicity conditioning. Hematological oncology, 2011, Volume: 29, Issue:4 Topics: Adult; Aged; Busulfan; Chimerism; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Myeloablative Agonists; Opportunistic Infections; Recurrence; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Young Adult	2011
Prognostic value of the International Scoring System and response in patients with advanced Waldenstrom macroglobulinemia. Haematologica, 2011, Volume: 96, Issue:5 Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease Progression; Disease-Free Survival; Female; Humans; International Classification of Diseases; Male; Middle Aged; Prognosis; Recurrence; Rituximab; Time Factors; Treatment Outcome; Vidarabine; Waldenstrom Macroglobulinemia	2011
Concomitant ABCG2 overexpression and FLT3-ITD mutation identify a subset of acute myeloid leukemia patients at high risk of relapse. Cancer, 2011, May-15, Volume: 117, Issue:10 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Disease-Free Survival; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Neoplasm Proteins; Prognosis; Recurrence; Remission Induction; Tandem Repeat Sequences; Vidarabine	2011
Tandem autologous/reduced-intensity conditioning allogeneic stem-cell transplantation versus autologous transplantation in myeloma: long-term follow-up. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2011, Aug-01, Volume: 29, Issue:22 Topics: Adult; Aged; Disease-Free Survival; Female; Follow-Up Studies; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Incidence; Kaplan-Meier Estimate; Male; Middle Aged; Multiple Myeloma; Myeloablative Agonists; Neoplasm Staging; Prospective Studies; Recurrence; Time Factors; Transplantation Conditioning; Transplantation, Autologous; Transplantation, Homologous; Treatment Outcome; Vidarabine	2011
Fludarabine and rituximab for relapsed or refractory hairy cell leukemia. Blood, 2012, Mar-01, Volume: 119, Issue:9 Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Female; Follow-Up Studies; Humans; Leukemia, Hairy Cell; Male; Middle Aged; Recurrence; Rituximab; Survival Analysis; Treatment Outcome; Vidarabine	2012
The increase from 2.5 to 5 mg/kg of rabbit anti-thymocyte-globulin dose in reduced intensity conditioning reduces acute and chronic GVHD for patients with myeloid malignancies undergoing allo-SCT. Bone marrow transplantation, 2012, Volume: 47, Issue:5 Topics: Adolescent; Adult; Aged; Animals; Antilymphocyte Serum; Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Middle Aged; Myelodysplastic Syndromes; Rabbits; Recurrence; Retrospective Studies; Survival Analysis; Transplantation Conditioning; Vidarabine	2012
Comparison of new flu-bu12-tg conditioning with the standard bu-cy myeloablative regimen in patients undergoing allogeneic stem cell transplantation for acute myeloid leukemia. Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia, 2011, Volume: 155, Issue:4 Topics: Adult; Antilymphocyte Serum; Busulfan; Cyclophosphamide; Disease-Free Survival; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Leukemia, Myeloid, Acute; Male; Middle Aged; Myeloablative Agonists; Recurrence; Survival Rate; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Young Adult	2011
Radiation-free allogeneic conditioning with fludarabine, carmustine, and thiotepa for acute lymphoblastic leukemia and other hematologic malignancies necessitating enhanced central nervous system activity. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2012, Volume: 18, Issue:9 Topics: Adult; Aged; Alemtuzumab; Antibodies, Monoclonal, Humanized; Carmustine; Central Nervous System; Cyclosporine; Drug Administration Schedule; Female; Follow-Up Studies; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence; Survival Analysis; Thiotepa; Transplantation Conditioning; Transplantation, Homologous; Vidarabine	2012
T-cell replete fludarabine/cyclophosphamide reduced intensity allogeneic stem cell transplantation for lymphoid malignancies. British journal of haematology, 2012, Volume: 157, Issue:5 Topics: Adult; Aged; Cyclophosphamide; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Lymphoproliferative Disorders; Middle Aged; Recurrence; Survival Analysis; T-Lymphocytes; Transplantation Conditioning; Transplantation, Homologous; Vidarabine	2012
Fludarabine, cytarabine, granulocyte-colony stimulating factor and amsacrine: an effective salvage therapy option for acute myeloid leukemia at first relapse. Leukemia & lymphoma, 2013, Volume: 54, Issue:2 Topics: Adolescent; Adult; Aged; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Prognosis; Recurrence; Salvage Therapy; Transplantation, Homologous; Treatment Outcome; Vidarabine; Young Adult	2013
Successful allogeneic hematopoietic cell engraftment after a minimal conditioning regimen in children with relapsed or refractory solid tumors. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2013, Volume: 19, Issue:2 Topics: Adolescent; Adult; Child; Child, Preschool; Chimerism; Hematopoietic Stem Cell Transplantation; Humans; Neoplasms; Recurrence; Remission Induction; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation; Young Adult	2013
Late relapses following reduced intensity allogeneic transplantation in patients with multiple myeloma: a long-term follow-up study. British journal of haematology, 2013, Volume: 160, Issue:2 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Combined Modality Therapy; Female; Follow-Up Studies; Graft vs Host Disease; Humans; Kaplan-Meier Estimate; Living Donors; Male; Melphalan; Middle Aged; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Proportional Hazards Models; Recurrence; Remission Induction; Retrospective Studies; Time Factors; Transplantation Conditioning; Transplantation, Autologous; Transplantation, Homologous; Treatment Outcome; Vidarabine; Whole-Body Irradiation	2013
Acute megakaryoblastic leukemia in a patient with xeroderma pigmentosum: discussion of pathophysiological, prognostic, and toxicological aspects. Acta haematologica, 2013, Volume: 129, Issue:2 Topics: Adult; Aneuploidy; Cytarabine; Daunorubicin; DNA Repair; Fatal Outcome; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Leukemia, Megakaryoblastic, Acute; Leukemia, Myeloid, Acute; Male; Neoadjuvant Therapy; Recurrence; Remission Induction; Transplantation, Homologous; Vidarabine; Xeroderma Pigmentosum	2013
Reduced-intensity conditioning with fludarabine and thiotepa for second allogeneic transplantation of relapsed patients with AML. Bone marrow transplantation, 2013, Volume: 48, Issue:7 Topics: Adult; Aged; Female; Follow-Up Studies; Graft vs Host Disease; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myeloablative Agonists; Recurrence; Retrospective Studies; Stem Cell Transplantation; Thiotepa; Time Factors; Transplantation Conditioning; Vidarabine	2013
Long-term follow-up of patients with CLL treated with allogeneic hematopoietic transplantation. Cytotherapy, 2002, Volume: 4, Issue:3 Topics: Adult; Antineoplastic Agents; Disease Progression; Disease-Free Survival; Female; Follow-Up Studies; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Recurrence; Survival Rate; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine	2002
Acute myocardial infarction as the presenting symptom of acute myeloblastic leukemia with extreme hyperleukocytosis. American journal of hematology, 2002, Volume: 71, Issue:1 Topics: Aminoglycosides; Anti-Bacterial Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Confusion; Cytarabine; Etoposide; Fatal Outcome; Female; Gemtuzumab; Humans; Idarubicin; Immunotherapy; Leukapheresis; Leukemia, Myeloid, Acute; Leukocytosis; Middle Aged; Mitoxantrone; Myocardial Infarction; Recurrence; Remission Induction; Salvage Therapy; Sialic Acid Binding Ig-like Lectin 3; Therapeutics; Vidarabine	2002
Reduced non-relapse mortality after reduced intensity conditioning in advanced chronic lymphocytic leukemia. Annals of hematology, 2002, Volume: 81 Suppl 2 Topics: Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Leukemia, Lymphocytic, Chronic, B-Cell; Recurrence; Remission Induction; Survival Rate; Transplantation Conditioning; Vidarabine	2002
Graft-versus-host disease following allogeneic transplantation from HLA-identical sibling with antithymocyte globulin-based reduced-intensity preparative regimen. Blood, 2003, Jul-15, Volume: 102, Issue:2 Topics: Acute Disease; Adolescent; Adult; Antilymphocyte Serum; Busulfan; Chronic Disease; Disease Progression; Disease-Free Survival; Female; Graft vs Host Disease; Hematologic Neoplasms; Histocompatibility; Humans; Immunosuppressive Agents; Incidence; Life Tables; Lymphocyte Transfusion; Male; Middle Aged; Neoplasms; Peripheral Blood Stem Cell Transplantation; Recurrence; Risk Factors; Siblings; Survival Analysis; T-Lymphocytes; Tissue Donors; Transplantation Conditioning; Treatment Outcome; Vidarabine	2003
Impact of graft-versus-host disease in reduced-intensity stem cell transplantation (RIST) for patients with haematological malignancies. British journal of haematology, 2003, Volume: 121, Issue:2 Topics: Acute Disease; Adolescent; Adult; Aged; Busulfan; Chronic Disease; Cladribine; Cyclophosphamide; Disease-Free Survival; Graft vs Host Disease; Hematologic Neoplasms; Humans; Immunosuppressive Agents; Middle Aged; Proportional Hazards Models; Recurrence; Stem Cell Transplantation; Survival Rate; Thyroglobulin; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation	2003
Retreatment with rituximab alone induces sustained remission in a patient with follicular lymphoma with multiple extranodal sites of involvement, relapsing soon after primary treatment with fludarabine-rituximab. The hematology journal : the official journal of the European Haematology Association, 2003, Volume: 4, Issue:2 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Humans; Lymphoma, Follicular; Male; Middle Aged; Recurrence; Remission Induction; Rituximab; Vidarabine	2003
Fludarabine versus cyclophosphamide, vincristine, and prednisone in recurrent low-grade lymphomas. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2003, Jul-01, Volume: 21, Issue:13 Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Humans; Lymphoma, Non-Hodgkin; Prednisone; Quality of Life; Randomized Controlled Trials as Topic; Recurrence; Reproducibility of Results; Social Behavior; Survival; Vidarabine; Vincristine	2003
Mylotarg, fludarabine, cytarabine (ara-C), and cyclosporine (MFAC) regimen as post-remission therapy in acute myelogenous leukemia. Cancer chemotherapy and pharmacology, 2003, Volume: 52, Issue:6 Topics: Acute Disease; Adult; Aged; Aminoglycosides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cyclosporine; Cytarabine; Female; Gemtuzumab; Humans; Leukemia, Myeloid; Male; Middle Aged; Recurrence; Remission Induction; Vidarabine	2003
Reduced-intensity conditioning with busulfan and fludarabine with or without antithymocyte globulin in HLA-identical sibling transplantation--a retrospective analysis. Bone marrow transplantation, 2004, Volume: 33, Issue:5 Topics: Acute Disease; Adult; Aged; Antilymphocyte Serum; Busulfan; Chronic Disease; Combined Modality Therapy; Female; Follow-Up Studies; Graft vs Host Disease; Hematologic Neoplasms; Hematopoiesis; Hematopoietic Stem Cell Transplantation; Histocompatibility Testing; Humans; Immunosuppressive Agents; Incidence; Male; Middle Aged; Recurrence; Retrospective Studies; Siblings; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Treatment Failure; Vidarabine	2004
Kinetics of engraftment in patients with hematologic malignancies given allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning. Blood, 2004, Oct-15, Volume: 104, Issue:8 Topics: Adolescent; Adult; Age Factors; Aged; Child; Chimera; Disease Progression; Female; Graft Rejection; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Kinetics; Male; Middle Aged; Recurrence; Survival Rate; T-Lymphocytes; Tissue Donors; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine	2004
In vitro sensitivity of leukemic cells to nucleoside derivatives in childhood acute leukemias: good activity in leukemic relapses. Neoplasma, 2005, Volume: 52, Issue:1 Topics: Adolescent; Adult; Antineoplastic Agents; Cell Death; Child; Child, Preschool; Cladribine; Cytarabine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Female; Humans; Infant; Infant, Newborn; Leukemia, Myeloid; Male; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Tumor Cells, Cultured; Vidarabine	2005
Comparison of ARF after myeloablative and nonmyeloablative hematopoietic cell transplantation. American journal of kidney diseases : the official journal of the National Kidney Foundation, 2005, Volume: 45, Issue:3 Topics: Acute Kidney Injury; Adolescent; Adult; Aged; Busulfan; Cohort Studies; Comorbidity; Cyclophosphamide; Cyclosporine; Female; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Incidence; Male; Methotrexate; Methylprednisolone; Middle Aged; Mycophenolic Acid; Patient Selection; Postoperative Complications; Recurrence; Renal Dialysis; Retrospective Studies; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation	2005
Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, Jun-20, Volume: 23, Issue:18 Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Chi-Square Distribution; Cyclophosphamide; Disease Progression; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Proportional Hazards Models; Recurrence; Remission Induction; Rituximab; Survival Analysis; Treatment Outcome; Vidarabine	2005
Comparison between antithymocyte globulin and alemtuzumab and the possible impact of KIR-ligand mismatch after dose-reduced conditioning and unrelated stem cell transplantation in patients with multiple myeloma. British journal of haematology, 2005, Volume: 129, Issue:5 Topics: Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antilymphocyte Serum; Antineoplastic Agents; Disease-Free Survival; Graft vs Host Disease; Humans; Immunophenotyping; Melphalan; Multiple Myeloma; Proportional Hazards Models; Receptors, Immunologic; Receptors, KIR; Recurrence; Risk; Stem Cell Transplantation; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine	2005
An unusual reoccurrence of Waldenstrom's macroglobulinemia as pleural effusions that had a discordant response with treatment. Clinical and laboratory haematology, 2005, Volume: 27, Issue:3 Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Disease Progression; Female; Humans; Pleural Effusion; Recurrence; Rituximab; Vidarabine; Waldenstrom Macroglobulinemia	2005
Superior quality and duration of responses among patients with mantle-cell lymphoma treated with fludarabine and cyclophosphamide with or without rituximab compared with prior responses to CHOP. Leukemia & lymphoma, 2005, Volume: 46, Issue:4 Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Humans; Lymphoma, Mantle-Cell; Middle Aged; Prednisone; Recurrence; Remission Induction; Retrospective Studies; Rituximab; Treatment Outcome; Vidarabine; Vincristine	2005
FLAG-IDA in the treatment of refractory/relapsed acute leukaemias: single centre study. JPMA. The Journal of the Pakistan Medical Association, 2005, Volume: 55, Issue:6 Topics: Acute Disease; Adolescent; Adult; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Child; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid; Male; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Vidarabine	2005
FLAG-IDA in the treatment of refractory/relapsed adult acute lymphoblastic leukemia. Annals of hematology, 2005, Volume: 84, Issue:12 Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Disease-Free Survival; Female; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Leukocyte Count; Liver; Male; Middle Aged; Mucositis; Platelet Count; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Remission Induction; Retrospective Studies; Salvage Therapy; Stem Cell Transplantation; Transplantation, Homologous; Treatment Outcome; Vidarabine	2005
[Allogeneic blood stem cell transplantation in high-risk patients after conditioning with treosulfan and fludarabine]. Deutsche medizinische Wochenschrift (1946), 2005, Sep-23, Volume: 130, Issue:38 Topics: Adult; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Busulfan; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Incidence; Male; Middle Aged; Recurrence; Regression Analysis; Remission Induction; Risk Factors; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Vidarabine	2005
Allogeneic hematopoietic cell transplantation following conditioning with 90Y-ibritumomab-tiuxetan. Leukemia & lymphoma, 2006, Volume: 47, Issue:1 Topics: Adult; Antibodies, Monoclonal; Antineoplastic Agents; Cyclophosphamide; Disease Progression; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Male; Radioimmunotherapy; Recurrence; Remission Induction; Retrospective Studies; Time Factors; Transplantation Conditioning; Treatment Outcome; Vidarabine; Yttrium Radioisotopes	2006
Allogeneic haematopoietic cell transplantation for chronic myelogenous leukaemia in the era of imatinib: a retrospective multicentre study. European journal of haematology, 2006, Volume: 76, Issue:1 Topics: Adolescent; Adult; Antineoplastic Agents; Benzamides; Busulfan; Cohort Studies; Combined Modality Therapy; Cyclophosphamide; Disease-Free Survival; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Myeloablative Agonists; Piperazines; Pyrimidines; Recurrence; Retrospective Studies; Risk Factors; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Whole-Body Irradiation	2006
A retrospective comparison of three sequential groups of patients with Recurrent/Refractory chronic lymphocytic leukemia treated with fludarabine-based regimens. Cancer, 2006, Jan-15, Volume: 106, Issue:2 Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase II as Topic; Cyclophosphamide; Disease-Free Survival; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Recurrence; Retrospective Studies; Rituximab; Treatment Outcome; Vidarabine	2006
Successful treatment of refractory peripheral T-cell lymphoma with a combination of fludarabine and cyclophosphamide. International journal of hematology, 2006, Volume: 83, Issue:5 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophosphamide; Cytarabine; Doxorubicin; Drug Resistance, Neoplasm; Etoposide; Humans; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, T-Cell, Peripheral; Male; Methylprednisolone; Neoplasms, Second Primary; Prednisone; Recurrence; Remission Induction; Time Factors; Vidarabine; Vincristine	2006
[Reduced-intensity stem cell transplantation using allogeneic peripheral blood stem cells from the same donor for relapsed leukemia after bone marrow transplantation]. [Rinsho ketsueki] The Japanese journal of clinical hematology, 2006, Volume: 47, Issue:7 Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Child, Preschool; Cyclosporine; Graft vs Host Disease; Humans; Infant; Male; Melphalan; Peripheral Blood Stem Cell Transplantation; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Tissue Donors; Transplantation Conditioning; Vidarabine	2006
Low-dose thalidomide in combination with oral fludarabine and cyclophosphamide is ineffective in heavily pretreated patients with chronic lymphocytic leukemia. Leukemia research, 2007, Volume: 31, Issue:3 Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dose-Response Relationship, Drug; Drug Administration Schedule; Follow-Up Studies; Humans; Injections, Intravenous; Leukemia, Lymphocytic, Chronic, B-Cell; Recurrence; Remission Induction; T-Lymphocytes, Regulatory; Thalidomide; Treatment Failure; Tumor Necrosis Factor-alpha; Vidarabine	2007
High-risk fludarabine-pretreated B-cell chronic lymphocytic leukemia's high response rate following sequential DHAP and alemtuzumab administration though in absence of molecular remission. Medical oncology (Northwood, London, England), 2006, Volume: 23, Issue:3 Topics: Adult; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophosphamide; Cytarabine; Dexamethasone; Female; Hematopoietic Stem Cell Mobilization; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Pilot Projects; Recurrence; Remission Induction; Stem Cells; Treatment Outcome; Vidarabine	2006
Impact of conditioning regimen intensity on outcome of allogeneic hematopoietic cell transplantation for advanced acute myelogenous leukemia and myelodysplastic syndrome. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2006, Volume: 12, Issue:10 Topics: Acute Disease; Adult; Aged; Bone Marrow Transplantation; Busulfan; Cyclophosphamide; Female; Graft Survival; Graft vs Host Disease; Humans; Incidence; Kaplan-Meier Estimate; Leukemia, Myeloid; Male; Middle Aged; Myelodysplastic Syndromes; Peripheral Blood Stem Cell Transplantation; Recurrence; Reoperation; Retrospective Studies; Tissue Donors; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Whole-Body Irradiation	2006
Lichenoid paraneoplastic pemphigus in the absence of detectable antibodies. Journal of the American Academy of Dermatology, 2007, Volume: 56, Issue:1 Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antibody Formation; Antineoplastic Combined Chemotherapy Protocols; Autoantibodies; B-Lymphocytes; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Esophageal Diseases; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Immunity, Cellular; Interleukin-2; Leukemia, Lymphocytic, Chronic, B-Cell; Lichenoid Eruptions; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Male; Middle Aged; Mucositis; Paraneoplastic Syndromes; Pemphigus; Prednisone; Recurrence; Rituximab; T-Lymphocytes; Vidarabine; Vincristine	2007
Progressive bicytopenia due to persistent parvovirus B19 infection after immunochemotherapy with fludarabine/cyclophosphamide and rituximab for relapsed B cell lymphoma. Haematologica, 2006, Volume: 91, Issue:12 Suppl Topics: Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Female; Humans; Immunocompromised Host; Immunoglobulins, Intravenous; Immunotherapy; Leukopenia; Lymphoma, Follicular; Middle Aged; Parvoviridae Infections; Parvovirus B19, Human; Prednisolone; Recurrence; Rituximab; Vidarabine; Vincristine; Viremia	2006
Improved outcome after relapse in children with acute myeloid leukaemia. British journal of haematology, 2007, Volume: 136, Issue:2 Topics: Acute Disease; Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Cytarabine; Cytogenetics; Disease-Free Survival; Female; Follow-Up Studies; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid; Male; Recurrence; Remission Induction; Statistics, Nonparametric; Stem Cell Transplantation; Survival Rate; Sweden; Treatment Outcome; Vidarabine	2007
Parvovirus B19 pneumonia in a child undergoing allogeneic hematopoietic stem cell transplantation. Bone marrow transplantation, 2007, Volume: 40, Issue:1 Topics: Adolescent; Antineoplastic Agents; Combined Modality Therapy; Erythema Infectiosum; Fatal Outcome; Hematopoietic Stem Cell Transplantation; Humans; Male; Parvovirus B19, Human; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Radiography, Thoracic; Recurrence; Thiotepa; Tomography, X-Ray Computed; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation	2007
Engraftment kinetics and hematopoietic chimerism after reduced-intensity conditioning with fludarabine and treosulfan before allogeneic stem cell transplantation. Annals of hematology, 2007, Volume: 86, Issue:8 Topics: Adolescent; Adult; Aged; Busulfan; Chimerism; Female; Graft Survival; Graft vs Host Disease; Hematologic Diseases; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Recurrence; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Vidarabine	2007
[Reactivation of familial hemophagocytic lymphohistiocytosis after non-myeloablative cord blood stem cell transplantation resulted in the early graft failure]. [Rinsho ketsueki] The Japanese journal of clinical hematology, 2007, Volume: 48, Issue:6 Topics: Antilymphocyte Serum; Child, Preschool; Cord Blood Stem Cell Transplantation; DNA; Female; Graft Rejection; Histocompatibility Testing; Humans; Killer Cells, Natural; Lymphocyte Activation; Lymphohistiocytosis, Hemophagocytic; Recurrence; T-Lymphocytes; Transplantation Conditioning; Vidarabine	2007
New myeloablative conditioning regimen with fludarabine and busulfan for allogeneic stem cell transplantation: comparison with BuCy2. Bone marrow transplantation, 2007, Volume: 40, Issue:6 Topics: Adolescent; Adult; Arterial Occlusive Diseases; Busulfan; Cyclophosphamide; Cytomegalovirus Infections; Disease-Free Survival; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Incidence; Leukemia; Male; Middle Aged; Myeloablative Agonists; Recurrence; Retrospective Studies; Risk Factors; Survival Rate; Transplantation Conditioning; Transplantation, Homologous; Vidarabine	2007
Long-term follow-up of allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning for patients with chronic myeloid leukemia. Blood, 2007, Nov-01, Volume: 110, Issue:9 Topics: Adolescent; Adult; Aged; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Follow-Up Studies; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Melphalan; Middle Aged; Myeloablative Agonists; Recurrence; Retrospective Studies; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Vidarabine	2007
Comparison between two fludarabine-based reduced-intensity conditioning regimens before allogeneic hematopoietic stem-cell transplantation: fludarabine/melphalan is associated with higher incidence of acute graft-versus-host disease and non-relapse mortal Leukemia, 2007, Volume: 21, Issue:10 Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia; Male; Melphalan; Middle Aged; Recurrence; Retrospective Studies; Time Factors; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine	2007
Intentional induction of mixed haematopoietic chimerism as platform for cellular therapy after HLA-matched allogeneic stem cell transplantation in childhood leukaemia patients. British journal of haematology, 2008, Volume: 140, Issue:3 Topics: Adolescent; Antigens, CD34; Antineoplastic Agents; CD3 Complex; Child; Child, Preschool; Disease-Free Survival; Female; Graft vs Leukemia Effect; Humans; Infant; Leukemia, Myeloid, Acute; Lymphocyte Transfusion; Male; Peripheral Blood Stem Cell Transplantation; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Probability; Prospective Studies; Recurrence; Stem Cells; Transplantation Chimera; Transplantation Conditioning; Transplantation, Homologous; Vidarabine	2008
Fludarabine/intermediate-dose cytarabine with or without allogeneic hematopoietic stem cell transplantation in poor-risk leukemia: a single center experience. International journal of hematology, 2008, Volume: 87, Issue:4 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Dose-Response Relationship, Drug; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia; Male; Middle Aged; Recurrence; Risk Factors; Survival Rate; Transplantation, Homologous; Vidarabine	2008
Fatal recurrence of autoimmune hemolytic anemia following pentostatin therapy in a patient with a history of fludarabine-associated hemolytic anemia. Annals of oncology : official journal of the European Society for Medical Oncology, 1995, Volume: 6, Issue:3 Topics: Anemia, Hemolytic; Antineoplastic Agents; Autoimmune Diseases; Fatal Outcome; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Pentostatin; Recurrence; Vidarabine	1995
Recurrence of autoimmune thrombocytopenia after treatment with fludarabine in a patient with chronic lymphocytic leukemia. Leukemia & lymphoma, 1994, Volume: 15, Issue:1-2 Topics: Aged; Anemia, Hemolytic, Autoimmune; Autoimmune Diseases; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Purpura, Thrombocytopenic, Idiopathic; Recurrence; T-Lymphocyte Subsets; Vidarabine	1994
Retreatment of chronic lymphocytic leukemia with 2-chlorodeoxyadenosine (CdA) at relapse following CdA-induced remission: no acquired resistance. Leukemia & lymphoma, 1994, Volume: 13, Issue:1-2 Topics: 2-Chloroadenosine; Aged; Chlorambucil; Drug Resistance; Erythrocyte Transfusion; Female; Follow-Up Studies; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphocytes; Male; Middle Aged; Platelet Transfusion; Recurrence; Remission Induction; Time Factors; Vidarabine	1994
Concomitant administration of chlorambucil limits dose intensity of fludarabine in previously treated patients with chronic lymphocytic leukemia. Leukemia, 1994, Volume: 8, Issue:8 Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chlorambucil; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm Staging; Platelet Count; Recurrence; Vidarabine	1994
Fludarabine potentiates metabolism of cytarabine in patients with acute myelogenous leukemia during therapy. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1993, Volume: 11, Issue:1 Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Administration Schedule; Drug Synergism; Humans; In Vitro Techniques; Leukemia, Myeloid, Acute; Middle Aged; Recurrence; Treatment Outcome; Vidarabine	1993
Subcutaneous CAMPATH-1H in fludarabine-resistant/relapsed chronic lymphocytic and B-prolymphocytic leukaemia. British journal of haematology, 1997, Volume: 96, Issue:3 Topics: Administration, Cutaneous; Aged; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Agents; Drug Resistance, Neoplasm; Female; Humans; Leukemia, B-Cell; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Prolymphocytic; Male; Recurrence; Vidarabine	1997
High remission rate, short remission duration in patients with refractory anemia with excess blasts (RAEB) in transformation (RAEB-t) given acute myelogenous leukemia (AML)-type chemotherapy in combination with granulocyte-CSF (G-CSF). Cytokines and molecular therapy, 1995, Volume: 1, Issue:1 Topics: Adult; Anemia, Refractory, with Excess of Blasts; Bone Marrow; Chromosome Aberrations; Chromosome Disorders; Confidence Intervals; Cytarabine; Disease-Free Survival; Drug Administration Schedule; Drug Therapy, Combination; Environment, Controlled; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Karyotyping; Leukemia, Myeloid, Acute; Middle Aged; Platelet Count; Probability; Prognosis; Recurrence; Remission Induction; Retrospective Studies; Survival Rate; Vidarabine	1995
Combined therapy with Fludarabine and cyclophosphamide in relapsed/resistant patients with B-cell chronic lymphocytic leukaemia and non-Hodgkin's lymphomas. European journal of haematology, 1997, Volume: 59, Issue:5 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Drug Resistance, Neoplasm; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Male; Middle Aged; Recurrence; Vidarabine	1997
Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1998, Volume: 16, Issue:8 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Female; Graft Enhancement, Immunologic; Graft vs Host Disease; Graft vs Host Reaction; Hematopoiesis; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Male; Middle Aged; Recurrence; Remission Induction; Vidarabine	1998
Autologous transplantation of chemotherapy-purged PBSC collections from high-risk leukemia patients: a pilot study. Bone marrow transplantation, 1999, Volume: 23, Issue:3 Topics: Acute Disease; Adolescent; Adult; Antineoplastic Agents; Bone Marrow Purging; Busulfan; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Disease Progression; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Length of Stay; Leukemia, Myeloid; Male; Mechlorethamine; Middle Aged; Mitoxantrone; Neoplasms, Second Primary; Neoplastic Stem Cells; Pilot Projects; Platelet Transfusion; Recurrence; Remission Induction; Risk; Salvage Therapy; Survival Analysis; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome; Vidarabine	1999
Fludarabine treatment in B-cell chronic lymphocytic leukemia: response, toxicity and survival analysis in 47 cases. Haematologica, 1999, Volume: 84, Issue:4 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Drug Resistance, Neoplasm; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Recurrence; Survival Analysis; Vidarabine	1999
Salvage chemotherapy using a combination of fludarabine and cyclophosphamide for refractory or relapsing indolent and aggressive non-Hodgkin's lymphomas. Leukemia & lymphoma, 1999, Volume: 33, Issue:1-2 Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-Free Survival; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Recurrence; Remission Induction; Salvage Therapy; Survival Rate; Vidarabine	1999
Cost-minimization analysis of CHOP, fludarabine and rituximab for the treatment of relapsed indolent B-cell non-Hodgkin's lymphoma in the U.K. British journal of haematology, 1999, Volume: 106, Issue:1 Topics: Ambulatory Care; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Costs and Cost Analysis; Cyclophosphamide; Doxorubicin; Humans; Length of Stay; Lymphoma, B-Cell; Middle Aged; Prednisone; Recurrence; Retrospective Studies; Rituximab; Vidarabine; Vincristine	1999
Dose-reduced conditioning for allogeneic blood stem cell transplantation: durable engraftment without antithymocyte globulin. Bone marrow transplantation, 2000, Volume: 26, Issue:2 Topics: Adult; Aged; Antilymphocyte Serum; Antineoplastic Agents; Busulfan; Disease-Free Survival; Female; Graft Survival; Graft vs Host Disease; Graft vs Tumor Effect; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Infections; Male; Middle Aged; Neoplasms; Nuclear Family; Prospective Studies; Recurrence; Survival Rate; T-Lymphocytes; Transplantation Chimera; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine	2000
Low-intensity conditioning is sufficient to ensure engraftment in matched unrelated bone marrow transplantation. Experimental hematology, 2001, Volume: 29, Issue:3 Topics: Adolescent; Adult; Antilymphocyte Serum; Bone Marrow Transplantation; Busulfan; Cell Count; Child; Cohort Studies; Disease-Free Survival; Female; Graft Survival; Histocompatibility; Humans; Leukemia; Life Tables; Lymphoma, Large-Cell, Anaplastic; Male; Middle Aged; Recurrence; Survival Analysis; T-Lymphocytes; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine	2001
Results of an outpatient-based stem cell allotransplant program using nonmyeloablative conditioning regimens. American journal of hematology, 2001, Volume: 66, Issue:4 Topics: Adolescent; Adult; Ambulatory Care; Busulfan; Child; Cyclophosphamide; Cyclosporine; Female; Follow-Up Studies; Graft Survival; Graft vs Host Disease; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Leukemia; Male; Methotrexate; Middle Aged; Neural Tube Defects; Program Evaluation; Recurrence; Survival Analysis; Thalassemia; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine	2001
Second allogeneic peripheral blood stem cell transplantation with fludarabine-based low-intensity conditioning regimen for relapsed myelodysplastic syndrome after allogeneic bone marrow transplantation. International journal of hematology, 2001, Volume: 73, Issue:1 Topics: Antineoplastic Agents; Bone Marrow Transplantation; Fatal Outcome; Hematopoietic Stem Cell Transplantation; Humans; Infections; Male; Middle Aged; Myelodysplastic Syndromes; Recurrence; Transplantation Conditioning; Transplantation, Homologous; Vidarabine	2001
Fludarabine and cytarabine as a sequential infusion regimen for treatment of adults with recurrent, refractory or poor prognosis acute leukemia. Leukemia & lymphoma, 2001, Volume: 41, Issue:3-4 Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Cytarabine; Cytogenetic Analysis; Disease-Free Survival; Drug Administration Schedule; Female; Hematologic Diseases; Humans; Infections; Infusion Pumps; Leukemia; Lung Diseases; Male; Middle Aged; Nervous System Diseases; Prognosis; Recurrence; Retrospective Studies; Survival Rate; Treatment Outcome; Vidarabine	2001
Autoimmune thrombocytopenia associated with the first cycle of fludarabine therapy in the treatment of relapsed non-Hodgkin's lymphoma. Clinical oncology (Royal College of Radiologists (Great Britain)), 2001, Volume: 13, Issue:4 Topics: Antineoplastic Agents; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Purpura, Thrombocytopenic, Idiopathic; Recurrence; Vidarabine	2001
A fludarabine-based dose-reduced conditioning regimen followed by allogeneic stem cell transplantation from related or unrelated donors in patients with myelodysplastic syndrome. Bone marrow transplantation, 2001, Volume: 28, Issue:7 Topics: Adult; Anemia, Refractory, with Excess of Blasts; Antilymphocyte Serum; Bone Marrow; Busulfan; Cell Count; Chromosomes, Human, Pair 7; Cyclophosphamide; Disease-Free Survival; Feasibility Studies; Graft Survival; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Hepatic Veno-Occlusive Disease; Histocompatibility; Humans; Infections; Karyotyping; Methotrexate; Middle Aged; Monosomy; Myelodysplastic Syndromes; Recurrence; Survival Rate; T-Lymphocytes; Tissue Donors; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine	2001
Reduced-intensity conditioning followed by allografting of hematopoietic cells can produce clinical and molecular remissions in patients with poor-risk hematologic malignancies. Blood, 2002, Jan-01, Volume: 99, Issue:1 Topics: Adult; Aged; Anemia, Refractory, with Excess of Blasts; Cyclophosphamide; Cyclosporine; Female; Graft vs Host Disease; Graft vs Tumor Effect; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Lymphocyte Transfusion; Lymphoma, Mantle-Cell; Male; Methotrexate; Middle Aged; Neoplasm, Residual; Polymerase Chain Reaction; Recurrence; Remission Induction; Survival Rate; Thiotepa; Transplantation Chimera; Transplantation Conditioning; Transplantation, Homologous; Vidarabine	2002
Nonmyeloablative conditioning followed by transplantation of genetically modified HLA-matched peripheral blood progenitor cells for hematologic malignancies in patients with acquired immunodeficiency syndrome. Blood, 2002, Jan-15, Volume: 99, Issue:2 Topics: Acquired Immunodeficiency Syndrome; Acute Disease; Adult; Anti-Bacterial Agents; Antiretroviral Therapy, Highly Active; Cyclophosphamide; Cyclosporine; Feasibility Studies; Ganciclovir; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Infection Control; Leukemia, Myeloid; Prednisone; Premedication; Recurrence; Remission Induction; Transplantation Conditioning; Treatment Outcome; Vidarabine; Viral Load	2002
High-dose chlorambucil for the treatment of chronic lymphocytic leukaemia and low-grade non-Hodgkin's lymphoma. British journal of haematology, 2002, Volume: 116, Issue:4 Topics: Adult; Aged; Aged, 80 and over; Anemia, Hemolytic, Autoimmune; Antineoplastic Agents, Alkylating; Chlorambucil; Drug Administration Schedule; Female; Humans; Immunosuppressive Agents; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Male; Middle Aged; Recurrence; Survival Rate; Vidarabine	2002
Stable mixed chimerism after T cell-depleted allogeneic hematopoietic stem cell transplantation using conditioning with low-dose total body irradiation and fludarabine. Bone marrow transplantation, 2002, Volume: 29, Issue:7 Topics: Adult; Cohort Studies; Disease Progression; Feasibility Studies; Female; Graft Survival; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Lymphocyte Depletion; Lymphocyte Transfusion; Male; Middle Aged; Recurrence; Retrospective Studies; Tissue Donors; Transplantation Chimera; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Whole-Body Irradiation	2002
Development and rapid dissemination of Merkel-cell carcinomatosis following therapy with fludarabine and rituximab for relapsing follicular lymphoma. European journal of haematology, 2002, Volume: 68, Issue:2 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Carcinoma, Merkel Cell; Humans; Lymphoma, Follicular; Male; Middle Aged; Neoplasms, Second Primary; Recurrence; Rituximab; Salvage Therapy; Vidarabine	2002
Effective treatment of relapsed acute myeloid leukaemia with drugs chosen by DiSC assay. British journal of haematology, 1992, Volume: 81, Issue:3 Topics: Acute Disease; Antineoplastic Agents; Cytotoxicity Tests, Immunologic; Drug Hypersensitivity; Etoposide; Female; Humans; Leukemia, Myeloid; Middle Aged; Mitoxantrone; Recurrence; Vidarabine	1992
Comparison between the plasma and intracellular pharmacology of 1-beta-D-arabinofuranosylcytosine and 9-beta-D-arabinofuranosyl-2-fluoroadenine 5'-monophosphate in patients with relapsed leukemia. Leukemia, 1987, Volume: 1, Issue:9 Topics: Adult; Arabinofuranosylcytosine Triphosphate; Arabinonucleotides; Cytarabine; DNA Replication; Drug Evaluation; Female; Half-Life; Humans; Leukemia; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence; Vidarabine	1987